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Abstract 
In breast and ovarian cancer, the primary source of mortality is metastasis. Even in patients 
who are thought to be cancer-free after initial treatment, metastatic recurrence after months or years 
of asymptomatic latency period in patients is common in both cancers. Cancer cells that stay 
dormant and evade chemotherapy have been thought to underpin the metastatic recurrence, but the 
underlying mechanisms are unclear thus far. Despite advances in cancer treatment, recurrent 
metastatic cancer is rarely curable. Thus, preventing metastatic recurrence by preemptively 
eliminating dormant cancer cells is a key to reduce the mortality in breast and ovarian cancers. To 
effectively target and destroy dormant cancer cells evading chemotherapy, well-established 
experimental platforms for a better understanding of their unique biological characteristics as well 
as development of novel therapeutic strategies are required.  
The work presented in this dissertation aims to provide facile in vitro and in vivo experimental 
platforms that enable the investigation of cancer dormancy in breast and ovarian cancers as well as 
to develop a novel therapeutic alternative to chemotherapy to destroy ovarian cancer cells, as 
current therapeutic options for ovarian cancer are much more limited than for breast cancer. In the 
first study, an in vitro platform that stably induced dormant state in breast and ovarian cancer cells 
was developed using cobalt chloride (CoCl2), a hypoxia mimetic agent. Hypoxia has been identified 
as a microenvironmental niche that harbors dormant cancer cells in many types of cancer, but its 
role in cancer dormancy has been poorly understood due to the lack of models that stably induce 
and maintain hypoxia and dormancy. CoCl2 created a robust hypoxia-mimicking microenvironment 
where breast and ovarian cancer cells could remain in a dormant state for molecular characterization. 
This platform enables investigation of poorly-understood molecular mechanisms underlying cancer 
dormancy under hypoxia in both cancers. To investigate hypoxic regulation of cancer dormancy in 
a more physiologically relevant context, an in vivo platform combining CoCl2 with biomaterial 
scaffolds composed of poly(lactide-co-glycolide; PLG) was also developed. The PLG scaffolds 
that release CoCl2 established an in vivo hypoxic niche that can recruit disseminating cancer cells, 
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enabling investigation of how a hypoxic niche harbors dormant cancer cells at metastatic sites. 
Though the in vivo platform was tested with a previously established breast cancer metastasis model, 
this platform could be also used to study ovarian cancer dormancy within a hypoxic niche in the 
body. 
Lastly, we present a novel biomaterial-based therapeutic strategy to destroy metastatic ovarian 
cancer cells via sonodynamic therapy. Conventional chemotherapy, which mainly targets rapidly 
proliferating cancer cells, has been ineffective for non- or slow-proliferating dormant cancer cells. 
To address this issue, an alternative therapeutic strategy was developed using graphene nanoribbons 
(GNR) functionalized with a sonosensitizer, chlorin e6 (Ce6). This biomaterial-based approach 
effectively destroyed ovarian cancer cells through sonodynamic ablation and could be used to 
reduce the metastatic recurrence resulting from the cancer cells evading chemotherapy. Altogether, 
the experimental platforms and therapeutic strategy established in this dissertation may provide us 
a better understanding of dormancy in breast and ovarian cancers as well as a new treatment option 
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Chapter 1 – Introduction 
 
1.1. Metastatic recurrence in breast and ovarian cancer 
Each year, more than 40,000 women die from breast cancer and about 14,000 
women die from ovarian cancer in the US. Notably, more than 90% of cancer-related deaths 
in breast and ovarian cancer are due to metastases that impair the function of vital organs 
[1–3]. In breast cancer, the 5-year survival rate for patients with metastasis is only 27% 
while that for patients without metastasis is 99% (Fig. 1-1), meaning that metastasis has a 
substantial influence on the length of survival. Though only 6% of new breast cancer cases 
have overt metastasis at the time of diagnosis, it has been estimated that 20-45% of all 
breast cancer patients will ultimately develop metastatic disease [4]. This pattern highlights 
that many patients with early-stage breast cancer have undetectable micrometastases 
present at the time of diagnosis, putting them at risk for later development of metastatic 
disease.  
 
Figure 1-1. Metastasis has a substantial influence on patient survival in breast cancer. (A) Percentage 
of patients in each cancer stage at the time of diagnosis. (B) 5-year relative survival rate by stage at 
diagnosis for females with breast cancer in the US [5].  
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In contrast to breast cancer, about 60% of ovarian cancer patients already have 
widespread metastasis at the time of diagnosis, with a 5-year survival rate of 29% compared 
with 92% for patients without metastasis (Fig. 1-2). For most ovarian cancer patients with 
widespread metastasis, debulking surgery to remove as many of the metastatic nodules as 
possible followed by adjuvant chemotherapy using platinum/taxane-based drugs has been 
the standard treatment [6]. Despite positive initial responses to chemotherapy in more than 
75% of patients, metastatic relapse occurring after the completion of initial treatment is 
very common in ovarian cancer, as the residual tumors frequently evade or develop 
resistance to chemotherapy, causing treatment failure and death in over 90% of patients [7]. 
Approximately 70% of all ovarian cancer patients will have tumor recurrence, and this 
number rises to 90-95% for patients diagnosed in advanced stages (stage III or stage IV) 
[8].  
 
Figure 1-2. Metastasis has a substantial influence on patient survival in ovarian cancer. (A) Percentage 
of patients in each cancer stage at the time of diagnosis. (B) 5-year relative survival rate by stage at 
diagnosis for ovarian cancer in the US [9].  
 
Over the past few decades, researchers have demonstrated the presence of residual 
tumor cells disseminated from the primary tumor within patients after the completion of 
initial therapy [4]. Some disseminated tumor cells (DTCs) were found to enter a dormant 
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state, during which DTCs do not proliferate or divide, thereby evading chemotherapy, 
which mainly targets rapidly proliferating cancer cells. The dormancy period can range 
from a few months to as long as decades, depending on the subtype of cancer, molecular 
characteristics, receptor expression, systemic inflammation, and many other factors [10]. 
Upon being stimulated by specific microenvironmental factors, these dormant cells can 
become reawakened and activated, eventually forming secondary metastases often with 
increased chemoresistance, leading to poor patient survival. Hence, preemptively targeting 
dormant DTCs by understanding the molecular mechanisms of cancer dormancy and 
developing novel therapeutic strategies that do not rely on targeting actively dividing cells 
offers a potential window of opportunity for the prevention of metastatic recurrence in 
breast and ovarian cancer patients. 
 
 
Figure 1-3. Possible fates of DTCs from primary tumor in breast cancer. Dormant DTCs give rise to 
the latency period before metastatic relapse in many breast cancer patients. Factors that lead to 
dormancy include microenvironmental cues, the balance of pro- and anti-angiogenic signals, immune 
response, and genetic changes [11]. 
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1.2. Dormancy precedes metastatic recurrence in breast cancer.  
In breast cancer patients, the presence of DTCs in bone marrow is a common 
phenomenon observed in more than 40% of patients at diagnosis [11]. Most of DTCs are 
already dead or eliminated by the shear stresses in blood stream during the dissemination, 
but a small fraction of DTCs may survive (Fig. 1-3) [11]. Compared with other types of 
cancer, breast cancer has been known to have particularly long periods of dormancy, which 
can be up to 25 years without any symptoms of disease, followed by a metastatic recurrence 
[11]. Approximately 60-70% of deaths from breast cancer occur beyond the 5-year survival 
window due to late metastatic recurrence after years or decades of disease-free latency [12]. 
Thus, understanding this stage of tumor progression is key to establish better therapeutic 
plans to prevent tumor recurrence in breast cancer patients. If a patient’s risk of recurrence 
can be predicted based on a better understanding of dormancy-associated biology, 
alternative targetred therapies could be explored to avoid overtreatment with chemotherapy 
that will be ineffective at killing the residual DTCs. However, this opportunity has not been 
realized because our understanding of the underlying mechanisms of cancer dormancy is 
limited due to the lack of well-established experimental models. 
 
1.2.1. Microenvironmental regulation of DTC dormancy 
Accumulating evidence has proposed that the residual DTCs can remain dormant 
either by entering a quiescent state, a reversible growth arrest in the G0/G1 phase of the 
cell cycle (cellular dormancy), or existing as micrometastases where the proliferation of 
the tumor mass is counterbalanced by cell death from the anti-tumoral activity of the 
immune system or the lack of vascularization to support tumor growth [4,11,13,14]. While 
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these two types of dormancy are not mutually exclusive and might even coexist in the entire 
population of DTCs of the same patient [11,15], this dissertation will focus on cellular 
dormancy.  
Previous studies using various tumor model systems highlight the important role of 
microenvironmental factors in regulating cellular dormancy. A recent study by Ghajar et 
al. found that the perivascular niche strongly impacts DTC dormancy [16]. This work 
identified that the resting endothelium produces thrombospondin-1 (TSP-1), which induces 
dormancy in DTCs. In contrast, endothelial tip cells in sprouting neovasculature promote 
proliferation of DTCs by secreting transforming growth factor beta 1 (TGFβ1) and 
periostin (POSTN). In addition to the perivascular niche, Lawson et al. found that the 
endosteal niche induces dormancy in bone marrow [17]. They found that dormant myeloma 
DTCs in bone marrow were engaging with osteoblasts in the endosteum, whereas 
proliferating DTCs were not. Remarkably, proliferating cells introduced to an experimental 
endosteal niche were able to enter a dormant state. In addition, dormant DTCs released 
from the endosteal niche could be reactivated through enhanced osteoclast activity induced 
by soluble receptor activator of nuclear factor kappa-Β ligand (sRANKL), suggesting that 
dormancy is a reversible state regulated by the microenvironment. Furthermore, Shiozawa 
et al. showed that osteoblast-derived growth arrest-specific 6 (GAS6) protein signaling 
through its receptor Axl induces dormancy in prostate cancer DTCs [18,19]. Interestingly, 
under hypoxic conditions a negative feedback loop of GAS6/Axl is inhibited, leading to 
increased Axl expression and possibly maintenance of dormancy in hypoxic 
microenvironments [20].  
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1.2.2. Hypoxic regulation of cancer dormancy 
As stated above, DTCs are frequently found in the bone marrow of cancer patients, 
even in patients with no evidence of metastases. The bone marrow microenvironment 
therefore seems to be inhibitory for cell growth and thus causes most DTCs enter dormancy. 
Bone marrow is a hypoxic tissue where the oxygen level is relatively low compared to 
other organs [13,14,21,22]. Recent evidence from experimental and clinical studies 
increasingly points to a fundamental role for hypoxia in cancer dormancy observed in the 
bone marrow. Johnson et al. suggested that tumor cells may enter dormant state through 
interactions with the hypoxic bone microenvironment. They found breast cancer cells stay 
dormant within hypoxic regions of bone marrow [22]. Recently, proteomic analysis of 
DTCs in bone marrow obtained from patients with breast cancer showed that these DTCs 
activate markers of the unfolded protein response (UPR) or the endoplasmic reticulum (ER) 
stress response as a cellular adaptation strategy to survive the hypoxic microenvironment 
in the bone marrow [28]. These findings suggest that the hypoxic microenvironment in 
secondary metastatic sites such as bone marrow may prime the DTCs to enter a dormant 
state.  
Hypoxia is also a prominent feature of the microenvironment of primary tumors 
[23,24]. In primary breast tumors, hypoxia was found to give rise to the heterogeneity of 
DTCs and spawn dormant tumor cells [25]. One of the early cellular responses to hypoxia 
is to decrease the proliferation rate in order to reduce oxygen consumption, hence hypoxic 
cells divide far more slowly and to remain viable over a prolonged period [26]. Li et al. 
observed that while tumor cells in the non-hypoxic periphery of primary tumors were 
proliferating, tumor cells in the hypoxic core of these tumors were not, suggesting that 
dormant tumors may be hypoxic and hypoxia may be related to low proliferation rates and 
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thus tumor dormancy [27]. Previous studies have also shown that cells exposed to hypoxia 
have a disproportionately long G1 phase or arrest in the G0/G1 phase of cell cycle, which 
is a key feature of dormancy [26]. It was also experimentally demonstrated that a vast 
majority of hypoxic tumor cells are negative for proliferation markers (e.g. Ki67, PCNA, 
BrdU) [11,26]. Taken together, these findings highlight that dormant DTCs may also result 
from cells that entered dormancy in hypoxic environments within the primary tumor.  
 
1.3. In vitro and in vivo models to study hypoxic regulation of cancer 
dormancy 
1.3.1. In vivo models  
One of the challenges in studying dormancy is that it is undetectable using 
conventional whole-body imaging tools due to the low frequency of dormant tumor cells. 
In addition, cancer dormancy is a difficult stage of tumor progression to track as it takes 
place over long periods. Thus, most research on cancer dormancy relies on rapidly growing 
cancer cell lines and aggressively growing metastasis/transgenic oncogene models. For 
instance, by using patient-derived xenografts and the transgenic MMTV polyoma middle 
T mouse model, Fluegen et al. found that naturally-occurring hypoxia in the primary tumor 
upregulates key dormancy markers including NR2F1, DEC2, and p27 in MDA-MB-231 
breast cancer cells [29]. Johnson et al. found that the leukemia inhibitory factor receptor 
(LIFR) signaling pathway confers a dormant phenotype in breast cancer cells disseminated 
to bone [22]. They also identified that hypoxia in the bone marrow reduces LIFR signaling 
in breast cancer cells and promotes proliferation with downregulation of dormancy-
associated genes. However, in vivo mouse models provide limited control of the organ 
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environment for controlled investigations. Moreover, high costs, heterogeneity, and the 
challenges of locating and imaging dormant cells in internal tissues make the use of in vivo 
models challenging [30]. Thus, in vitro models have gained attention since they can 
recapitulate hypoxia in a simple and relatively reproducible way, as well as enable the 
facile control of environmental factors and measurement of cellular responses.  
 
1.3.2. In vitro models using hypoxic chambers or chemical inducers 
There have been few in vitro models to induce dormancy in tumor cells thus far, 
and these models rely on using a hypoxic chamber or gas-controlled incubator. 
Conventional methods of studying hypoxia in vitro include (i) using a hypoxic chamber or 
gas-controlled incubator with an air-tight seal and introducing specific gas concentrations 
or (ii) inducing a hypoxia-mimicking response using chemical inducers (e.g. CoCl2, 
deferoxamine; DFO). These two methods provide unique benefits, as well as limitations, 
for investigating cells under hypoxia to characterize dormant tumor cells. The hypoxic 
chambers employed in most previous studies have the advantage of not using chemicals 
that may change cell behavior independently of the hypoxic response. Endo et al. reported 
that AsPC-1, a pancreatic cell line, can survive 2-3 weeks of chronic hypoxia (1% O2) 
maintained within a hypoxic chamber by entering a dormant state with no proliferation, no 
death, and metabolic suppression [31]. In another study by Prati et al., it was found that 
exposing MDA-MB-231 cells to three or more cycles of hypoxia (1% O2) and 
reoxygenation using a gas-controlled incubator can establish a hypoxia-tolerating MDA-
MB-231 cell line that can stably survive under 1% O2 condition by entering a dormant state, 
as characterized by arrest in G0/G1 phase and low metabolism [32]. However, not all types 
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of experiments can be performed with hypoxic chambers as opening the chamber for 
manipulation (e.g. media change) is not allowed to maintain hypoxia. HIF1a, a master 
regulator protein of the cellular response to hypoxia, is highly unstable and rapidly 
destroyed upon exposure to oxygen, with an extremely short half-life of less than 5 minutes 
under normoxic conditions [33]. Thus, oxygen that reenters the chamber at each opening 
quickly establishes normoxia and reoxygenates the hypoxic cells, reducing the reliability 
of the system. Since repeated cycles of hypoxia and reoxygenation can trigger drastic 
changes of gene expression in some cell types [34,35], cell responses under fluctuations of 
hypoxia and reoxygenation in hypoxic chambers are likely different from actual in vivo 
hypoxic responses.  
As opposed to the hypoxic chamber method, biochemical induction can stably 
provide hypoxic microenvironments regardless of oxygen level. Despite its well-
characterized hypoxia-mimicking effects in many studies [36], the biochemical induction 
method has not been previously used to investigate cancer dormancy. In this dissertation, 
a well-known chemical inducer CoCl2 was employed for stable biochemical induction of 
in vitro and in vivo hypoxia. Epstein et al. identified that cobalt ions can inhibit enzymatic 
degradation of HIF1a in the presence of oxygen by inactivating prolyl hydroxylases 
involved in proteasomal degradation of HIF1a [37]. The underlying mechanisms are not 
fully understood, but it has been suggested that cobalt replaces iron at the core of prolyl 
hydroxylase, which is essential for enzymatic activity. Additional evidence proposed by 
Yuan et al. suggested that cobalt inhibits the interaction between HIF1α and von Hippel-
Lindau tumor suppressor protein (VHL) by direct binding to the VHL-binding domain of 
HIF1α, thereby preventing the degradation of HIF1α [38]. Since biochemical induction 
using CoCl2 can stably mimic hypoxia without being affected by the presence of oxygen, 
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this method could enable facile molecular characterization of cancer dormancy that could 
not be performed in hypoxic chambers.  
 
1.3.3. Biomaterials to study hypoxic regulation of cancer dormancy 
Different in vitro and in vivo models of hypoxia-induced tumor dormancy can be 
also achieved by using biomaterials. In recent years, there has been a growing interest in 
utilizing components typically employed in tissue engineering (e.g., biomaterial scaffolds, 
hydrogels) to study the tumor microenvironment and its role in governing tumor dormancy. 
Fang et al. discovered that culturing cells in 3D hydrogel systems that limit the access of 
oxygen and nutrients can lead to reduced cell proliferation and quiescence [39]. When 
cancer cells were encapsulated in a transglutaminase-crosslinked gelatin gel (Col-gel) for 
a few days, gradually decreasing diffusion of nutrients and oxygen toward the center of the 
Col-gel induced quiescence or necrosis of encapsulated cells at the center, while higher 
proliferation of cells in the peripheral region of the gel was observed. Another study by 
Fluegen et al. used an implantable nano-intravital device that can deliver a sustained dose 
of DFO in defined microenvironments of solid tumors to mimic local hypoxia in vivo [29]. 
Delivery of DFO using the device implanted near the primary tumor was able to upregulate 
both hypoxia markers HIF1a and GLUT1 as well as dormancy markers DEC2, NR2F1, 
and p27 in a reversible manner.  
While previous biomaterial-based systems have focused on recapitulating 
dormancy in primary tumor hypoxia, hypoxia also affects DTCs at metastatic sites, playing 
a critical role in dormancy of DTCs upon arrival. However, hypoxic regions within 
metastatic sites in the body are difficult to access with current imaging techniques. In 
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addition, there has been no experimental platform that allows investigation of how hypoxia 
induces and maintains dormancy at metastatic sites. As a consequence, many questions 
including why a hypoxic metastatic niche harbors dormant tumor cells and what causes 
cells to reawaken remain unsolved. To address this issue, poly(lactide-co-glycolide; PLG) 
scaffolds were used in combination with CoCl2 in this dissertation. PLG scaffolds were 
previously shown to recruit metastatic cancer cells when implanted in mice by 
recapitulating the immune microenvironment of the metastatic niche, which is a key to 
tumor cell homing to secondary metastatic sites [40]. In addition, PLG scaffolds have been 
used for local delivery of various molecules in vivo [41]. Thus, PLG scaffolds that release 
CoCl2 could establish an in vivo hypoxic niche that recruits metastatic cancer cells, 
enabling us to investigate mechanisms underlying hypoxic regulation of cancer dormancy 
at metastatic sites.  
 1.4. Dormancy is linked to chemoresistance in ovarian cancer metastasis 
At the cellular level, ovarian 
cancer metastasis begins when tumor 
cells are shed into the peritoneal cavity, 
where they exist in suspension as 
multicellular spheroids [6]. The 
dissemination of ovarian cancer spheroids 
leads to the accumulation of large 
quantities of ascites, a malignant body 
fluid commonly developed in advanced 
ovarian cancer patients, in the peritoneal 
cavity [42]. Once suspended in ascites, 
Figure 1-4. Dissemination of ovarian cancer spheroids 
from the primary tumor in ovarian cancer metastasis. 
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the disseminated ovarian cancer spheroids flow throughout the peritoneal cavity and seed 
the formation of secondary metastatic lesions (Fig. 1-4) [6,42]. 
As mentioned above, ovarian cancer has spread beyond the ovaries by the time of 
diagnosis in the majority of cases. Treatment options for ovarian cancer are much more 
limited than for breast cancer, with cytoreductive surgery platinum/taxane-based 
chemotherapy being the only treatment option for most patients. However, 20-30% of 
patients exhibit recurrence within 6 months of completing treatment, indicating that the 
cancer was chemoresistant [43], and frequent recurrence in patients with advanced disease 
remains a therapeutic challenge. For recurrent ovarian cancer, treatment options become 
even more limited as chemotherapy becomes ineffective. Thus, developing a novel 
therapeutic strategy that provides an alternative to destroy chemoresist cells as well as 
understanding the biology of chemoresistance have been urgent needs in ovarian cancer 
treatment.   
Although mechanisms underlying the development of chemoresistance are still 
unclear, accumulating evidence has linked chemoresistance to dormancy in ovarian cancer. 
It has been suggested that a small subpopulation of dormant ovarian cancer spheroids 
persist during and after treatment of metastatic ovarian cancer, remain undetectable to 
current screening technologies, and evade chemotherapy [44,45]. These dormant spheroids 
can be reactivated when growth conditions become favorable, eventually seeding the 
formation of secondary metastatic lesions. Correa et al. discovered that tumor spheroids of 
ovarian cancer cell lines or spheroids isolated directly from patients’ ascites were able to 
enter a dormant state to evade chemotherapy [45]. The dormant spheroids arrested in the 
G0/G1 phase exhibited reduced AKT (protein kinase B) activity as well as increased 
expression of retinoblastoma-like protein 2 (RBL2) and p27 CDK inhibitor, both of which 
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increase in expression during G0/G1 arrest. Importantly, dormant spheroids suspended in 
ascites were able to reactivate upon adhesion to surfaces and reinitiate proliferation in an 
AKT-dependent manner, suggesting that dormant spheroids present in patient ascites retain 
their ability to seed and grow as secondary metastatic lesions. In fact, the presence of 
ovarian cancer spheroids in ascites has been a negative prognosis factor for patient outcome 
in ovarian cancer. Thus, therapeutic strategies to eliminate ovarian cancer spheroids 
evading chemotherapy could reduce metastatic recurrence in ovarian cancer.  
 
1.5. Therapeutic strategies to target ovarian cancer spheroids  
1.5.1. Integrin inhibitors  
Due to the unique metastatic pathway of ovarian cancer, in which the cells or 
spheroids detach from the primary ovarian tumor and disseminate throughout the peritoneal 
cavity by the flow of ascites, ovarian cancer rarely metastasizes beyond the peritoneal 
cavity. As the peritoneal cavity is lined by a continuous single layer of mesothelial cells, 
the mesothelial cell layer is the first layer which ovarian cancer spheroids adhere to. Thus, 
an increasing number of studies have been highlighting the importance of mesothelial 
adhesion of spheroids in ovarian cancer metastasis and therapeutic focus has been placed 
on disrupting the mesothelial adhesion to prevent reactivation of dormant cancer spheroids 
and formation of metastatic nodules.  
The adhesion of ovarian cancer spheroids to the mesothelial layer is mediated 
through interactions between surface adhesion receptors of spheroids such as integrins and 
ECM proteins on the mesothelial layer such as fibronectin and collagens [46]. Several 
integrins have been identified as important mediators of ovarian cancer metastasis to the 
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mesothelial layer [6], suggesting that use of integrin inhibitors could be a therapeutic 
strategy to prevent the adhesion of spheroids to the peritoneal cavity. For instance, Casey 
et al. demonstrated that blocking a5b1 integrin completely inhibited spheroid adhesion to 
ECM proteins including fibronectin, laminin, and type IV collagen, suggesting that the 
a5b1 integrin-fibronectin interaction is essential for the spheroid adhesion at sites of 
secondary tumor growth [47]. In addition, Iwanicki et al. reported that interfering with the 
interactions between a5b1 integrin and fibronectin can significantly decrease spheroid-
induced mesothelial clearance [48].  
Some integrin inhibitors have progressed to clinical studies. For instance, 
Volociximab, an anti-a5b1 integrin antibody showed increased overall survival with 
reduced metastases and tumor burden in a mouse xenograft model of ovarian cancer [49]. 
However, in a phase II clinical trial with platinum-resistant, advanced stage ovarian cancer 
patients, Volociximab was not efficacious and led to adverse events in most patients 
(NCT00516841) [50]. Despite great progress towards targeting integrins and the promising 
effectiveness of integrin inhibitors in preclinical studies, none of the approaches using 
integrin inhibitors has demonstrated evident clinical benefit thus far [49–51]. These 
findings suggest that multiple receptors and ligands support adhesion of ovarian cancer 
spheroids to the mesothelial layer and that targeting a single molecule (i.e. integrin) will 
be insufficient to disrupt the complex interactions between ovarian cancer spheroids and 
mesothelial cells.  
 
1.5.2. Potential use of biomaterials to eliminate ovarian cancer spheroids 
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 The primary use of biomaterials in ovarian cancer therapy has been as a drug carrier 
to improve targeted delivery of platinum-based drugs by preventing premature activation 
before reaching the site of action or to deliver other sensitizer molecules that exert cytotoxic 
effects upon external triggers such as light for tumor-specific treatment [52]. Though 
therapeutic strategies using biomaterials have not been employed to specifically target 
ovarian cancer spheroids, a wide variety of biomaterials including polymer micelles, 
liposomes, and graphene-based materials have been exploited for ovarian cancer therapy. 
Among these biomaterial carriers, graphene-based materials have become a potential 
candidate for ovarian cancer therapy owing to their exceptional physiochemical properties 
[52,53].  
Graphene is a one atom-thick densely packed network of 2D planar carbon atoms 
arranged in a hexagonal crystal lattice. Graphene-based materials exhibit different 
structural features, physicochemical properties, and biological responses based on the 
synthesis method [39]. Some examples of graphene-based materials include graphene 
nanoribbon (GNR), a ribbon-shaped graphene stack synthesized by unzipping multiwalled 
carbon nanotubes, and graphene oxide (GO), an irregularly or disk-shaped multilayered 
graphene nanoparticle synthesized from graphite. The hydrophobic planar structure of 
graphene with functional groups (e.g. epoxyl, carboxyl, hydroxyl groups) present on the 
planar surface and its edges allowing for covalent and noncovalent tethering of various 
amphiphilic functionalities to improve aqueous stability, biocompatibility, and even tumor 
targeting ability. In addition, the high surface area-to-mass ratio and the network of 
abundant hydrophobic pi bonds allow covalent and noncovalent functionalization 
strategies to increase loading of hydrophobic or aromatic anticancer drugs. Due to these 
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properties, functionalized forms of graphene-based materials are promising potential 
platforms for ovarian cancer therapy.  
A recent study by Tiwari et al. reported that polyvinylpyrrolidone (PVP)-
functionalized GO (GO-PVP) can be used as a carrier for anticancer drug cocktails 
composed of quercetin and gefitinib for ovarian cancer treatment [54]. The study revealed 
that the combined drug system loaded on the GO-PVP was significantly more effective 
than free drugs toward PA-1 ovarian cancer cells. Another study by Choi et el. reported 
that reduced GO–silver nanoparticle nanocomposites (rGO–Ag) can be used to selectively 
kill highly tumorigenic ALDH+CD133+ ovarian cancer stem cells by inducing the 
generation of toxic reactive oxygen species (ROS) as well as mitochondrial dysfunction 
[55]. Moreover, when combined with Salinomycin, a drug targeting cancer stem cells, 
rGO-Ag induced synergistic effects with up to 5-fold higher levels of apoptosis than 
Salinomycin alone, suggesting that rGO-Ag can be used in combination with 
chemotherapy. While these approaches have shown promising outcomes in ovarian cancer 
treatment, off-target damage in healthy tissues due to enhanced toxic effects are still a 
challenge to be addressed.  
Recently, considerable research has been directed toward developing tumor-
specific treatment with external triggers by which the therapeutic toxicity is generated only 
at the tumor site while the normal tissue or organ experiences minimal damage. Graphene-
based materials have been widely used for photodynamic therapy (PDT) which uses 
photosensitizers that absorb incident light to generate toxic ROS. Multiple groups have 
reported that the chlorin e6 (Ce6) photosensitizer loaded onto GO functionalized with folic 
acid or polyethylene glycol (PEG) could be used for tumor targeting therapy [56,57]. Their 
results showed that Ce6 loaded onto GO can be activated by photo irradiation and kill 
 17 
MGC803 human gastric cancer and nasopharyngeal epidermal carcinoma KB cells with 
negligible toxicity without light irradiation. Sonodynamic therapy (SDT) using ultrasound 
and sonosensitizers that generate toxic ROS upon ultrasound irradiation has also emerged 
as an alternative method to PDT since the low tissue-penetrating depth of light in PDT 
hinders the treatment of deep-seated tumors. In a recent report by Dai et al., reduced GO 
(rGO) loaded with a TiO2 sonosensitizer enhanced SDT efficacy against cancer by taking 
advantage of the ultrathin planar nanostructure and abundant surface chemistry of rGO 
nanosheets [58]. Repeated SDT using rGO-TiO2 could completely eradicate 4T1 breast 
tumor in nude mice without obvious recurrence over 2 weeks, while PDT or sensitizer 
alone exhibited rapid growth of tumor volume. While using treatment with external triggers 
has not been reported for ovarian cancer, these results from previous in vitro and in vivo 
investigations provide evidence that graphene-based materials can be utilized for 
photodynamic- and sonodynamic-based cancer therapy.  
 
1.6. Overview of work completed in this dissertation 
The scope of this dissertation is to establish in vitro and in vivo experimental 
platforms that enable investigation of cancer dormancy under hypoxic microenvironments 
in the primary tumor and metastatic target organs as well as to develop an alternative 
therapeutic strategy to destroy cancer cells evading chemotherapy to prevent metastatic 
recurrence. Chapter 2 will focus on an in vitro experimental platform using CoCl2 to study 
breast and ovarian cancer dormancy under hypoxia. In Chapter 3, an in vivo experimental 
platform using PLG scaffolds with CoCl2 to study hypoxic regulation of cancer dormancy 
at metastatic sites will be discussed. Chapter 4 presents a novel therapeutic strategy to 
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target ovarian cancer spheroids that are known to evade chemotherapy by using graphene-
based materials for sonodynamic therapy. Future directions that warrant further study will 
be discussed in Chapter 5.  
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Chapter 2 – In vitro platform to study cancer dormancy under 
hypoxia using CoCl2 
 
Adapted with permission from “Lee, HR., Leslie, F., and Azarin, S.M. A facile in vitro 
platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2. 




During tumor progression, some disseminated tumor cells (DTCs) are capable of 
surviving in a prolonged quiescent state [59]. These dormant cells can reside at secondary 
sites without any clinical evidence for months to years before reawakening and causing 
metastatic recurrence [60,61], as evidenced by the large fraction of cancer patients who 
exhibit an asymptomatic period before metastatic relapse [59,62]. Developing strategies to 
destroy these dormant DTCs will require a better understanding of their unique biological 
characteristics, as they are able to evade current chemotherapeutic approaches that target 
rapidly dividing cells. It has been postulated that DTC dormancy could be induced by 
microenvironmental stresses encountered by the cells either within the primary tumor prior 
to dissemination or upon arrival at a secondary site [59,63]. Over the past few decades, 
significant effort has been directed toward understanding how microenvironmental cues 
regulate cancer dormancy [61,64,65]. However, the lack of suitable platforms to induce 
and maintain dormancy has limited the ability to probe the switch between dormant and 
active states in cancer cells. 
Accumulating evidence in multiple types of cancer has revealed that dormant DTCs 
are detected in the bone marrow at a particularly high rate, suggesting that DTCs favor 
bone marrow despite its hostile microenvironmental conditions such as hypoxia and 
hypoglycemia [61,66]. Previous analysis of breast cancer cells has identified several genes 
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involved in dormancy that are regulated by hypoxia [67,68]. In addition, a recent study 
found that hypoxic microenvironments in the primary tumor give rise to a subpopulation 
of DTCs programmed to become dormant [25]. However, the precise role of hypoxia in 
regulating dormancy remains poorly understood due to a lack of well-established in vivo 
and in vitro models. Hypoxia studies are typically performed using incubation chambers 
that maintain an oxygen depleted environment through regulation of gas composition in 
the chamber [36,69]. These chambers limit the range of conditions that can be evaluated in 
an individual study, and the cells quickly establish normoxia each time they are removed 
for manipulation. In vivo models have the advantage of recapitulating the complex 
microenvironment of the tumor or metastatic site, but dormant cells are rare and thus it is 
difficult to identify and isolate them in vivo. In addition, regulation of hypoxia in vivo 
requires placement of mice in hypoxia chambers, which limits study size and also tunability 
of the hypoxic environment. In vitro models also present challenges, as the cells must be 
maintained in both hypoxic and dormant states, both of which are relatively unstable, 
during characterization. Thus, we sought to develop a robust in vitro model capable of 
stably inducing and maintaining dormancy of cancer cells under hypoxic 
microenvironments.  
In this work, CoCl2, a well-known hypoxia-mimetic agent, was used to establish 
hypoxia-mimicking microenvironments in vitro. The response to hypoxia is generally 
characterized by expression of the heterodimeric hypoxia induction factor 1 (HIF1) protein 
that consists of two subunits: HIF1α and HIF1β. HIF1β is constitutively expressed in the 
nucleus, whereas HIF1α is regulated by oxygen tension. It has been shown that the HIF-
specific prolyl hydroxylases that facilitate HIF1α degradation have an iron-binding core, 
and the iron at this core is thought to be essential for their enzymatic activities [70]. This 
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iron can be replaced by cobalt, resulting in the inhibition of HIF1α degradation [70]. In 
addition, cobalt inhibits the interaction between HIF1α and von Hippel Lindau (VHL) 
protein, another protein involved in HIFα degradation, thereby preventing the degradation 
of HIF1α [38]. Since CoCl2 mimics hypoxia by stabilizing HIF1α expression regardless of 
oxygen levels, this method has the advantage of being more stable than conventional 
hypoxic chambers. In addition, it has been demonstrated that CoCl2 and true hypoxia result 
in similar regulation of hypoxia-related downstream targets such as erythropoietin and 
glucose transporter 1 (GLUT1) [71–73]. It has been documented that CoCl2 can be used to 
mimic hypoxia in multiple cancer cell lines including breast and ovarian cancer cells 
[74,75]. While the ability of CoCl2 to mimic hypoxic conditions in cancer cells has been 
established, it has not yet been demonstrated that the induction of dormancy in cancer cells 
lines in response to hypoxia can be recapitulated by CoCl2. 
 In this manuscript, we evaluate whether CoCl2-induced hypoxia-mimicking 
microenvironments can trigger and maintain dormancy in vitro in breast and ovarian cancer 
cell lines, with cancer dormancy defined as reversible quiescence throughout this report. 
Moreover, we show that CoCl2 affects tumor dormancy directly through HIF1α 
stabilization by investigating effects of CoCl2 on MCF-7 cells containing knockdown of 
HIF1α expression. In addition, we investigate whether the cellular response to CoCl2 
recapitulates the differential response to true hypoxia in estrogen receptor (ER)-positive 
and ER-negative breast cancer cells, which exhibit different dormancy signatures in vivo 
[67], to further validate our model. This CoCl2-based model offers a facile tool for detailed 
investigation of cancer dormancy under hypoxic conditions, which could serve as an 




2.2. Materials and Methods 
Cell culture and growth analysis. The human breast cancer cell lines, MCF-7 and MDA-
MB-231 (ATCC), were maintained in Dulbecco’s Modified Eagle’s Media (DMEM, 4500 
mg/L glucose, Sigma Aldrich) supplemented with 10% (v/v) fetal bovine serum (FBS; 
Thermo Fisher Scientific) and 1% (v/v) penicillin-streptomycin (PS; Thermo Fisher 
Scientific). The human ovarian cancer cell line, OVCAR-3 (ATCC), was cultured in 
Roswell Park Memorial Institute 1640 (RPMI 1640) media supplemented with 10% (v/v) 
FBS, 1% (v/v) PS (Thermo Fisher Scientific), and 0.001% (w/v) bovine insulin (Sigma 
Aldrich). For cell growth analysis, cells were seeded at a density of 1×105 cells per well in 
6-well plates or 35mm dishes. Prior to counting, cells were singularized using 0.25% 
trypsin-EDTA (Thermo Fisher Scientific) and treated with a 1:1 ratio of Trypan blue 
(Thermo Fisher Scientific), after which the live cell number was determined using a 
Countess II FL automated cell counter (Thermo Fisher Scientific).  
 
Generation of cell aggregates and encapsulation of cells for three-dimensional (3D) 
models. Cell aggregates were generated using non-adhesive poly(2-hydroxyethyl 
methacrylate; pHEMA, Sigma Aldrich)-coated plates. pHEMA was dissolved in 95% 
ethanol to a final concentration of 3 mg/ml and sterile-filtered. The pHEMA solution was 
added to cell culture plates, which were left to dry overnight at room temperature. Cells 
were seeded in the pHEMA-coated plates at a density of 5×104 cells/cm2 for aggregate 
generation. Collagen gels were prepared by diluting collagen type I (rat tail, Corning) with 
cell culture media to a final concentration of 2.5 mg/ml and neutralizing with 1N sodium 
hydroxide (Sigma Aldrich). Cells were mixed with the diluted collagen solution at a density 
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of 5×106 cells/ml, and 100 µl of the solution was plated in 35mm dishes and gelled at 37°C 
for 30 minutes. In order to harvest cells for characterization, cell aggregates were 
singularized by StemPro Accutase (Gibco) for 15 minutes with gentle pipetting, and 
collagen gels were dissociated by collagenase type 1 (Sigma Aldrich) for 15 minutes at 
37°C.  
 
CoCl2 treatment and exposure to true hypoxia. For 2D cultures, treatment with CoCl2 
or true hypoxia was initiated when cells reached 50% confluence. For 3D cultures, 
treatment with CoCl2 or true hypoxia was initiated immediately after cells were seeded in 
pHEMA-coated plates or embedded in collagen gels. For CoCl2 treatment, CoCl2 (Sigma 
Aldrich) was dissolved in distilled water and sterile-filtered. The resulting aqueous CoCl2 
solution was directly added to the cell culture media. Hypoxic culture was performed by 
incubating cells with 0.1% O2 and 5% CO2 in the EVOS FL Auto on-stage incubator 
(Thermo Fisher Scientific). 
 
Cell cycle analysis. Cells cultured for the indicated time periods were singularized using 
0.25% trypsin-EDTA (Thermo Fisher Scientific) and fixed with 70% ethanol for 1 hour at 
-20 °C. Then, cells were stained with 50 µg/mL propidium iodide (PI; Thermo Fisher 
Scientific) for 30 minutes in the dark at room temperature. Flow cytometric analysis of PI 
staining intensity was performed using a LSR II flow cytometer (BD Biosciences), and 
data were analyzed using Modfit LT software (Verity Software House) to determine cell 
cycle distribution.  
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Immunofluorescence assays. Cells grown on glass-bottom dishes or well plates were 
fixed with 4% paraformaldehyde for 10 minutes at room temperature. Cells embedded in 
collagen gels or cell aggregates grown in pHEMA-coated plates were fixed for 20 minutes 
at room temperature. Blocking and permeabilization were performed in blocking buffer, 
phosphate buffered saline (PBS) containing 10% Normal Goat Serum (Thermo Fisher 
Scientific) and 0.3% Triton X-100 (Sigma Aldrich), for 1 hour. Then, the cells were stained 
with rabbit anti-human Ki67 (D3B5; 1:400 dilution, Cell Signaling Technology), mouse 
anti-human HIF1α (54/HIF1α, 1:200, BD Biosciences), or mouse anti-human GLUT1 
(SPM498, 1:200, Thermo Fisher Scientific) in antibody dilution buffer, PBS containing 1% 
bovine serum albumin (Sigma Aldrich) and 0.3% Triton X-100, overnight at 4 °C. Next, 
cells were labeled for 1 hour at room temperature with corresponding secondary antibodies: 
goat anti-rabbit Alexa Fluor 594 (1:1000, Thermo Fisher Scientific) for Ki67, goat anti-
mouse Alexa Fluor 647 (1:1000, Thermo Fisher Scientific) for HIF1α, and goat anti-mouse 
Alexa Fluor 488 (1:1000, Thermo Fisher Scientific) for GLUT1. Nuclei were labeled with 
DAPI (300 nM, Thermo Fisher Scientific). Samples were imaged using an EVOS FL Auto 
fluorescence microscope, with the same light intensity and exposure time applied across 
all samples. Quantification was performed with ImageJ software (National Institutes of 
Health). 
 
Western blotting. For protein extraction, cells were washed twice with ice-cold PBS and 
lysed using RIPA buffer (Thermo Fisher Scientific). Whole cell lysates were separated on 
a SDS-PAGE gradient gel (4-15%) and transferred to a polyvinylidene difluoride (PVDF) 
membrane (Bio-Rad). HIF1α, p21, p27, p38 mitogen-activated protein kinase (MAPK), 
phospho-p38 (pp38) MAPK, extracellular signal-regulated kinase (ERK(1/2)), and 
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phospho-ERK(1/2) (pERK(1/2)) were detected in 30 µg of whole cell lysates. β-actin was 
detected in 10 µg of whole cell lysates. The membranes were blocked in 5% non-fat dry 
milk (Bio-Rad) or bovine serum albumin (Sigma Aldrich) in Tris-buffered saline 
containing 0.05% Tween-20 (TBS-T; Sigma Aldrich) at room temperature for 1 hour.  Next, 
the membranes were incubated with mouse anti-human HIF1α primary antibody 
(54/HIF1α, 1:1000, BD Biosciences) for 2 hours or HRP (horseradish peroxidase)-
conjugated β-actin (13E5, 1:2000, Cell Signaling Technology) for 1 hour at room 
temperature. For p21, p27, p38 MAPK, pp38 MAPK, ERK(1/2), and pERK(1/2), the 
membranes were incubated with rabbit anti-human p21 primary antibody (12D1), rabbit 
anti-human p27 primary antibody (D69C12), rabbit anti-human p38 MAPK primary 
antibody, rabbit anti-human pp38 MAPK primary antibody, rabbit anti-human ERK(1/2) 
primary antibody and rabbit anti-human pERK(1/2) primary antibody (1:1000, Cell 
Signaling Technology) overnight at 4 °C. For HIF1α blots, the membrane was incubated 
with goat anti-mouse polyclonal HRP-conjugated secondary antibody (1:10000, Thermo 
Fisher Scientific) at room temperature for 45 minutes. For p21, p27, p38 MAPK, pp38 
MAPK, ERK(1/2), and pERK(1/2),  goat anti-rabbit polyclonal HRP-conjugated secondary 
antibody (1:2000, Cell Signaling Technology) was used. Protein expression was detected 
using SuperSignal West Pico Chemiluminescent substrate (Thermo Fisher Scientific) and 
a ChemiDoc Imager (Bio-Rad). Western blot quantification was performed by ImageLab 
(Bio-Rad). The p38 to ERK activity ratio was calculated as previously reported [76]. 
Briefly, quantified values for pp38 MAPK were divided by the values for total p38 MAPK 
and the same was done for pERK(1/2) and ERK(1/2). Then, the pp38 MAPK/p38 MAPK 
ratio value was divided by pERK(1/2)/ERK(1/2) ratio value.  
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Cell viability assays. The cell viability under CoCl2 treatment was measured using a 
Live/Dead Viability/Cytotoxicity Kit (Thermo Fisher Scientific). For this assay, 1×105 
cells per well were seeded in 6-well plates. After the indicated periods of CoCl2 treatment, 
cells were washed with PBS twice and incubated with 2 µM calcein AM and 4 µM ethidium 
homodimer-1 for 30 minutes at room temperature. Imaging was performed using an EVOS 
FL Auto fluorescence microscope.  
 
HIF1α knockdown in MCF-7 cells. For HIF1α suppression in MCF-7 cells, a HIF1α-
specific shRNA construct in a lentiviral GFP vector was used (5' 
ACAAGAACCTACTGCTAATGCCACCACTA 3', OriGene, TL320380D). A non-
effective scrambled shRNA cassette (5' GCACTACCAGAGCTAACTCAGATAGTACT 
3',  OriGene, TR30021) was used as a negative control. To produce lentiviral particles, 
human embryonic kidney 293T cells (HEK293T; kindly provided by Dr. Benjamin Hackel) 
were transfected with HIF1α-specific shRNA constructs and the Lenti-Vpak packaging kit 
(OriGene, TR30037) in Opti-MEM I (Thermo Fisher Scientific). Lentiviral particles were 
collected 24 hours after transfection and filtered through a 0.45 µm syringe filter (Merck 
Millipore). For transduction, MCF-7 cells were transduced with the lentiviral particles for 
24 hours in DMEM containing 10% FBS and polybrene (8 µg/mL, Sigma Aldrich). 
Selection of successfully transduced cells was achieved by exposing the cells to DMEM 
containing 10% FBS and 0.5 µg/mL puromycin (Life Technologies) for one week, with 
media changes performed every 2-3 days. 
 
Quantitative Real-time PCR (qRT-PCR). qRT-PCR was performed using a CFX 
Connect Real-Time PCR Detection System (Bio-Rad). Total RNA was extracted from cells 
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using a RNeasy Mini kit (Qiagen) followed by cDNA synthesis through the reverse 
transcription of 1 µg of total RNA using an Omniscript RT kit (Qiagen) according to the 
manufacturer’s protocol. Quantitative PCR reactions were performed using iTaq Universal 
SYBR Green Supermix (Bio-Rad) and PrimePCR SYBR Green Assays (Bio-Rad) with 
primers specific to each of the target mRNAs: CDKN1A (qHsaCID0014498), CDKN1B 
(qHsaCID0012509), CDK2 (qHsaCED0043984), CDK4 (qHsaCED0003626), CCNA2 
(qHsaCID0017452), CCND1 (qHsaCID0013833), CCNE1 (qHsaCID0015131), and MYC 
(qHsaCID0012921). TBP (TATA-box binding protein, qHsaCID0007122) was used as 
reference gene.  
 
Senescence-Associated b-galactosidase assay. b-galactosidase activity was measured 
using the Senescence β-Galactosidase Staining Kit (Cell Signaling Technology). Briefly, 
cells were washed with PBS and fixed with 1x fixative solution for 15 minutes. Then, β-
galactosidase staining solution with a final pH between 5.9 and 6.1 was prepared and added 
to fixed cells. Samples were sealed with parafilm to prevent evaporation and placed in a 
dry 37 °C incubator overnight. Imaging was performed using an EVOS FL Auto 
fluorescence microscope. For the positive control, cells were treated with 12.5 µM 
etoposide (Cell Signaling Technology) for 6 days and allowed to recover for 2 days in 
normal growth media.  
 
Statistical Analysis. All data are represented as mean ± SD of three biological replicates 
from one of three representative independent experiments. P values were determined using 
an unpaired Student’s t-test, with P<0.05 considered to be statistically significant. 
Statistical analysis was performed using GraphPad Prism.  
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2.3. Results 
2.3.1. CoCl2 treatment inhibits proliferation of MCF-7 cells 
To explore the growth dynamics of MCF-7 cells under hypoxia-mimicking 
conditions induced by CoCl2 treatment, MCF-7 cells were exposed to various 
concentrations of CoCl2 (50-500 µM). Hypoxia-mimicking effects of CoCl2 were verified 
under tested concentrations through comparison to true hypoxic conditions (0.1% O2) by 
immunofluorescence analysis of HIFα and GLUT1 (Fig. 2-1A). Inhibition of MCF-7 
proliferation without significant cell death was observed in a dose-dependent manner up to 
300 µM and maintained for approximately 20 days under CoCl2 treatment (Fig. 2-1B, C). 
At doses of 1 mM or higher, toxicity led to significant cell death, whereas doses lower than 
50 µM did not result in distinguishable changes in cell growth (data not shown). 
Importantly, Ki67 (a cellular marker for actively cycling cells) was markedly attenuated in 
MCF-7 cells showing restrained growth under CoCl2 treatment (Fig. 2-1B), implying that 
growth inhibition is in part attributed to emergence of a quiescent population of MCF-7 
cells. In addition, the attenuated Ki67 expression and restrained growth of MCF-7 became 
more noticeable at 300 µM CoCl2 than 100 µM CoCl2, indicating the dose-dependent 
cellular response of MCF-7 to CoCl2 treatment. Consistent with the restrained growth and 
attenuated Ki67 expression, during CoCl2 treatment a significant increase in the cell 
population arrested in G0/G1 phase, a hallmark of the quiescent state, was observed 
through flow cytometric analysis of propidium iodide (PI) staining. In MCF-7 cells treated 
with 300 µM CoCl2 for 6 days, 82.2 ± 0.1% of the cells were in G0/G1 phase, as compared 
to 55.0 ± 1.7% prior to CoCl2 treatment (Fig. 2-1C). In addition, the population in S phase 
decreased from 32.6 ± 0.9% to 7.1 ± 0.3% after 6 days of CoCl2 treatment (Fig. 2-1C). 
Taken together, the restrained growth in conjunction with downregulation of Ki67, actively 
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present in G1, S, G2 and M phases of the cell cycle but absent in G0 phase [77,78], and 
accumulation of cells in the G0/G1 phase by PI analysis demonstrate that at doses which 
increase HIF1α expression, CoCl2-induced hypoxia-mimicking conditions can trigger 
dormancy in MCF-7 cells. 
 
Figure 2-1. CoCl2-induced hypoxia-mimicking conditions can lead to prolonged growth inhibition in 
MCF-7 cells. (A) Representative fluorescence images of HIF1α (red) and GLUT1 (green) expression in 
MCF-7 cells after 72 hours of treatment with 300 µM CoCl2 or 0.1% O2 compared to untreated control 
cells. Nuclei were stained with DAPI (blue). Scale bars indicate 200 µm. (B,C) Cell growth (B) and cell 
cycle distribution analysis using flow cytometry (C) of MCF-7 cells. Flow cytometry data were analyzed 
by Modfit LT software (* P < 0.001 compared to untreated control). (D) Representative fluorescence 
images of cell cycling marker Ki67 (red) expression in MCF-7 cells treated with 100 and 300 μM 
CoCl2 for 6 days compared to untreated control cells (day 6 of culture). Nuclei were stained with DAPI. 
Scale bars indicate 200 μm. (E) Live/dead images of MCF-7 cells after 72 hours of treatment with 
varying concentrations of CoCl2. Scale bars indicate 400 µm.  
 
2.3.2. Dormant cells resume proliferation upon removal of CoCl2  
Unlike senescent cells, which are permanently trapped in a non-proliferative state, 
a hallmark of dormant cancer cells is the ability to reawaken upon removal of the 
environmental stresses that led them to enter dormancy, defined as reversible quiescence 
in this study [79,80]. Thus, we determined whether the cell growth inhibition under CoCl2 
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treatment could be reversed. To this end, MCF-7 cells were treated with 300 µM CoCl2 for 
6 days (from day 4 to day 10 of cell culture) followed by recovery in the normal growth 
media (from day 10 to day 16, Fig. 2-2). Cell growth analysis showed that while 
proliferation was restrained during the 6-day CoCl2 treatment period, cells resumed growth 
after removal of CoCl2 (Fig. 2-2A), providing further evidence that growth-arrested cells 
under CoCl2 treatment were dormant and not senescent. Reversible quiescence of MCF-7 
cells under CoCl2 treatment was also observed by Ki67 immunofluorescence analysis (Fig. 
2-2B). The 6-day exposure to 300 µM CoCl2 led to significant loss of Ki67 expression 
in the majority of MCF-7 cells (Fig. 2-2B, top right) as compared to control cells prior to 
treatment. After 12 days of CoCl2 treatment without recovery, Ki67-positive cells were 
hardly seen, suggesting that most cells under prolonged hypoxia-mimicking conditions 
remained dormant (Fig. 2-2B, bottom left). When cells recovered from CoCl2 treatment for 
6 days, expression of Ki67 increased, indicating that cells were re-entering a proliferative 
state (Fig. 2-2B bottom right). Flow cytometric analysis following PI staining also 
confirmed reversible quiescence of MCF-7 cells under CoCl2-induced hypoxia-mimicking 
conditions. After 6 days of recovery in normal growth media following CoCl2 treatment, 
the percentage of cells arrested in G0/G1 decreased from 88.0 ± 1.2% at day 10 to 53.0 ± 
0.4% at day 16, while the percentage of cells in S phase increased from 6.3 ± 0.1% to 30.9 
± 0.2% (Fig. 2-2C). This transient growth arrest of MCF-7 cells under CoCl2 treatment 
indicates that MCF-7 cells were in a dormant state, as opposed to a senescent state. To 
further demonstrate that the cells were not senescent, we evaluated senescence-associated 
β-galactosidase activity. MCF-7 cells treated with CoCl2 had low β-galactosidase activity 
similar to untreated cells, whereas MCF-7 cells treated with etoposide, a well-known 
inducer of cell senescence, exhibited higher β-galactosidase activity (Fig. 2-2D). 
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Collectively, these results confirm that MCF-7 cells under CoCl2-induced hypoxia-
mimicking conditions are dormant and resume proliferation when CoCl2 is removed. 
 
Figure 2-2. Quiescent MCF-7 cells can resume growth upon removal of CoCl2. (A) Cell growth 
analysis of MCF-7 cells treated with 300 μM CoCl2 for 6 days (from day 4 to day 10) compared to 
untreated control cells. Cells recovered in normal growth media after the 6-day 
CoCl2 treatment. (B) Representative fluorescence images of cycling marker Ki67 (red) and nuclei (blue) 
in MCF-7 cells. Scale bars indicate 200 μm. (C) Flow cytometric analysis of PI staining intensity in 
MCF-7 cells treated with 300 µM CoCl2 for 6 days (from day 4 to day 10), followed by recovery (from 
day 10 to day 16), compared to untreated control at day 4. Cell populations are reported as percentage 
of cells in each phase. Data were analyzed by Modfit LT software (* P < 0.01 compared to untreated 
control (day 4); # P < 0.01 compared to 6-day CoCl2 treatment (day 10)). (D) Representative bright field 
images of MCF-7 cells stained with β-galactosidase in each condition: untreated, 6-day 300 µM CoCl2 
treatment followed by 2-day recovery in normal growth media, and 6-day 12.5 µM etoposide treatment 
followed by 2-day recovery in normal growth media (positive control). 
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2.3.3. Induction of dormancy by CoCl2 is similar to true hypoxia.  
We subsequently compared cell responses under true hypoxic conditions and CoCl2 
treatment to confirm that dormancy hallmarks of MCF-7 cells under CoCl2 and true 
hypoxia are similar. To this end, MCF-7 cells were exposed to 300 µM CoCl2 or true 
hypoxic conditions (0.1% O2). Cell growth analysis demonstrated similar inhibition of cell 
growth during the treatment period (Fig. 2-3A). During recovery, cells in both conditions 
resumed growth upon removal of either CoCl2 or true hypoxia. The short delay observed 
in CoCl2 treatment, but not in true hypoxia, could be attributed to the extended time 
required for elimination of residual CoCl2 that has visibly accumulated within the cells, 
delaying recovery from hypoxia-mimicking conditions even after CoCl2 has been removed 
from the culture media. Immunofluorescence analysis further supported that both 
conditions led to similar responses, with exposure to 300 µM CoCl2 and 0.1% O2 both 
leading to attenuated expression of Ki67 (Fig. 2-3B). Flow cytometric analysis of PI 
staining further demonstrated that both conditions led to a significant increase in the cell 
population arrested in G0/G1 phase, 80.0 ± 2.2% under true hypoxia and 92.5 ± 0.7% under 
CoCl2 treatment (day 10), compared with 55.0 ± 1.8% in untreated MCF-7 cells (day 6; 
Fig. 2-3C). During normoxic recovery, a reduction in the arrested G0/G1 cell population 
was observed in both conditions, with 60.7 ± 3.2% G0/G1 phase cells in the population 
recovering from true hypoxia at day 12 and 64.0 ± 1.2% G0/G1 phase cells in the 
population recovering from CoCl2 treatment at day 14 (Fig. 2-3C), indicating that cells 
under both conditions exhibited reversible quiescence. The increase in the G0/G1 cell 
population at day 14 observed in cells recovering from true hypoxia could be attributed to 
contact inhibition, as cells recovered and proliferated rapidly, reaching confluence in the 
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culture dish. Collectively, these results show that the regulation of cancer dormancy under 
true hypoxic conditions can be mimicked by CoCl2.   
 
Figure 2-3. Induction of quiescence by CoCl2 treatment is similar to effects of true hypoxia. (A) Cell 
growth analysis of MCF-7 cells treated with 300 μM CoCl2 or true hypoxic conditions (0.1% O2) for 
4 days (from day 6 to day 10) compared to untreated cells. (B) Representative fluorescence images of 
Ki67 expression in MCF-7 cells after 6 days of exposure to 300 μM CoCl2 or 0.1% O2 compared to 
untreated control cells (day 6 of culture). Nuclei were stained with DAPI. Scale bars indicate 
200 μm. (C) Flow cytometric analysis of PI staining in cells exposed to true hypoxic conditions (0.1% 
O2, left) or 300 μM CoCl2 treatment (right). Cell populations are reported as percentage of cells in each 
phase. Data were analyzed by Modfit LT software (* P < 0.05 compared to untreated control (day 
6); # P < 0.05 compared to day 10 of the respective condition) 
 
2.3.4. Effects of CoCl2 on cancer dormancy result directly from modulation of HIF1α 
To verify that unknown effects of CoCl2, separate from HIF1α-stabilizing effects, 
were not responsible for induction of cancer dormancy, we tested whether CoCl2 could 
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induce dormancy in breast cancer cells in a HIF1α-independent manner. To this end, we 
knocked down HIF1α expression in MCF-7 cells using short hairpin RNA (shRNA).  MCF-
7 cells transduced with HIF1α-specific shRNA demonstrated significantly suppressed 
expression of HIF1α upon treatment with 300 µM CoCl2, as compared to MCF-7 cells 
transduced with shRNA containing a scrambled sequence (Fig. 2-4A, B).  
 
Figure 2-4. Induction of dormancy by CoCl2 is dependent on HIF1α. (A) Representative fluorescence 
images of HIF1α expression in MCF-7 cells transduced with HIFα-specific shRNA (bottom row) and 
scrambled shRNA (middle row) after 72 hours of treatment with 300 µM CoCl2 compared to untreated 
MCF-7 cells transduced with scrambled shRNA (top row). Nuclei were stained with DAPI. Scale bars 
indicate 200 µm. (B) Western blot analysis of HIF1α and β-actin expression in MCF-7 cells. Lanes 1-4 
represent untreated control (lane 1), MCF-7 cells treated with 300 µM CoCl2 for 72 hours (lane 2), 
HIF1α-silenced MCF-7 cells treated with 300 µM CoCl2 for 72 hours (lane 3), and MCF-7 cells treated 
with true hypoxia for 72 hours (0.1% O2, lane 4). (C) Cell growth analysis of HIF1α-suppressed MCF-
7 cells treated with 300 μM CoCl2 for 6 days (from day 4 to day 10) compared to untreated HIF1α-
suppressed MCF-7 cells. Treated and untreated MCF-7 cells transduced with shRNA containing a 
scrambled sequence served as additional control groups. (D) Representative fluorescence images of 
Ki67 (red) and nuclei (blue) in HIF1α-suppressed MCF-7 cells (top) and MCF-7 cells transduced with 
scrambled shRNA (bottom) after 4-day treatment with 300 μM CoCl2. Scale bars indicate 200 μm. 
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Furthermore, the growth of HIF1α-suppressed MCF-7 cells was less affected by 300 µM 
CoCl2 treatment than MCF-7 cells transduced with scrambled shRNA, suggesting that 
restrained growth of MCF-7 cells under CoCl2 is linked to the expression of HIF1α (Fig. 
2-4C). The slight reduction in growth rate observed in HIF1α-suppressed MCF-7 at later 
timepoints could result from incomplete knockdown efficiency, as HIF1α expression is 
observed in some cells following CoCl2 treatment (Fig. 2-4A). In addition, a significantly 
higher number of Ki67-positive cells was observed in HIF1α-suppressed MCF-7 cells after 
4 days of 300 µM CoCl2 treatment compared to MCF-7 cells transduced with scrambled 
shRNA (Fig. 2-4D). Collectively, these results demonstrate that the hypoxia-mimicking 
effects of CoCl2 are responsible for its ability to modulate cancer dormancy. 
 
2.3.5. CoCl2 treatment induces dormancy in ovarian cancer cells  
To confirm that the link between hypoxic microenvironments and cancer dormancy 
extends to other types of cancer, we subsequently investigated the ovarian adenocarcinoma 
cell line OVCAR-3 under CoCl2 treatment. OVCAR-3 cells were found to have higher 
sensitivity to CoCl2 than MCF-7 cells, showing similar hypoxic responses at 100 µM CoCl2 
to the MCF-7 response at 300 µM CoCl2 (Fig. 2-5). OVCAR-3 cells treated with 100 µM 
CoCl2 exhibited significant upregulation in HIF1α and GLUT1 expression compared with 
untreated cells, indicating that 100 µM CoCl2 generated an effective hypoxia-mimicking 
microenvironment in OVCAR-3 cultures (Fig. 2-5A). Furthermore, growth patterns similar 
to MCF-7 under both CoCl2 treatment and recovery were observed by cell growth analysis 
(Fig. 2-5B). In addition, Ki67 expression was markedly attenuated in cells showing 
restrained growth during CoCl2 treatment (Fig. 2-5C,D), with 28.4 ± 3.3% Ki67-positive 
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cells in CoCl2-treated populations, compared to 86.4 ± 2.8% in untreated populations. 
Importantly, reversible quiescence of OVCAR-3 cells was also observed by Ki67 
expression, with the percentage of Ki67-positive cells increasing from 28.4 ± 3.3% after 
CoCl2 treatment to 49.5 ± 3.7% after 6 days of recovery in normal growth media (Fig. 2-
5C,D). Flow cytometric analysis of PI staining provided further evidence of reversible 
quiescence, with the percentage of G0/G1 phase cells increasing from 62.6 ± 1.2% in 
untreated cells to 78.2 ± 0.4% under CoCl2 treatment and returning to 62.8 ± 0.7% after 6 
days of recovery in normal growth media (Fig. 2-5E). These results show that CoCl2 can 
also be used to induce and maintain dormancy in OVCAR-3 cells by establishing a 
hypoxia-mimicking microenvironment. 
 
Figure 2-5. CoCl2 treatment also induces dormancy in OVCAR-3 cells. (A) Representative 
fluorescence images of HIF1α (red) and GLUT1 (green) expression in OVCAR-3 cells after 72 h of 
100 μM CoCl2 treatment compared to untreated control cells. Scale bars indicate 200 μm. (B) Cell 
growth analysis of OVCAR-3 cells treated with 100 μM CoCl2 for 6 days (from day 6 to day 12) 
compared to untreated cells. Cells recovered in normal growth media after the 6-day 
CoCl2 treatment. (C) Percentages of Ki67-positive cells in untreated control, 6-day 100 μM 
CoCl2 treatment, and 6-day 100 μM CoCl2 treatment followed by 6-day recovery in normal growth 
media (* P < 0.001 compared to untreated control; # P < 0.001 compared to 6-day CoCl2 treatment). 
Quantification was performed with ImageJ software. (D) Representative fluorescence images of Ki67 
(red), GLUT1 (green) and nuclei (blue) in OVCAR-3 cells in untreated control, 6-day 100 μM 
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CoCl2 treatment, and 6-day 100 μM CoCl2 treatment followed by 6-day recovery in normal growth 
media. Scale bars indicate 200 μm. (E) Cell cycle distribution of OVCAR-3 after 6-day treatment with 
100 µM CoCl2, or 6-day treatment with 100 µM CoCl2 followed by 6-day recovery in normal growth 
media, compared to untreated control. Cell populations are reported as percentage of cells in each phase. 
Data were analyzed by Modfit LT software (* P < 0.05 compared to untreated control; # P < 0.05 
compared to 6-day CoCl2 treatment).  
 
2.3.6. CoCl2-induced hypoxia-mimicking conditions recapitulate heterogeneous 
cellular response to hypoxia in breast cancer cell lines  
It has been demonstrated that cellular responses to hypoxia vary depending on 
subtypes of cancer cells [25,81].  For example, unlike estrogen receptor (ER)-positive 
MCF-7 cells, hypoxic stress alone is not sufficient to induce dormancy in vitro in ER-
negative MDA-MB-231 cells [25].  
 
Figure 2-6. In vitro cellular responses to hypoxia in ER-negative MDA-MB-231 cells can be mimicked 
by CoCl2. (A) Cell growth analysis of MDA-MB-231 cells treated with CoCl2 (100, 300 and 500 μM) 
or true hypoxic conditions (0.1% O2) for 6 days (from day 2 to day 8) compared to untreated 
cells. (B) Representative fluorescence images of Ki67 (red; left column), HIF1α (red; right column), 
GLUT1 (green; right column), and nuclei (blue) in MDA-MB-231 cells after 4 days of treatment with 
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300 μM CoCl2 or 0.1% O2, compared to untreated control cells (day 2 of culture). (C) Live/dead images 
of MDA-MB-231 cells after 72 hours of CoCl2 treatment at varying concentrations. Scale bars indicate 
400 µm.  
 
Given that the in vitro cellular response of ER-positive MCF-7 cells to CoCl2 treatment 
matched that of true hypoxia, we hypothesized that the same would hold for ER-negative 
breast cancer cells. To evaluate this hypothesis, ER-negative MDA-MB-231 cells were 
tested with CoCl2 and true hypoxic conditions (0.1% O2). Growth curve analyses showed 
that unlike MCF-7 cells, MDA-MB-231 cells did not exhibit restrained cell growth under 
true hypoxic conditions (0.1% O2) (Fig. 2-6A). Although MDA-MB-231 cell growth was 
inhibited at higher doses of CoCl2, given the lack of reduction in Ki67 expression (Fig. 2-
6B) and the significant cell death observed (Fig. 2-6C), it is likely that the restrained cell 
growth can be primarily attributed to cell death, not induction of dormancy. 
Immunofluorescence analysis also showed that cellular responses of MDA-MB-231 to true 
hypoxia and CoCl2 treatment were similar. HIF1α expression was upregulated in both true 
hypoxia and CoCl2 treatment (Fig. 2-6B). In addition, no significant upregulation in 
GLUT1 was seen, and neither CoCl2 treatment nor exposure to true hypoxia led to a 
decrease in Ki67 expression (Fig. 2-6B). These results suggest that CoCl2 can recapitulate 
the in vitro cellular response to true hypoxia in heterogeneous breast cancer cell lines, 
further demonstrating the robustness of this platform for evaluating induction of breast 
cancer dormancy under hypoxia-mimicking microenvironments.   
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Figure 2-7. Differential hypoxic regulation of dormancy in MCF-7 and MDA-MB-231 cells can be 
recapitulated by CoCl2 in 3D culture models. (A-C) Representative fluorescence images of cycling 
marker Ki67 (red) and nuclei (blue) in MCF-7 cells embedded in collagen gels (A) or grown in pHEMA-
coated plates (B), and quantification of the percentage of Ki67-positive cells (C) in each condition: 
untreated, 3-day 300 μM CoCl2 treatment, and 3-day 300 μM CoCl2 treatment followed by 3-day 
recovery in normal growth media (* P < 0.001 compared to untreated control; # P < 0.005 compared to 
3-day CoCl2 treatment). (D-F) Representative fluorescence images of cycling marker Ki67 (red) and 
nuclei (blue) in MDA-MB-231 cells embedded in collagen gels (D) or grown in pHEMA-coated 
plates (E), and quantification of the percentage of Ki67-positive cells (F) in each condition: untreated, 
3-day 300 μM CoCl2 treatment, and 6-day 300 μM CoCl2 treatment. Quantification was performed with 
ImageJ software. Scale bars indicate 200 μm. 
 
 
2.3.7. 3D cell culture models using CoCl2 recapitulate cancer dormancy under 
hypoxia  
We also demonstrated that CoCl2 can be combined with 3D cell culture models to 
investigate cancer dormancy under 3D hypoxic microenvironments. For 3D models, cells 
were embedded in collagen gels or grown in non-adhesive pHEMA-coated plates. MCF-7 
and MDA-MB-231 cells cultured in 3D were found to have stabilized HIF1a expression 
in response to CoCl2, but only MCF-7 cells exhibited hallmarks of the dormant state, 
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consistent with our observations in in 2D culture. Ki67 expression in 3D-cultured MCF-7 
cells decreased from 75.6 ± 9.3% (pHEMA) or 77.2 ± 1.9% (collagen gel) to 21.3 ± 3.6% 
(pHEMA) or 23.0 ± 2.0% (collagen gel) after 3-day CoCl2 treatment, and recovered to 59.4 
± 7.3%  (pHEMA) or 57.2 ± 1.1% (collagen gel) following 3-day recovery in CoCl2-free 
normal growth media (Fig. 2-7A-C). Unlike MCF-7, MDA-MB-231 cells exhibited no 
significant change in Ki67 expression, which is also consistent with the results from 2D 
culture (Fig. 2-7D-F).  
 
Figure 2-8. Induction of quiescence under hypoxia can be recapitulated by CoCl2 in 3D cell culture 
models. (A,B) Flow cytometric analysis of PI staining in MCF-7 cells embedded in collagen gels (A) 
or grown in pHEMA-coated plates (B). Cells were exposed to 300 µM CoCl2 treatment (left) or true 
hypoxic conditions (0.1% O2, right). Cell populations are reported as percentage of cells in each phase. 
Data were analyzed by Modfit LT software (* P < 0.05 compared to untreated control; # P < 0.05 













































































































































Cell cycle analysis also demonstrated reversible quiescence of MCF-7 cells, with an 
increased percentage of cells arrested in G0/G1 phase under CoCl2 treatment compared to 
untreated cells, and release from G0/G1 phase upon removal of CoCl2 in both 3D culture 
models (Fig. 2-8). Importantly, these key features of the dormant state were also found in 
3D-cultured MCF-7 cells under true hypoxic conditions (0.1% O2), suggesting that the 3D 
CoCl2-based platform can also recapitulate cellular responses to hypoxia (Fig. 2-9).  
 
Figure 2-9. Differential Ki67 expression in response to true hypoxia is observed in MCF-7 and MDA-
MB-231 cells in 3D culture systems. Representative fluorescence images of Ki67 expression in MCF-
7 and MDA-MB-231 cells embedded in collagen gels (A) or grown in pHEMA-coated plates (B) in 
each condition: untreated, 3-day treatment with 0.1% O2, and 3-day treatment with 0.1% O2 followed 
by 3-day recovery in normal growth media (MCF-7 only). Nuclei were stained with DAPI. Scale bars 
indicate 200 µm. 
 
Furthermore, MCF-7 cells cultured in 2D and 3D systems under CoCl2 treatment exhibited 
similar key signaling features of dormant cells. Western blot analysis of p38 MAPK and 
ERK(1/2) activity showed that MCF-7 cells treated with CoCl2 for 6 days had an increased 
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reported as a signaling hallmark of the dormant state [76,82], in both 2D and 3D cultures 
(Fig. 2-10). These results suggest that the CoCl2-based platform is not limited to 2D culture 
but also can be combined with well-established 3D cell culture models to study cancer 
dormancy under hypoxic microenvironments.  
 
Figure 2-10. CoCl2-treated MCF-7 cells exhibit an increased p38 to ERK activity ratio, a signaling 
hallmark of dormant state, in both 2D and 3D models. (A) Western blot analysis of p38 MAPK, 
phosphorylated p38 (pp38) MAPK, ERK(1/2) and phosphorylated ERK(1/2) (pERK(1/2)) in MCF-7 
cells after 72 hours of CoCl2 treatment compared to untreated control in 2D and 3D (pHEMA-coated 
plate) cultures. (B) Quantification of p38 to ERK signaling activity ratios in 2D and 3D-cultured MCF-
7 cells from the western blot analysis, with results represented as mean ± SD of three independent 
experiments (* P < 0.001 compared to untreated control). 
 
2.3.8. CoCl2 treatment differentially regulates gene and protein expression in MCF-7 
and MDA-MB-231 cells  
To investigate possible molecular mechanisms that lead to differential responses to 
hypoxic microenvironments in MCF-7 and MDA-MB-231 cells, expression profiles of cell 
cycle-associated genes under CoCl2 treatment were examined. Protein and gene expression 
of the CDK inhibitor p27 (CDKN1B) showed no upregulation in response to CoCl2 
treatment in MCF-7 cells, while p21 (CDKN1A) was significantly upregulated by CoCl2. 
In contrast, no significant change in the expression of either p27 or p21 was observed in 
2D 3D





























MDA-MB-231 cells (Fig. 8A-C). p21 inhibits the cell cycle through inactivation of 
multiple CDK-cyclin complexes [33,83]:  CDK2-cyclin E (CCNE1), CDK2-cyclin A 
(CCNA2) and CDK4-cyclin D1 (CCND1). Accordingly, p21 upregulation was 
accompanied by downregulation of CDK2, CCNE1, CCNA2, CDK4, and CCND1 in MCF-
7 cells treated with CoCl2 (Fig. 8A). Furthermore, MYC, a proto-oncogene that plays an 
integral role in hypoxic adaptation [84], also exhibited differential expression, with 
significant downregulation in MCF-7 cells and upregulation in MDA-MB-231 cells upon 
treatment. These findings collectively suggest that CoCl2 treatment in MCF-7 and MDA-
MB-231 cells impacts different molecular mechanisms, giving rise to their distinct 
responses to CoCl2 treatment.  
 
Figure 2-11. MCF-7 and MDA-MB-231 cells exhibit differential gene and protein expression profiles 
in response to CoCl2 treatment. (A) Fold change in mRNA expression of CDKN1A, CDKN1B, CDK2, 
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untreated control (* P < 0.05 compared to untreated control). (B) Western blot analysis of HIF1α, p21, 
p27 and β-actin (control) expression in MCF-7 and MDA-MB-231 cells after 72 h of CoCl2 treatment 
in 2D and 3D (pHEMA-coated plate) cultures compared to untreated control. c Relative protein 
expression of p21 normalized to β-actin, with results represented as mean ± SD of three independent 
experiments (* P < 0.05 compared to untreated control). 
 
2.4. Discussion  
This study demonstrates that a CoCl2-based platform can be used for investigation 
of cancer dormancy under hypoxia. Several types of models recapitulating the interactions 
between microenvironments and DTCs have been suggested to date, with a focus on 
cellular[85] and molecular [16,86] components such as stromal cells and the extracellular 
matrix. However, there have been few models focused on non-cellular factors such as 
oxidative stresses in local microenvironments [87,88], which may also play a critical role. 
Previous studies of breast cancer have identified that breast cancer cells under hypoxia 
became dormant, as evidenced by upregulation of several genes implicated in cancer 
dormancy [25,32]. In addition, restrained growth with reversible arrest in G0/G1 phase was 
observed in breast cancer cells under hypoxia, supporting hypoxic regulation of cancer 
dormancy [89]. Given the emerging evidence of hypoxic regulation of entrance into the 
dormant state, the establishment of a robust in vitro model of cancer dormancy under 
hypoxia is critical for better understanding of mechanisms through which hypoxia induces 
dormancy of DTCs.  
 Our results demonstrated that CoCl2-induced hypoxia-mimicking conditions can 
stably trigger and maintain dormancy in MCF-7 cells in a HIF1α-dependent manner. CoCl2 
treatment showed similar effects to those of a conventional hypoxia chamber in restraining 
proliferation of MCF-7 cells, reducing expression of cell cycling marker Ki67 in 
conjunction with upregulation of hypoxia markers HIF1α and GLUT1 and reversible cell 
 45 
cycle arrest in G0/G1 phase. Furthermore, OVCAR-3 ovarian cancer cells also exhibited 
these hallmarks of dormancy in CoCl2-induced hypoxia-mimicking microenvironments. 
Unlike breast cancer, a direct link between hypoxia and ovarian cancer dormancy has not 
yet been fully established. However, it has been documented that several pathways 
including autophagy [90,91] and p38 signaling [92] that have been implicated in ovarian 
cancer dormancy are affected by hypoxia. Collectively, these results suggest that this 
CoCl2-based platform can be used as a tool to study dormant cancer cells under hypoxia. 
 Previous studies have identified multiple effects of CoCl2 beyond hypoxia-
mimicking effects, such as the development of reactive oxygen species [93] and the 
activation of NF-κB signaling, which mediates carcinogenesis [94]. Since CoCl2 treatment 
was unable to induce dormancy in MCF-7 cells when HIFα was downregulated in the cells, 
it is likely that CoCl2 is inducing dormancy in a HIF1α-dependent manner. However, given 
the heterogeneity of cellular responses to hypoxia and CoCl2 in different types of cancer, 
further investigation into alternative effects of CoCl2 apart from mimicking hypoxia may 
be necessary in the future. 
Unlike ER-positive MCF-7 cells, ER-negative MDA-MB-231 cells did not exhibit 
dormant behavior under either true hypoxia or CoCl2 treatment. Previous studies have 
identified heterogeneity in cellular responses to hypoxia in different subtypes of breast 
cancer cell lines [81,89,95]. However, the underlying mechanisms that give rise to their 
differential ability to enter a dormant state in hypoxic microenvironments have yet to be 
elucidated. In our study, CDK inhibitor p21 and its associated CDKs and cyclins exhibited 
contrasting expression in MCF-7 and MDA-MB-231 cells under CoCl2 treatment. These 
results are consistent with previous findings that differential regulation of p21 in MCF-7 
and MDA-MB-231 cells in response to various environmental stimuli impacts cell cycle 
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progression [96,97], and they suggest that the distinct responses to hypoxic stress we 
observed in these two cell lines are in part p21-mediated. Interestingly, expression of MYC, 
which represses p21 in normoxia [84,98], exhibits the opposite trend as p21 in MCF-7 and 
MDA-MB-231 cells. Previous studies have found that hypoxia induces p21 activation by 
repressing MYC through a different regulatory mechanism from the classical hypoxia-
inducible genes such as GLUT1 [84,98]. Thus, MDA-MB-231 cells may overcome 
hypoxia-induced cell cycle arrest by overexpressing MYC, which in turn deactivates p21 
to enable cell cycle progression. Another CDK inhibitor (p27) was not significantly 
upregulated in either cell line under CoCl2 treatment. Given that hypoxia can induce cell 
cycle arrest independent of p27 or p21 [99], our findings suggest that dormancy observed 
in MCF-7 cells under CoCl2 treatment is in part mediated by p21 upregulation but not p27. 
p21 can also trigger cellular senescence in a chronic state of G0 cell cycle arrest [83]. 
However, low activity of senescence-associated β-galactosidase in MCF-7 cells under 
CoCl2 treatment indicated that cells were not in a senescent state. In addition, an increased 
ratio of p38 MAPK activity to ERK(1/2) activity, which has been associated with p21 
activation in dormant tumor cells [82,100], was observed in MCF-7 cells under CoCl2 
treatment, providing further evidence of p21-mediated dormancy. Overall, our findings 
suggest that MCF-7 and MDA-MB-231 employ different molecular mechanisms that are 
in part regulated by p21-mediated pathways in response to hypoxic microenvironments. 
Although the role of p21 in hypoxic regulation of dormancy remains to be determined, 
these findings suggest that our platform can be used to investigate molecular mechanisms 
underlying hypoxic regulation of cancer dormancy.  
 As with other in vitro models, this simplified platform also reflects limited aspects 
of in vivo tumor microenvironments. It lacks geometrical complexity, cellular components 
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including immune cells and organ-specific stromal cells, and extracellular matrix 
components. However, as opposed to conventional hypoxia models that rely on a hypoxic 
chamber, the CoCl2-based platform can be readily integrated with previously established 
models centered on cellular and molecular components to better mimic in vivo tumor 
microenvironments conducive to cancer dormancy. For example, we demonstrated that 
CoCl2 can be combined with 3D cell culture models, which more closely mimic the in vivo 
tumor microenvironment than 2D monolayer cell culture [100]. Our results showed that 
CoCl2 recapitulated differential hypoxic regulation of cancer dormancy in MCF-7 and 
MDA-MB-231 cells in two different 3D models, further indicating the robustness of this 
platform. Furthermore, this platform allows for real-time characterization of dormant 
cancer cells that has not been practical with hypoxic chambers due to the extremely short 
half-life of HIF1α (t1/2 < 5 min) upon reoxygenation [33]. Thus, oxygen entering the 
chamber at each opening results in re-oxygenation that can disrupt the hypoxic response 
[36,101]. In addition, the ability to generate a large population of dormant cells in the CoCl2 
platform could enable the investigation of the heterogeneity among dormant cancer cells 
under hypoxia. Given that hypoxia and cancer dormancy have been associated with 
limiting the effectiveness of chemotherapy and increasing the risk for recurrence, resulting 
in poor clinical outcomes [102,103], information extracted from dormant cancer cells has 
the potential to identify novel therapeutic strategies for preventing recurrence. Taken 
together, the CoCl2-based platform we have established in this report provides an enabling 
tool that has potential use in the investigation of undiscovered mechanisms of cancer 





There have been a limited number of studies on cancer dormancy under hypoxic 
microenvironments in part due to a lack of well-established platforms. In the present study, 
we report a facile CoCl2-based in vitro platform mimicking hypoxic regulation of cancer 
dormancy as well as recapitulating differing responses to hypoxia among breast cancer cell 
lines. A critical advantage of this CoCl2-based platform over conventional systems is the 
ability to stably induce and maintain dormancy in vitro, even in the presence of oxygen. 
Thus, this platform enables investigation of the poorly-understood molecular mechanisms 
underlying hypoxic regulation of cancer dormancy, offering a tool to develop potential 
therapeutic strategies to reduce tumor recurrence. 
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 Chapter 3 – In vivo biomaterial platform to establish a hypoxic 
metastatic niche  
 
Adapted with permission from “Lee, HR., Pelaez, F., Silbaugh, A.M., Leslie, F., Racila, 
E., and Azarin, S.M. Biomaterial platform to establish a hypoxic metastatic niche in vivo. 





Hypoxia, a condition resulting from the deficiency of available oxygen within cells 
or tissues, has been recognized as a potent mediator of tumor metastasis, with wide-ranging 
regulatory roles in multiple steps of the metastatic cascade [102,104–106]. Previous reports 
have identified that tumor hypoxia and activation of hypoxia-inducible factor (HIF) 
signaling influence most elements of early and late-stage metastasis, including the 
epithelial-mesenchymal transition, invasion, intravasation and extravasation, metabolic 
adaptation, survival and growth at distant organs [107–109]. In addition, hypoxia has been 
found to be a master regulator of the formation of the pre-metastatic niche, facilitating 
metastatic progression [105,110,111]. However, most previous investigations of hypoxic 
regulation during metastasis have been centered on the effects of primary tumor hypoxia. 
Given that hypoxic effects are not just confined to the primary tumor, as DTCs can also 
encounter hypoxic microenvironments upon arriving at target organs, the precise 
mechanisms through which hypoxia in the metastatic niche affects the fate of DTCs during 
the late stages of metastasis need to be better characterized.  
Recently, the significance of hypoxic regulation at target organs has been 
recognized in several studies [63,68,112,113]. For instance, hypoxic microenvironments 
in the liver were found to select for a subpopulation of DTCs with the ability to adapt to 
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metabolic stresses under hypoxia in colorectal cancer [109]. Moreover, it was found that 
hypoxia mediates the metabolic adaptation of metastatic breast cancer cells in the liver 
through the activation of HIF1 and pyruvate dehydrogenase kinase 1 (PDK1), a HIF1 target 
gene that mediates glycolytic reprogramming [114]. The hypoxic microenvironment in 
secondary target organs can also determine whether DTCs enter a dormant or proliferative 
state. Johnson et al. found that hypoxia regulates leukemia inhibitor factor receptor (LIFR) 
signaling, which can confer a dormant phenotype in breast cancer cells disseminated to 
bone marrow [68], a popular hypoxic metastatic niche for dormant DTCs in many types of 
cancer [59]. Aguirre-Ghiso et al. proposed a different view, that growth-suppressive target 
organ microenvironments such as hypoxia can activate stress signals in DTCs, 
consequently inducing dormancy of DTCs in conjunction with primary tumor hypoxia 
[59,63,115]. Hypoxia also plays a central role in late stages of metastasis at target organs, 
which require the establishment of new vasculature for growth of the metastases. Folkman 
et al. suggested that the failure to construct new vasculature at target organs may result in 
dormant metastases, a phenomenon termed angiogenic dormancy [116]. Hypoxia 
stimulates angiogenesis through HIF signaling, which leads to the production of vascular 
endothelial growth factor-A (VEGF-A), a proangiogenic factor, in hypoxic tumor and 
stromal cells, promoting the recruitment and proliferation of endothelial cells and pericytes 
for angiogenesis [117]. VEGF-A expression under hypoxia also mediates the recruitment 
of tumor-associated macrophages (TAMs), a key cellular component in the metastatic 
niche that impacts tumor progression [118]. It has been suggested that macrophages are 
functionally plastic cells such that they can switch between anti-tumorigenic and pro-
tumorigenic functions depending on the microenvironment. TAMs were found to be 
recruited to hypoxic areas of growing tumors and to promote tumor angiogenesis, 
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suggesting that hypoxia may regulate the transition of TAM function in a metastatic niche 
[119,120].  
Despite its emerging importance, it has been challenging to study the detailed 
mechanisms behind how hypoxia in the metastatic niche dictates the fate of DTCs in 
concert with other niche factors due to the lack of appropriate experimental models. It is 
difficult to locate natural metastatic niches in vivo, as the small number of DTCs present 
in the metastatic niche at early stages is typically below the detection limit of traditional 
imaging techniques [121–123]. In addition, it is not always feasible to access regions with 
specific microenvironments such as hypoxia, further impeding translational studies to 
identify therapeutic interventions [112]. To overcome these issues, synthetic metastatic 
niches have recently been established using biomaterial scaffolds to generate 
experimentally accessible in vivo metastatic sites [40,121,124–126], with niche-mimicking 
biomaterials offering many advantages compared to other strategies for studying in vivo 
metastatic niches [121]. In one such approach utilizing microporous poly(lactide-co-
glycolide) (PLG) scaffolds to recruit metastasizing breast cancer cells, it was found that 
the local foreign body response to the implanted scaffolds established an inflammatory cell 
distribution similar to that of metastatic organs such as the lung and liver, recapitulating 
the unique immune microenvironment of pre-metastatic niche. These immune cells that 
accumulated at implanted PLG scaffolds secreted various factors that facilitated the 
subsequent recruitment of DTCs to the scaffold [40,127]. More importantly, cellular and 
molecular niche factors such as immune cells, exosomes, and soluble factors can be 
incorporated to further tune the synthetic metastatic niche to reflect cancer or organ-
specific microenvironments [121].  
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Other biomaterial-based strategies such as hydrogels [128], bioactive glass [129] 
or gelatin nanofibrous scaffolds [130] have been employed to mimic hypoxic niches in vivo 
for tissue engineering applications. However, to our knowledge, none of these approaches 
have been demonstrated to facilitate recruitment of tumor cells. Thus, we aimed to develop 
a method for establishing an in vivo hypoxic metastatic niche which is implantable in a 
readily accessible region, such as beneath the skin, enabling future investigation of hypoxic 
regulation within the metastatic niche in determining the fate of DTCs. In this report, we 
hypothesized that incorporation of a hypoxia-mimetic agent into a metastatic niche-
mimicking biomaterial scaffold could enable generation of an in vivo hypoxic metastatic 
niche. To test this hypothesis, CoCl2, a hypoxia-mimetic agent, was incorporated into 
microporous PLG scaffolds. The hypoxia-mimicking effects of CoCl2 have been validated 
in a number of previous studies in tissue engineering and cancer biology[131,132], which 
demonstrated its ability to recapitulate hypoxic regulation of downstream targets such as 
glucose transporters[133], erythropoietin[71] and VEGF[134]. CoCl2 is known to mimic 
hypoxia through the stabilization of the HIF1a transcription factor, a master regulator of 
cellular and molecular responses to hypoxia, even in the presence of oxygen[135]. Thus, 
the hypoxia-mimicking effects of CoCl2 are stable compared to that of oxygen-depleting 
or scavenging approaches.  
In this study, we evaluated the ability of CoCl2-containing PLG (Co-PLG) scaffolds 
to establish hypoxic niches in vivo and recruit metastasizing tumor cells. Hypoxia-
mimicking effects of Co-PLG scaffolds were demonstrated through in vitro and in vivo 
characterization of signature hypoxic responses including angiogenesis and stabilized 
HIF1a expression. In vivo metastatic niche-mimicking effects of Co-PLG scaffolds were 
validated in the 4T1 mouse breast cancer metastasis model to demonstrate that the addition 
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of CoCl2 did not negatively affect the ability of the PLG scaffold to recruit metastatic tumor 
cells. This engineered scaffold provides a versatile tool for detailed investigation of the 
hypoxic metastatic niche at target organs, which could facilitate studies of how hypoxia 
affects the fate of DTCs upon arrival at a distal site. 
 
3.2. Materials and methods 
Scaffold fabrication. To fabricate Co-PLG and PLG scaffolds, microspheres were 
fabricated using an established method[136]. 2% (w/w) and 6% (w/w) solutions of PLG 
(Lakeshore Biomaterials; 75:25 lactide:glycolide, inherent viscosity = 0.76 dL/g) in 
dichloromethane (DCM) were emulsified in 1% poly(vinyl alcohol) (PVA), followed by 
centrifugation and four washes in deionized water. Then, 80 mg of the PLG particles was 
resuspended in 5 ml of deionized water (PLG) or aqueous CoCl2 solution containing 5 mg 
(5-Co-PLG) or 15 mg (15-Co-PLG) of CoCl2 and flash-frozen in liquid nitrogen, followed 
by lyophilization for 48 hours. For the double emulsion (water-in-oil-in-water) method, 
200 µl of aqueous CoCl2 solution containing 5 mg of CoCl2 was mixed with 80 mg of PLG 
in 3ml DCM. Then, the mixture was sonicated at 40 watts for 15 seconds on ice to form a 
primary emulsion. The primary emulsion was mixed with 25 ml of 5% (w/v) PVA aqueous 
solution and homogenized at 7000 rpm for 45 seconds to form a secondary emulsion. The 
homogenized solution was added to 50 ml of 1% PVA aqueous solution and stirred for 2 
hours to evaporate the DCM. The resulting microspheres were frozen in liquid nitrogen 
and lyophilized for 48 hours. For fabrication of the inner disk, 2 mg of Co-PLG 
microspheres was pressed into a 3mm disk using a hand press (Pike Technologies) and dip-
coated in 2% (w/w) PLG solution in DCM. For the outer microporous layer, 6% (w/w) 
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PLG microspheres were mixed at a 1:30 ratio with 250 - 420 µm sodium chloride particles. 
Next, the inner disk was placed in the center of the outer layers and the mixture was pressed 
at 1500 psi using a 5-mm diameter steel die (Specac). The resulting scaffolds were gas-
foamed and sodium chloride particles were leached out in water for 90 min. Scaffolds were 
rinsed with water and sterilized in 70% (v/v) ethanol for 1 minute before surgical 
implantation.  
 
Measurement of CoCl2 loading efficiency. 5 mg of CoCl2 (Winitial) was added to 80 mg 
of PLG microspheres (WPLG,before loading) via either the flash freezing or double emulsion 
method. The actual amount of CoCl2 loaded (Wloaded) was calculated by measuring the 
increased weight of PLG microspheres after CoCl2 loading (WPLG,after loading), as determined 
after the final lyophilization step. As 10% weight loss of PLG microspheres during the 
fabrication process was observed even without CoCl2 loading, this loss was considered in 
the calculation of Wloaded. Accordingly, the CoCl2 loading efficiencies for the flash freezing 
and double emulsion methods were calculated using the following equations (where W 
indicates weight): 
Wloaded = WPLG,after loading – (WPLG,before loading × 0.9)     (1) 
% loading = [(Winitial – Wloaded) / Winitial] × 100      (2) 
 
Scanning Electron Microscopy (SEM). The structure of layered Co-PLG scaffolds was 
imaged using a cold field emission gun scanning electron microscope (Hitachi S-4700, 
Hitachi High-Technologies Corp.). Scaffolds were cut in half and pre-coated with a 10 nm-
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thick Pd layer using an EM ACE600 sputter coater (Leica) prior to imaging. Imaging was 
performed at 2kV accelerating voltage.  
 
In vitro CoCl2 release test. To evaluate the release of cobalt ions, Co-PLG scaffolds were 
immersed in 5 ml of Dulbecco's phosphate-buffered saline (PBS) at 37 °C for 14 days. The 
resulting PBS solutions were collected at 1, 3, 7, and 14 days, with a complete replacement 
with fresh PBS at each collection. The amount of released cobalt ions was measured using 
inductively coupled plasma optical emission spectrometry (ICP-OES). ICP-OES was 
conducted using a Thermo Scientific iCAP 6000 Series ICP Spectrometer, and each 
condition was tested in triplicate.  
 
Cell culture. Human umbilical vein endothelial cells (HUVECs; ATCC CRL-1730) were 
maintained in Endothelial Growth Medium-2 (EGM-2, Lonza) containing 2% (v/v) fetal 
bovine serum (FBS) and growth supplements (EGM-2 bullet kit, Lonza). The MCF-7 
human breast cancer line (ATCC HTB-22) and  OVCAR-3 human ovarian cancer cell line 
(ATCC HTB-161) were cultured as previously described[132]. 
 
In vitro cell viability assay. Cell viability was evaluated using a Live/Dead 
Viability/Cytotoxicity Kit and an alamarBlue assay (Thermo Fisher Scientific). For the 
Live/Dead assay, HUVECs at 40-50% confluence were incubated with Co-PLG scaffolds 
for 72 hours. To evaluate the effect of CoCl2 released from the scaffold on cell viability, 
HUVECs were grown in 2-D culture dishes, and Co-PLG scaffolds were placed in the 
culture media above cells. Then, cells were rinsed twice with PBS and stained as per the 
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manufacturer’s instructions. The EVOS FL Auto fluorescence microscope (Thermo Fisher 
Scientific) was used for imaging. For the alamarBlue assay, after 24-hour or 72-hour 
incubation with Co-PLG scaffolds HUVECs were incubated with 10% alamarBlue solution 
for 4 hours at 37 °C. 100 µl of alamarBlue solution was collected from each well after the 
4-hour incubation and analyzed using a Synergy H1 spectrophotometer (BioTek).    
 
Immunofluorescence assays. Fixation, blocking/permeabilization and staining were 
performed as previously described [132]. Primary and secondary antibodies used in 
immunofluorescence assays are summarized in Tables 3-1 and 3-2. Images were taken with 
an EVOS FL Auto fluorescence microscope. 
 




species Vendor Clone or product number Dilution 
HIF1α Mouse BD Biosciences 610098; clone 54/HIF1α, 1:200 
GLUT-1 Mouse ThermoFisher MS-10637-P1; clone SPM498 1:200 
 
Table 3-2. Secondary antibodies used for immunofluorescence assays 
Species reactivity Host Conjugate Vendor Dilution 
Mouse Goat Alexa Fluor 647 A21240; ThermoFisher 1:1000  
Mouse Goat Alexa Fluor 488 A11001; ThermoFisher 1:1000 
 
Western blotting. Protein extraction and western blotting were performed as previously 
described [132]. For detection of HIF1α and β-actin, 25 µg and 10 µg of whole cell lysates 
were used, respectively. Primary and secondary antibodies used for western blots are 
summarized in Tables 3-3 and 3-4.  
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Table 3-3. Primary antibodies used for western blotting 
Target antigen Antibody species Vendor Clone or product number Dilution 




Rabbit Cell Signaling Technology 5125S; clone 13E5 1:1000 
 
Table 3-4. Secondary antibodies used for western blotting 
Species reactivity Host Conjugate Vendor Dilution 
Mouse Goat Polyclonal HRP G21040; ThermoFisher 1:6000  
 
In vitro tube formation assay. Prior to cell seeding, 24-well cell culture plates were coated 
with growth factor-reduced Matrigel (10.1 mg/ml, BD Bioscience) and incubated at 37 °C 
for 1 hour. HUVECs that had been passaged at least twice after thawing (passage 2-5) were 
pre-stained with calcein AM and seeded on top of the Matrigel layer at a density of 10,000 
cells/cm2. Endothelial Basal Media-2 (EBM-2, Lonza) and Endothelial Growth Medium-2 
(EGM-2, Lonza) were used as a negative and positive control, respectively. HUVECs were 
incubated with Co-PLG scaffolds or in a hypoxia chamber (maintained at 1% O2) for 24 
hours in EBM-2. To evaluate the effect of CoCl2 released from the scaffolds on tube 
formation ability, incubation of the HUVECs with Co-PLG scaffolds was performed by 
suspending the scaffolds in the culture media above the HUVECs. True hypoxia (1% O2) 
was achieved by controlling gas flow using a single flow meter connected to a hypoxia 
chamber (STEMCELL Technologies). For studies with the hypoxia chamber, to minimize 
effects from reoxygenation, imaging was performed immediately after HUVECs were 
removed from the chamber. Images were taken at the timepoint at which peak levels of 
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tube formation were observed (8-12 hours post-seeding) using an EVOS FL Auto 
fluorescence microscope. Quantification was performed with ImageJ software. 
 
In vivo studies. Animal studies were conducted in accordance with and approved by the 
University of Minnesota Institutional Animal Care and Use Committee (IACUC). BALB/c 
mice (The Jackson Laboratory) received two scaffolds in the upper dorsal subcutaneous 
space. The implanted scaffolds were retrieved 2 weeks post-implantation for further 
characterization. To evaluate tumor cell recruitment, 2×106 4T1 breast cancer cells in 50 
µL PBS were injected into the right mammary pad of 8-week-old female BALB/c mice. 
Tumor-free mice were injected with 50 µL PBS as a negative control. Tumor width and 
length were measured weekly using digital calipers and tumor volume was calculated using 
the formula [137] Volume = (Width2 ´ Length)/2. PLG and Co-PLG scaffolds were 
implanted into the subcutaneous region of the mice 7 days post-tumor inoculation. The 
implanted scaffolds were retrieved 14 days after scaffold implantation and immediately 
frozen in liquid nitrogen and stored at −80 °C.   
 
Quantitative real-time PCR (qRT-PCR). Tumor metastasis to the scaffold was 
quantified by qRT-PCR using a previously described assay [138]. Briefly, homogenization 
of scaffolds was performed at 10,000 rpm on ice for 20 seconds in RLT cell lysis buffer 
(Qiagen) containing 1% 2-mercaptoethanol (Sigma-Aldrich). Total RNA extraction, 
cDNA synthesis, and qRT-PCR were performed as previously described[132]. Primers for 
MT2 (Forward sequence: GCCTGCAAATGCAAACAATGC, Reverse sequence: 
AGCTGCACTTGTCGGAAGC, PrimerBank) and GAPDH (Forward sequence: 
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CAATGTGTCCGTCGTGGA, Reverse sequence: GATGCCTGCTTCACCACC, 
PrimerBank) were used. Gene expression of HUVECs in response to Co-PLG scaffolds 
was also assessed using the PrimePCR SYBR Green Assays (Bio-Rad) summarized in 
Table 3-5. Fold change in gene expression was calculated using following equations, where 
CT indicates the threshold cycle number:  
ΔCT = CT (target gene)−CT (reference gene)     (3) 
DDCT = ΔCT(treated sample) − ΔCT(control sample)    (4) 
Fold change = 2-DDCT          (5) 
Table 3-5. Primers used for qRT-PCR 
Gene Vendor ID Number 
VEGFA BioRad qHsaCED0006937 
FLT1 BioRad qHsaCID0010190 
KDR BioRad qHsaCID0006310 
ANGPT1 BioRad qHsaCID0008671 
ANGPT2 BioRad qHsaCID0017615 
ACTB BioRad qHsaCED0036269 
 
Histological analysis and immunohistochemistry (IHC). Retrieved organs and scaffolds 
were immediately fixed in 4% paraformaldehyde for 48 hours and transferred to 70% 
ethanol. The fixed tissues were paraffin-embedded and sliced at 4 µm thickness with an 
HM 315 microtome (Microm). Hematoxylin and eosin (H&E) or terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed to 
evaluate the biocompatibility of implanted scaffolds. Histopathological examination of 
H&E stained sections was performed through blinded analysis by a pathologist. For the 
quantification, 10 areas at 40x magnification were examined in each scaffold, and 3 or 
more scaffolds were evaluated per condition. To evaluate lungs and livers, 4 tissues per 
group were assessed. For immunohistochemistry, slides were blocked with Rodent Block 
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M (Biocare Medical) for 30 min at room temperature in a humidified chamber. Then, 
blocked slides were stained with polyclonal rabbit anti-HIF1a (1:50, GeneTex GTX30647), 
anti-CD31 (1:100, Thermo Fisher Scientific RB-10333-P1), or anti-GLUT1 (1:100, Abcam 
ab15309) primary antibodies overnight at 4 °C, followed by Rabbit-on-Rodent HRP 
Polymer (Biocare Medical RMR622G) for 30 min at room temperature. Chromogen 
detection was conducted using 3,3'-diaminobenzidine (DAB) chromogen concentrate and 
substrate buffer (Biolegend). The EVOS FL Auto fluorescence microscope was used to 
image the sections. 
 
Statistical Analysis. GraphPad Prism was used for statistical analysis. All data are 
presented as mean ± standard deviation (SD). For in vitro studies, representative data 
shown are from one of three independent experiments. For in vivo results, n is specified in 
each figure legend. P values were calculated using an unpaired Student’s t-test, and a P 
value less than 0.05 was considered statistically significant.  
 
3.3. Results and discussion 
3.3.1. Optimization of CoCl2 loading into PLG scaffolds  
Previous studies have shown that microporous PLG scaffolds implanted in mice 
can recruit disseminated metastatic tumor cells in vivo by recapitulating the local immune 
microenvironment of the pre-metastatic niche [40,127,136]. To develop a platform for 
generating a hypoxic metastatic niche, CoCl2, a hypoxia mimetic agent, was incorporated 
into the PLG scaffolds. Two methods, flash freezing and double emulsion (water-in-oil-in-
water), were initially compared for incorporation of CoCl2 into PLG scaffolds (Fig. 3-1A).  
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Figure 3-1. Fabrication of CoCl2-containing PLG (Co-PLG) scaffolds. (A) CoCl2 was incorporated into 
PLG microspheres using the flash freezing method, and the Co-PLG was used to fabricate layered and 
non-layered scaffolds. (B) The percentage of Co2+ loss during a 90-min leaching step as measured by 
ICP-OES (*P < 0.05 compared to non-layered, #P < 0.05 compared to layered). (C) Evaluating the effect 
of dip-coating the CoCl2-containing inner disk with 2% (w/w) PLG solution in DCM to introduce a 
protective layer that minimized the loss of CoCl2 during the fabrication process. Blue color indicates 
that the CoCl2 remains in an anhydrous state, whereas light pink color indicates that the CoCl2 has 
become hydrated by contact with water. White color indicates that all of the CoCl2 has leached out of 
the polymer disk. In the uncoated Co-PLG disk (a), the CoCl2 within the disk is quickly hydrated, with 
the disk becoming white within 60 minutes of immersion in water. In contrast, the Co-PLG disk with a 
protective PLG coating (b) exhibits significantly reduced hydration of the CoCl2 that is confined at the 
rim over the same time period. (D) SEM images showing a cross-sectional view of a layered Co-PLG 
scaffold consisting of a microporous outer PLG layer and a Co-PLG inner disk. The dashed white lines 
indicate the inner disk containing CoCl2. Scale bars indicate 1 mm. 
 
The loading efficiency of each method was evaluated by adding 5 mg of CoCl2 to 80 mg 
of PLG microspheres (5-Co-PLG). It was found that 80% of the CoCl2 was incorporated 
onto PLG microspheres by the flash freezing method, whereas less than 20% was 
incorporated by the double emulsion method (Table 3-6). In addition, the loading 
efficiency of the flash freezing method remained constant when loading higher amounts 
(15mg) of CoCl2 onto PLG microsphere (15-Co-PLG) (Table 3-6).  
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Material CoCl2:PLG  ratio (w:w) 
% of CoCl2  
loaded 
5-Co-PLG (DE) 1:16 19.8 ± 7.0 
5-Co-PLG (FF) 1:16 81.7 ± 3.9 
15-Co-PLG (FF) 3:16 79.5 ± 2.4 
 
Table 3-6. Loading efficiency of double emulsion (DE) and flash freezing (FF) methods.  
 
Thus, the flash freezing method was utilized to add CoCl2 to PLG microspheres for 
the remainder of the studies. To optimize the scaffold design, layered and non-layered 
scaffold geometries were also tested. For layered scaffolds, Co-PLG microspheres were 
incorporated as a disk in between two microporous PLG layers, while for the non-layered 
scaffolds the porous structure was fabricated directly from the Co-PLG microspheres (Fig. 
3-1A and 3-2A). As the scaffold fabrication process includes a 90-minute salt leaching step 
and serial washes in water, the high solubility of CoCl2 in water led to significant loss of 
CoCl2 in non-layered scaffolds during the fabrication process (Fig. 3-1B and 3-2B). In 
contrast, the layered scaffold was able to retain most of the loaded CoCl2 during the 
fabrication process (Fig. 3-1B). Addition of a protective PLG coating onto the surface of 
the Co-PLG inner disk further reduced the loss of CoCl2 during leaching in water (Fig. 3-
1B, C), which is required to generate pores in the scaffold fabrication process. Most of the 
area within Co-PLG disks with a PLG protective coating (disk b, Fig. 3-1C) remained non-
hydrated (with blue color indicative of anhydrous CoCl2) after 60 minutes in water, 
whereas Co-PLG disks without a protective PLG coating were fully hydrated (as evidenced 
by pink color) within one minute (disk a, Fig. 3-1C). Without the protective coating, Co-
PLG disks appeared white at the end of the 60-minute water incubation, indicating that all 
of the CoCl2 had leached out of the disk. Thus, all further studies were performed with 
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layered Co-PLG scaffolds containing a PLG-coated CoCl2 inner disk embedded in a 
microporous PLG outer layer (Fig. 3-1D). 
 
Figure 3-2. Photomicrographs of microspheres and scaffolds. (A) Images of PLG microspheres (left) 
and Co-PLG microspheres fabricated using double emulsion (middle) or flash freezing method (right). 
(B) Images of microporous scaffolds before (left column) or after (right column) 90 minutes of leaching 
in water for the following samples: non-layered scaffolds from the double emulsion (top row) or flash 
freezing (middle) method, and layered scaffolds from the flash-freezing method (bottom). Scale bars 
indicate 1 mm.  
 
3.3.2. In vitro cobalt ion release kinetics and cytotoxicity  
The release of cobalt ions (Co2+) from Co-PLG scaffolds was analyzed by ICP-
OES. 5-Co-PLG and 15-Co-PLG scaffolds showed sustained release of cobalt ions in PBS 
over 2 weeks (Fig 3-3A), with a burst release observed within first 24 hours. Importantly, 
the cumulative concentration of cobalt ions released from both 5-Co-PLG and 15-Co-PLG 
scaffolds remained within the physiologically acceptable concentration range (3-15 ppm; 
parts per million) [129,139]. To evaluate the toxicity of released cobalt ions, HUVECs 
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were incubated with Co-PLG scaffolds. No significant cell death or reduction in 
proliferation were observed after 72-hour incubation with 5-Co-PLG or 15-Co-PLG 
scaffolds (Fig. 3-3B, C). However, cumulative cobalt release eventually became toxic at a 
higher CoCl2 loading (30 mg CoCl2; 30-Co-PLG), as HUVECs incubated with 30-Co-PLG 
for 72 hours showed a 20% reduction in proliferation (Fig. 3-3B) and significant cell death 
(Fig. 3-3C). These results demonstrate that cumulative cobalt release from 5-Co-PLG and 
15-Co-PLG scaffolds is within a biologically safe range.  
 
Figure 3-3. In vitro evaluation of release kinetics and cytotoxicity of Co-PLG scaffolds. (A) Cumulative 
release of Co2+ at day 1, 3, 7, and 14 from bare PLG, 5-Co-PLG, and 15-Co-PLG scaffolds measured 
using ICP-OES. (B) Proliferation of HUVECs after 72 hours of incubation with Co-PLG scaffolds with 
varying concentrations of CoCl2 was evaluated using an alamarBlue assay. Mean fluorescence intensity 
was normalized to an untreated control (*P < 0.05 compared to untreated control). (C) Cell viability of 
HUVECs after 72 hours of incubation with Co-PLG scaffolds with varying concentrations of CoCl2 was 
evaluated using a fluorescence assay in which live cells were stained with calcein AM (green) and dead 
cells were stained with ethidium homodimer-1 (red). Scale bars indicate 1 mm. 
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3.3.3. HUVECs incubated with Co-PLG scaffolds express hypoxia markers HIF1α 
and GLUT1 
HIF signaling has been recognized as a major regulator of downstream 
transcriptional responses to hypoxia [140,141]. HIF is a heterodimer that consists of an 
oxygen-sensitive α-subunit and a constitutively expressed β-unit. Three isoforms of HIFα 
have been reported: HIF1α, HIF2α, and HIF3α. As HIF1α is present in all human tissues 
while HIF2α and HIF3α are restricted to specific tissues or cell types [142,143], HIF1α 
was used as an indicator of hypoxic responses in our study. In accordance with previous 
findings that HIF1α is stabilized and translocates to the nucleus to dimerize with HIF1b 
under hypoxic conditions [144], we evaluated stabilization and nuclear localization of 
HIF1α in vitro by western blotting and immunofluorescence analysis of HUVECs 
incubated with either Co-PLG scaffolds or 1% O2 (positive control), as compared to 
untreated cells (Fig. 3-4). Western blotting of HIF1α demonstrated the stabilized HIFα 
expression in HUVECs incubated with 15-Co-PLG scaffolds or 1% O2 for 24 hours 
compared to untreated HUVECs under normoxic conditions (Fig. 3-4A).  
 
Figure 3-4. Hypoxia markers HIF1a and GLUT1 were upregulated in HUVECs cultured with Co-PLG 
scaffolds or 1% O2. (A) Western blot analysis of HIF1a and b-actin (loading control) expression in 
HUVECs incubated with 15-Co-PLG scaffolds or 1% O2 for 24 hours compared to untreated control. 
(B) Representative fluorescence images of HIF1a (red) and nuclei (blue) in HUVECs incubated with 
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Co-PLG scaffolds or 1% O2 for 24 hours compared to untreated control. Scale bars indicate 200 µm. 
(C) Representative fluorescence images of GLUT1 (green) and nuclei (blue) in HUVECs incubated 
with Co-PLG scaffolds or 1% O2 for 24 hours compared to untreated control. Scale bars indicate 
200 µm. 
 
Untreated HUVECs under normoxic conditions exhibited faint HIF1α expression 
spread throughout the cytoplasm (Fig. 3-4B). In contrast, HUVECs incubated with Co-
PLG scaffolds or 1% O2 for 24 hours showed strong HIF1α expression localized in the 
nucleus. In addition to HIF1a, the expression of glucose transporter 1 (GLUT1) was also 
examined as glucose transporters including GLUT1 are known to be upregulated under 
hypoxia to mediate metabolic adaptation of cells to hypoxic conditions [145]. HUVECs 
cultured with Co-PLG scaffolds or 1% O2 also exhibited increased GLUT1 expression (Fig. 
3-4C). To validate hypoxia-mimicking effects of Co-PLG scaffolds in other cellular 
components of metastatic niche, human cancer cells were also tested. Overall, in vitro 
hypoxia-mimicking effects, as evaluated by HIF1α and GLUT1 expression, were more 
pronounced in 15-Co-PLG scaffolds than in 5-Co-PLG scaffolds with no significant 
difference in cytotoxicity, and thus 15-Co-PLG scaffolds were used for the remaining 
studies. 
 
3.3.4.  Co-PLG scaffolds can recapitulate in vitro angiogenic responses to hypoxia   
Another hallmark of the response to hypoxia is enhanced angiogenesis, which is an 
attempt to restore homeostasis by increasing the oxygen supply to the hypoxic 
microenvironment [144]. As previous findings have identified that HIF is a key 
transcriptional regulator of angiogenic processes under hypoxia [146,147], we 
hypothesized that Co-PLG scaffolds activating HIF signaling would also recapitulate 
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angiogenic responses under true hypoxia. To evaluate the level of angiogenesis, an in vitro 
tube formation assay was performed with HUVECs. HUVECs pre-stained with calcein AM 
were seeded on top of a thin layer of Matrigel. EBM-2, media without serum or growth 
supplements, served as negative control, while EGM-2, fully supplemented with 2% serum 
and pro-angiogenic growth factors, served as positive control in this assay. HUVECs 
cultured in EBM-2 exhibited low levels of angiogenesis, whereas HUVECs cultured in 
EGM-2 showed well-structured tube networks at 8-12 hours post-seeding under normoxic 
conditions. HUVECs cultured in EBM-2 with 15-Co-PLG scaffolds or under hypoxic 
conditions (1% O2) exhibited significantly enhanced angiogenesis that peaked at 8-12 
hours post seeding compared to HUVECs cultured in EBM-2 under normoxic conditions 
(Fig. 3-5A). In addition, both 15-Co-PLG and hypoxic conditions exhibited comparable 
levels of angiogenesis as the EGM-2 positive control. The average number of complete 
loops and mean tube length were quantified to further evaluate the level of angiogenesis in 
each condition. HUVECs cultured with 15-Co-PLG scaffolds and 1% O2 had a similar 
number of complete loops per image, with an average of 53 ± 6 loops with Co-PLG 
scaffolds and 50 ± 4 loops under 1% O2, compared to 22 ± 6 loops in HUVECs cultured 
with EBM-2 under normoxic conditions (Fig. 3-5B). These values were also comparable 
to the 55 ± 6.2 loops observed with EGM-2 (Fig. 3-5B). Moreover, HUVECs treated with 
1% O2 or Co-PLG scaffolds also exhibited similar mean tube length, 194 ± 71 µm with 
Co-PLG scaffolds and 199 ± 81 µm with 1% O2, both of which were longer compared to 
167 ± 83 µm with EBM-2 under normoxic conditions (Fig. 3-5B). Expression of hypoxia-
inducible angiogenic genes was also investigated in HUVECs incubated with 15-Co-PLG 
scaffolds or 1% O2 for 12 hours. Angiopoietin 2 (ANGPT2), a hypoxia-inducible gene that 
is known to promote vascular remodeling and angiogenic sprouting, was significantly 
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upregulated in HUVECs incubated with Co-PLG scaffolds or 1% O2 for 12 hours (Fig. 3-
5C). In contrast, the expression of angiopoietin 1 (ANGPT1) which is antagonized by 
ANGPT2 [148], was significantly downregulated in both conditions. This distinct hypoxic 
regulation of angiopoietins has been reported in previous studies, which showed that 
hypoxia increased ANGPT2 expression in a HIF-dependent manner but decreased ANGPT1 
expression due to antagonistic effects [149,150]. We also examined the expression of 
vascular endothelial growth factor A (VEGFA) and its binding receptors VEGFR1 (FLT1) 
and VEFGR2 (KDR), all of which are also mediated by hypoxia. VEGFA, known as the 
most potent contributor to the formation of new blood vessels and growth of pre-existing 
blood vessels[134,149], was also significantly upregulated in HUVECs cultured with Co-
PLG scaffolds or 1% O2 (Fig. 3-5C). While its receptor VEGFR2 was upregulated in 
HUVECs cultured with Co-PLG scaffolds or 1% O2, expression of VEGFR1 remained 
unchanged in both conditions (Fig. 3-5C). This differential regulation of VEGFA receptors 
in HUVECs was also in agreement with previous findings[151]. Given that pro-angiogenic 
genes ANGPT2 and VEGFA have previously shown concurrent upregulation during 
angiogenesis [149,152], the upregulation of both genes in HUVECs incubated with Co-
PLG scaffolds or 1% O2 likely led to the enhanced angiogenesis observed in these 
conditions. These parameters collectively suggest that Co-PLG scaffolds can recapitulate 
enhanced in vitro angiogenic responses under hypoxia.  
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Figure 3-5. Co-PLG scaffolds recapitulate angiogenic responses to hypoxia in HUVECs. (A) 
Representative fluorescence images of tube networks formed by HUVECs 8 hours after seeding onto 
Matrigel under each condition: EBM-2 (negative control), EBM-2 with 15-Co-PLG scaffold, EBM-2 
with 1% O2, and EGM-2 (positive control). HUVECs were pre-stained with calcein AM (green) for 30 
min prior to the seeding. Scale bars indicate 1 mm. (B) The average number of complete loops and tube 
length were quantified using ImageJ software (*P < 0.05 compared to EBM-2). (C) HUVECs incubated 
with Co-PLG scaffolds or 1% O2 exhibited similar angiogenic gene expression profiles. Fold change in 
mRNA expression of angiogenesis-related genes VEGFA, FLT1, KDR, ANGPT1, and ANGPT2 relative 
to the untreated control (cultured under normoxia) was measured by qRT-PCR (*P < 0.05 compared to 
untreated control).  
 
3.3.5. In vivo biocompatibility of Co-PLG scaffolds 
Prior to the evaluation of in vivo hypoxia-mimicking effects of Co-PLG scaffolds, 
we first examined in vivo biocompatibility of Co-PLG scaffolds, as released cobalt ions 
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from the scaffolds could be toxic in the body. To this end, two 15-Co-PLG scaffolds were 
implanted into the subcutaneous region of a BALB/c mouse and retrieved two weeks post-
implantation, as this enables sufficient time for the scaffolds to integrate with host tissues, 
and the in vitro studies showed sustained CoCl2 release at least for 2 weeks (Fig. 3-3A). In 
vivo biocompatibility of Co-PLG scaffolds was examined by H&E and TUNEL staining of 
tissue sections, using PLG scaffolds as a control (Fig. 3-6). H&E stained sections of PLG 
and Co-PLG scaffolds showed that both types of scaffolds were infiltrated by host cells 
and integrated with host tissues (Fig. 3-6A), with similar total numbers of cells infiltrating 
the scaffolds (Fig. 3-6B, left). Histopathological analysis revealed that cellular components 
within the PLG and Co-PLG scaffolds were similar, containing fibroblasts, endothelial 
cells, and inflammatory immune cells including multinucleated giant cells, neutrophils, 
lymphocytes, and macrophages. The average number of multinucleated cells was 
quantified, as this population is indicative of a typical foreign body response to polymeric 
biomaterials in the body [153], and no statistically significant difference was observed 
between PLG and Co-PLG scaffolds, with an average of 8.9 ± 0.4 multinucleated giant 
cells per imaged area in PLG scaffolds, compared with 10 ± 1.8 multinucleated giant cells 
per area in Co-PLG scaffolds (Fig. 3-6B, middle). Vascular density, as evaluated by the 
number of blood vessels per imaged area, was higher within Co-PLG scaffolds compared 
with PLG scaffolds (Fig. 3-6B, right). Other organs such as the liver and kidney, where 
toxins accumulate in the body, were also examined to investigate potential systemic effects 
of released CoCl2 using H&E staining. H&E stained liver and kidney sections from the 
mice that received normal PLG and Co-PLG scaffolds showed no significant structural or 
morphological changes such as inflammation, fibrosis, blood vessel formation or necrotic 
regions (Fig. 3-6A) upon histopathological examination. 
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Figure 3-6. Histological analysis of Co-PLG scaffolds to evaluate in vivo biocompatibility. Tissue-
laden scaffolds were harvested 2 weeks after implantation. (A) H&E-stained sections of scaffold, liver 
and kidney from the mice that received normal PLG scaffolds (top) or Co-PLG scaffolds (bottom). Scale 
bars indicate 200 µm. (B) Quantification of H&E stained sections of scaffolds (n ³ 3 scaffolds per 
group): total cell number (left), number of multinucleated giant cells (middle), and number of blood 
vessels (right) per imaged area within a scaffold. (*P < 0.05 compared to PLG scaffolds).  (C) TUNEL-
stained sections of scaffolds and surrounding tissue from the mice that received normal PLG or Co-PLG 
scaffolds (n ³ 3 scaffolds per group). Quantification was performed with ImageJ software. Scale bars 
indicate 100 µm. 
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Thus, these results collectively suggest that released CoCl2 affects the local tissue 
environment but does not lead to significant remodeling of distal tissues. In addition, 
TUNEL staining, which selectively detects apoptotic cells, showed no signs of significant 
apoptosis within PLG or Co-PLG scaffolds or the surrounding tissue, with less than 4% 
apoptotic cell populations present at all locations evaluated (Fig. 3-6C), suggesting no 
differences in biocompatibility between PLG and Co-PLG scaffolds.  
 
3.3.6. Co-PLG scaffolds can establish in vivo hypoxic microenvironments  
Biomaterial-based strategies to induce in vivo hypoxia have been developed to 
stimulate the vascularization of implanted materials for tissue engineering applications, as 
the lack of vascularization leads to insufficient integration with host due to the development 
of necrotic regions [129]. For example, an oxygen-depleting hydrogel which consumes 
oxygen during gel formation was shown to promote vascularization in vivo, as evidenced 
by the larger number and size of blood vessels surrounding and penetrating the hydrogel 
as compared to a non-hypoxic hydrogel [128]. Porous scaffolds releasing a hypoxia-
mimetic agents such as CoCl2 [129,131] and desferoxamine (DFO) [154,155] have been 
also reported. DFO-releasing gelatin nanofibrous scaffolds stimulated in vivo bone 
regeneration through enhanced angiogenesis [154]. CoCl2-releasing scaffolds made of 
bioactive glass were not tested in vivo but were shown to promote in vitro angiogenesis 
[129]. In our study, we hypothesized that sustained release of CoCl2 from Co-PLG 
scaffolds could establish an in vivo hypoxic microenvironment within the metastatic niche 
conditioned by the microporous PLG scaffold. To evaluate in vivo hypoxic responses 
within Co-PLG scaffolds, histological analysis of HIF1a, endothelial marker CD31, and 
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GLUT1 were conducted. Immunohistochemistry staining of HIF1a revealed that HIF1a 
was stabilized and localized in the nuclei of cells infiltrating the Co-PLG scaffolds, 
whereas most cells in normal PLG scaffolds did not exhibit positive expression and nuclear 
localization (Fig 3-7A). Furthermore, immunohistochemical analysis of CD31 revealed 
that more blood vessels had formed within Co-PLG scaffolds compared to normal PLG 
scaffolds by two weeks post-implantation, with an average of 69 ± 14 blood vessels per 
section observed in Co-PLG scaffolds compared to 27 ± 11 per section in normal PLG 
scaffolds (Fig. 3-7B, C). In addition, the average diameter of blood vessels within Co-PLG 
scaffolds was larger, with an average diameter of 24.4 ± 9.5 µm within Co-PLG scaffolds, 
compared to 12.7 ± 4.5 µm within PLG scaffolds (Fig. 3-7B, C). These results demonstrate 
that the hypoxic microenvironment within Co-PLG scaffolds promoted the formation and 
growth of blood vessels. Histological analysis of GLUT1 revealed that GLUT1 was also 
upregulated in the Co-PLG scaffolds compared to PLG scaffolds (Fig. 3-7D). These results 
collectively suggest that implanted Co-PLG scaffolds can establish an in vivo hypoxic 
microenvironment within the scaffold. Considering the significance of inducing in vivo 
hypoxic microenvironments in regenerative medicine as well as cancer research, Co-PLG 
scaffolds have the potential to be applicable to a broad range of biomedical applications. 
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Figure 3-7. Histological analysis of HIF1a, CD31, and GLUT1 demonstrate hypoxic responses within 
Co-PLG scaffolds compared to normal PLG scaffolds. (A,B) Representative IHC images of HIF1a (A) 
or CD31 (B) expression, with zoomed-in images of boxed regions shown on the right. (C) The average 
number of blood vessels and vessel diameter per section were quantified with ImageJ software (n = 4 
scaffolds per group; *P < 0.05 compared to PLG scaffolds). (D) Representative IHC images of GLUT1 
expression, with higher magnification images of boxed regions shown on the right. All scale bars 
indicate 200 µm.  
 
3.3.7. Co-PLG scaffolds can recruit metastatic tumor cells in vivo.  
 Although an increasing number of studies have reported in vitro and in vivo 
hypoxia-mimicking materials for applications such as bone regeneration and wound 
healing, an in vivo platform that is able to establish a hypoxic metastatic niche has not yet 
been reported. As microporous PLG scaffolds have been previously used to capture 
metastatic tumor cells [40] and can be readily combined with other niche elements such as 
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soluble factors [136], we hypothesized that the engineered Co-PLG scaffold could still 
capture metastatic tumor cells even with the addition of CoCl2. To determine whether Co-
PLG scaffolds can still serve as a metastatic niche that captures disseminating tumor cells, 
we examined tumor cell recruitment to Co-PLG scaffolds. The number of metastatic breast 
cancer cells recruited to this type of polymer scaffold is low, which makes quantification 
of metastasis through histological analysis challenging [127,136]. Thus, we employed a 
previously established qRT-PCR-based assay for tumor cell quantification in the 4T1 
breast cancer metastasis model [138]. The prior work found that the expression of MT2, 
which is highly expressed in 4T1 breast tumors [156], was significantly higher in scaffolds 
from tumor-bearing mice compared to the scaffolds from tumor-free mice, indicating that 
the recruitment of 4T1 cells to the scaffolds could be detected by qRT-PCR-based analysis 
of MT2[138]. Therefore, we examined MT2 expression in Co-PLG scaffolds to evaluate 
tumor cell recruitment, with normal PLG scaffolds serving as a positive control (Fig. 3-
8A). To generate a 4T1 primary tumor, 2 million 4T1 metastatic breast cancer cells were 
orthotopically injected into the right mammary pad of the mice prior to scaffold 
implantation, with PBS injections performed as negative control. Two 15-Co-PLG or bare 
PLG scaffolds were implanted into the subcutaneous region of the mice at 7 days post-
tumor inoculation. The primary tumors became visible and palpable in all mice at 7-14 
days post-tumor inoculation and continuously grew until removal of the implanted 
scaffolds. The implanted scaffolds were retrieved 14 days after implantation for qRT-PCR 
analysis. Our results showed that both Co-PLG and normal PLG scaffolds from the tumor-
bearing mice exhibited significantly higher MT2 expression compared to scaffolds from 
the tumor-free mice, indicating that both Co-PLG and PLG scaffolds recruited 4T1 
metastatic breast cancer cells (Fig. 3-8B). Furthermore, MT2 expression in Co-PLG 
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scaffolds was similar to that in PLG scaffolds, suggesting that the addition of CoCl2 to PLG 
scaffolds did not negatively affect the ability of PLG scaffolds to recruit metastatic tumor 
cells. Given that the microenvironment within the Co-PLG scaffolds was still hypoxic at 
the time tumor cells were recruited into the scaffolds (day 14 post scaffold implantation, 
Fig. 3-7), these results suggest that Co-PLG scaffolds can serve as in vivo hypoxic 
metastatic niche.  
 
Figure 3-8. Co-PLG scaffolds can recruit 4T1 metastatic breast cancer cells. (A) Schematic of mouse 
metastasis model for assessment of in vivo tumor cell recruitment: a) Tumor inoculation at day 0, b) 
Scaffold implantation at day 7, c) Scaffold harvest and RNA extraction at day 21, and d) qRT-PCR 
analysis of MT2 expression. (B) qRT-PCR analysis of MT2 expression to evaluate in vivo tumor cell 
recruitment into the implanted scaffolds (n ³ 4 scaffolds per group). Fold change in mRNA expression 
of MT2 relative to scaffolds from mice receiving PBS injection instead of tumor inoculation (negative 
control) by qRT-PCR (*P < 0.05 compared to PBS control). 
 
Subcutaneous sites were chosen in this study for their accessibility and amenability to non-
invasive imaging, which can be combined with Co-PLG scaffolds in the future. While 
subcutaneous implantation does not recapitulate all cellular elements of the native 
metastatic niche, previous studies have demonstrated that subcutaneously implanted 
scaffolds can recapitulate the immune cell populations present in the metastatic niche [127]. 
Given that these scaffolds can be readily combined with other niche-specific elements such 
as extracellular matrix components, niche-specific cells, and soluble factors to better mimic 
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desired features of natural metastatic niches [40,136,157], Co-PLG scaffolds can provide 
a versatile, experimentally accessible platform in the subcutaneous region that enables 




As a growing body of studies have suggested, hypoxia in metastatic niches 
regulates cues directing the fate of DTCs that reside in the niche. Despite its emerging 
clinical importance, detection of hypoxic metastatic niches in target organs with current 
imaging techniques has been challenging due to their often inaccessible and unpredictable 
locations. Consequently, hypotheses related to dormancy, proliferation, and metabolic 
adaptation of DTCs in hypoxic niche at target organs have not been fully examined. Thus, 
appropriate in vivo experimental platforms that enable the detailed investigation of hypoxic 
regulation in metastatic niches are needed. In this work, PLG scaffolds that have previously 
been used as an in vivo metastatic niche were engineered to establish a hypoxic 
microenvironment via the addition of CoCl2. We demonstrated that Co-PLG scaffolds 
combining the hypoxia-mimicking ability of CoCl2 and tumor cell-recruiting ability of 
microporous PLG scaffolds can generate an experimentally accessible in vivo hypoxic 
metastatic niche in an area beneath the skin, enabling the examination of hypotheses that 
were untestable using previous approaches. 
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Chapter 4 – Sonosensitizer-functionalized graphene nanoribbon 
for adhesion blocking and sonodynamic ablation of ovarian 
cancer spheroids.  
 
4.1. Introduction 
Development of therapeutic strategies that reduce metastatic spread of cancer 
spheroids in peritoneal cavity has been a key issue in ovarian cancer treatment. Ovarian 
cancer spheroids disseminated from the primary tumor are transported throughout the 
peritoneal cavity by ascites fluid and eventually adhere to the peritoneal organs covered by 
mesothelial layer [158–160]. This unique mode of ovarian cancer metastasis allows for 
many metastases to develop simultaneously within the peritoneal cavity, rendering the 
disease untreatable with standard treatments such as debulking surgery or chemotherapy. 
One alternative therapeutic strategy has been used to disrupt integrin-mediated interactions 
with ECM proteins on mesothelial layer that mediate mesothelial adhesion of ovarian 
cancer spheroids [46]. For example, monoclonal antibody against integrin b1 subunits 
significantly blocked mesothelial adhesion of ovarian cancer spheroids in vitro [46,161] 
and in vivo [49]. Despite their potential in preclinical studies, none of integrin blocking 
approaches have demonstrated clinical benefit thus far [49–51],  indicating that inhibition 
of a single type of integrin is not sufficient to prevent metastatic spread of ovarian cancer 
or that non-integrin associated pathways are also involved [46,158]. Thus, a novel 
therapeutic strategy to reduce the seeding of ovarian cancer spheroids throughout the 
peritoneal cavity is needed.  
Graphene-based materials including graphene oxide (GO) and graphene 
nanoribbon (GNR) have shown potential in biomedical applications including cancer 
therapy due to their unique physical and chemical properties [56,162,163]. For example, 
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the presence of various functional groups (e.g. hydroxyl, epoxyl, and carboxyl groups) in 
their chemical structure allows for additional functionalization to ensure high solubility 
and stability in physiological solutions and to facilitate drug and biomolecule loading 
[164,165]. Furthermore, these functional groups in a polyaromatic domain of graphene-
based materials can adsorb ECM proteins through hydrophobic interactions, electrostatic 
forces, and hydrogen bonding [166], enabling cell adhesion to graphene-based materials. 
Previous studies found that adhesion of mesenchymal stem cells to graphene-based 
materials involve surface adhesion receptors implicated in mesothelial adhesion of ovarian 
cancer spheroids such as integrin b1 [167,168]. While graphene-based materials have not 
been previously shown to associate with ovarian cancer spheroids, these previous findings 
suggest that graphene-based materials can be used to target integrin receptors on the 
ovarian cancer spheroids. 
The hydrophobic polyaromatic domain of graphene-based materials can also 
provide exceptionally high loading capacity of aromatic drug molecules via pi-pi stacking 
[169,170], making these materials a versatile carrier for a wide variety of chemotherapeutic 
drugs [164,170,171]. Recently, graphene-based materials have also been integrated with 
sensitizing agents that generate cytotoxic effects upon external triggers such as light or 
ultrasound for tumor-specific treatment [56,172]. Graphene-based materials have widely 
been employed as a carrier for photosensitizers in photodynamic therapy (PDT) but low 
penetration depth of light limits its efficacy for deep-seated tumors [56,173,174]. As 
compared to conventional PDT, sonodynamic therapy (SDT) using ultrasound and a 
sonosensitizer has shown better therapeutic potential with high tissue-penetrating ability 
when combined with graphene-based materials [172,175]. For instance, graphene 
nanosheets loaded with a sonosensitizer significantly enhanced the efficacy of SDT [172]. 
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Thus, we hypothesized that targeting metastatic ovarian cancer spheroids with 
sonosensitizer-loaded graphene-based materials could block the mesothelial adhesion of 
the spheroids as well as kill the spheroids via targeted delivery of sonosensitizers coupled 
with ultrasound irradiation. 
In this work, two graphene-based materials, GO, a single or few-layered two-
dimensional carbon sheet, and GNR, narrow strips of unzipped multi wall carbon 
nanotubes (CNTs), were tested to target ovarian cancer spheroids in ascites. Our results 
demonstrated that GNR functionalized with 4-arm polyethylene glycol (GNR-PEG) 
exhibited better cytocompatibility to mesothelial cells and adhesion blocking effects than 
GO-PEG. GNR-PEG was able to disrupt mesothelial adhesion of ovarian cancer spheroids, 
providing sustained adhesion blocking effects compared to conventional antibody blocking 
approaches. In addition, GNR-PEG loaded with sonosensitizer Ce6 (GNR-PEG-Ce6) was 
able to kill ovarian cancer spheroids via sonodynamic therapy, which was not possible in 
conventional approaches that only focus on blocking spheroid adhesion. Adhesion 
blocking and sonodynamic effects of GNR-PEG-Ce6 were also observed in the tests with 
ovarian cancer spheroids derived from patient ascites fluid, providing further evidence of 
therapeutic potential. This approach for blocking adhesion of ovarian cancer spheroids and 
ablating them even once they have had adhered offers a promising therapeutic strategy to 
reduce metastatic spread of ovarian cancer in peritoneal cavity.  
 
 4.2. Materials and methods 
Synthesis of GO/GNR. GO was synthesized via the modified Hummer’s method [176]. 
Briefly, 2 g of graphite powder (Sigma-Aldrich 282863) was dispersed in a 98% sulfuric 
acid solution followed by the slow addition of 7 g of potassium permanganate (KMnO4; 
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Sigma-Aldrich 223468) to the mixture. The mixture was incubated at 35°C for 2 h in a 
water bath. Next, 200 mL of DI water was slowly added to the mixture in an ice bath. Then, 
10 mL of hydrogen peroxide (H2O2; Sigma-Aldrich H1009) was added. The resulting GO 
solution was filtered through a paper filter and repeatedly washed in a 10% (v/v) 
hydrochloric acid and deionized (DI) water solution to remove the remaining manganese 
impurities. The prepared GO was resuspended in DI water and lyophilized for at least 48 
h. GNR was also prepared as previously described [177]. To prepare GNR, 1 g of multiwall 
carbon nanotubes (Hanwha Chemical CM150) was dispersed in 100 mL of 98% sulfuric 
acid with vigorous stirring. Then, 3.5 g of KMnO4 was slowly added to the dispersion and 
stirred at 35°C for 15 h. 100 mL of deionized water was slowly added to this solution in an 
ice bath. Next, 100 mL of H2O2 was slowly added to the mixture to terminate the oxidation 
of carbon nanotubes by KMnO4. To remove the acidic reaction solution, GNR was 
centrifuged at 15,000 rpm for 1 hour at 4°C, and precipitated GNR was washed in DI water 
several times. The purified GNR was resuspended in DI water and lyophilized for at least 
48 h. 
 
PEGylation of GO or GNR. For PEGylation with 4-arm PEG, GO or GNR were diluted 
to 1 mg/mL. 5 mg/mL of amine-terminated 4-arm PEG (average Mn = 2,000; Sigma-
Aldrich JKA7032) was added to the GO or GNR solution and bath-sonicated for 5 min. 
Then, 5 µM of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC; 
Thermo Fisher Scientific 22980) was added to the mixture and bath-sonicated for 30 min. 
Additional EDC was added to mixture to the final concentration of 20µM, and the mixture 
was stirred overnight at room temperature. To remove unbound 4-arm PEG, the resulting 
GO-PEG or GNR-PEG solution was centrifuged at 15,000 rpm for 1 hour, and precipitated 
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GO-PEG or GNR-PEG was resuspended in sterile water at a final concentration of 1 
mg/mL. PEGylation was confirmed using Fourier-transform infrared spectroscopy (FTIR). 
FTIR was conducted using the Nicolet 6700 FTIR spectrometer (Thermo Fisher Scientific). 
To evaluate stability in physiological buffers, GO-PEG or GNR-PEG were suspended in 
cell culture media containing 10% (v/v) fetal bovine serum (FBS; Thermo Fisher Scientific 
16000044) and 1% (v/v) penicillin-streptomycin (PS; Thermo Fisher Scientific 15140122). 
Aggregation was monitored over 24 h after a brief sonication. 
 
Synthesis and characterization of GNR-PEG-Ce6.  Ce6 (Santa Cruz Biotechnology sc-
263067) was dissolved in dimethyl sulfoxide (DMSO), followed by dilution in water to 
achieve the desired final concentration. For Ce6 loading onto GNR-PEG, Ce6 was added 
to 1 mg/ml GNR-PEG in water to the final concentration of 0.01 mg/ml and stirred 
overnight at room temperature. Unloaded excess Ce6 in the supernatant was removed after 
brief centrifugation of GNR-PEG-Ce6 followed by washing in water. This step was 
repeated until the green color of Ce6 in the supernatant disappeared. UV-Vis spectrometry 
was performed using the Evolution 220 UV-Visible spectrophotometer (Thermo Fisher 
Scientific) to evaluate Ce6 loading.  
 
Cell culture. SKOV-3 human ovarian cancer cells (ATCC HTB-77) were maintained in 
McCoy’s 5A media (Thermo Fisher Scientific 16600) supplemented with 10% (v/v) FBS 
and 1% (v/v) PS. LP-9 human peritoneal mesothelial cells (Coriell Institute AG07085) 
were maintained on flasks pre-coated with gelatin (0.1 w/v%;  STEMCELL Technologies 
07903) in media prepared by mixing Dulbecco’s Modified Eagle Media (DMEM, Sigma-
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Aldrich D6429) and Media 199 (GE Healthcare Life Science SH30253.01) in a 1:1 ratio, 
supplemented with 15% FBS, 10 ng/ml EGF (PeproTech AF-100-15), and 0.4 μg/ml 
hydrocortisone (Sigma-Aldrich).  
 
Cancer spheroid generation on a pHEMA-coated plate. To make the poly(2-
hydroxyethyl methacrylate) (pHEMA, Sigma-Aldrich P3932) solution, 1.2 g of pHEMA 
pellets were dissolved in 38 mL of 95% ethanol in water. The solution was stirred overnight 
at room temperature, then sterile-filtered using a tube top filter unit (Miliporesigma 
SCGP00525) and stored at 4 ℃ prior to future use. Cell culture plates were coated with 
pHEMA (15µL/cm2) and dried overnight at room temperature in a biosafety cabinet. For 
spheroid generation, 2 million SKOV-3 cells suspended in 10 mL of maintenance media 
were plated on a 100 mm diameter pHEMA-coated culture dish. Patient ascites spheroids 
were also maintained on a pHEMA-coated culture dish in McCoy’s 5A media 
supplemented with 10% (v/v) FBS and 1% (v/v) PS. Spheroid size, represented as an 
average of two perpendicular diameters, was measured using ImageJ software.  
 
Treatment with graphene-based materials or monoclonal antibodies (mAbs). SKOV-
3 spheroids had been cultured on a pHEMA-coated dish in McCoy’s 5A media 
supplemented with 10% (v/v) FBS and 1% (v/v) PS for 24h before treated with graphene-
based materials or mAbs. Graphene-based materials or mAbs were directly added to the 
media and incubated with SKOV-3 spheroids for 48 h. For blocking surface receptors, 100 
µg/mL of antibody against each receptor was used. Monoclonal antibodies used for 
blocking surface receptor are listed in Table 4-1. 
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Table 4-1. Monoclonal antibodies for blocking surface receptors 
Target antigen Antibody species Vendor Clone or product number 
integrin b1 Mouse Santa Cruz Biotechnology SC-13590L; clone P5D2 
CD44 Mouse BD 550990; clone 515 
E-cadherin Rat ThermoFisher 16-3249-82; clone DECMA-1 
 
Spheroid adhesion tests on ECM proteins. For adhesion tests, 96-well plates with non-
tissue culture treated surfaces were coated with 50 μg/mL of collagen I (Corning 354249), 
collagen IV (Sigma-Aldrich C5533), or fibronectin (Sigma-Aldrich F1141) in distilled 
water overnight at 37 ℃ prior to spheroid plating. Spheroids were resuspended in serum-
free McCoy’s 5A media, and 100 μL of the suspension was added to each well of a 96-
well plate, providing 50-100 spheroids per well. The total number of spheroids in each well 
was manually counted prior to incubation. After incubation, non-adhered spheroids were 
washed out and the number of remaining spheroids were counted. The percentage of 
adhered spheroids in each well was calculated as the number of remaining spheroids 
divided by the total number of spheroids before incubation.  
 
Spheroid adhesion test on LP-9 mesothelial cell layer. LP-9 mesothelial cells were 
cultured on gelatin-coated 6-well plates until a confluent monolayer was formed. Then, 
SKOV-3 spheroids cultured for 24 h on the pHEMA-coated surface were mixed with 50 
μg/mL of GNR-PEG or GNR-PEG-Ce6 in 2 mL of the LP-9 cell maintenance media and 
50-100 spheroids were transferred on top of the LP-9 cell monolayer. The plates were 
gently rotated on the orbital shaker at 50 rpm during the test. The adhesion rate was 
evaluated as described above for adhesion tests on the ECM proteins.  
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Scanning Electron Microscopy (SEM). Spheroids were prepared for SEM imaging as 
previously described [178]. Briefly, spheroids were fixed in 2.5% (v/v) glutaraldehyde 
(Sigma-Aldrich G5882) in phosphate-buffered saline (PBS) for 60 min at room 
temperature, followed by cross-linking in 0.5% (w/w) osmium tetroxide (OsO4; Acros 
Organics AC197450010) for 30 min at room temperature. Fixed spheroids were dehydrated 
with a graded ethanol series from 25% to 100% anhydrous ethanol. Then, dehydrated 
spheroids were resuspended in hexamethyldisilazane (HMDS, Sigma-Aldrich 440191), a 
chemical dehydrant, and placed on a silicon wafer for drying overnight prior to imaging.  
Prepared spheroids were coated with 10 nm of iridium using an EM ACE600 sputter coater 
(Leica). For bare or PEG-conjugated GO/GNR, 10 μL of diluted GO/GNR solution (0.05 
mg/mL) was dropped onto a silicon wafer and dried in a vacuum oven at 100 ℃ for 2 h. 
The samples were coated with 2 nm of iridium using the EM ACE600 sputter coater. 
Imaging was performed at 2 kV accelerating voltage using a field emission gun scanning 
electron microscope (SU-8230, Hitachi).  
 
Spheroid disaggregation and spreading assay. For the spheroid disaggregation and 
spreading assay, 24-well plates were coated with 50 µg/mL of collagen I, IV, or fibronectin 
overnight at 37 °C prior to spheroid seeding. Spheroids treated with GO-PEG or GNR-
PEG for 48 hours were suspended in 10% serum-supplemented McCoy’s 5A media and 
transferred to the ECM protein-coated plates. The spheroids that had not adhered were 
washed out after 2 h of incubation. The adherent spheroids were imaged at 4 and 24 h after 
the final washing using the EVOS FL Auto fluorescence microscope (Thermo Fisher 
Scientific). To evaluate the average spreading distance of adhered spheroids, the four 
 86 
farthest distances between the outer boundary of spreading cell layer and the boundary of 
non-disaggregated center of adhered spheroids at each time point were measured using 
ImageJ software.   
 
Immunofluorescence assays. Immunofluorescence staining was performed as previously 
described[179]. Primary and secondary antibodies used for staining are listed in Tables 4-
2 and 4-3. Imaging was conducted with an EVOS FL Auto fluorescence microscope.  




species Vendor Clone or product number Dilution 
F-actin Phalloidin ThermoFisher A12379; Alexa Fluor™ 488 Phalloidin 1:200 
CA125 Mouse ThermoFisher MA5-11579; clone Ov185:1 1:200 
CK7 Mouse ThermoFisher MA5-11986; clone OV-TL 12/30 1:200 
 
Table 4-3. Secondary antibodies used for immunofluorescence assays 
Species reactivity Host Conjugate Vendor Dilution 
Mouse Goat Alexa Fluor 594 A21240; ThermoFisher 1:1000  
Mouse Goat Alexa Fluor 488 A11001; ThermoFisher 1:1000 
 
Western blot analysis. Western blots were performed as previously described[179]. For 
detection of integrin a5, integrin β1, CD44, E-cadherin, and talin-1, 20 µg of whole cell 
lysate was used. For detection of β-actin, 10 µg of whole cell lysate was used. Primary and 
secondary antibodies used in Western blot analysis are listed in Tables 4-4 and 4-5. 
Table 4-4. Primary antibodies used for western blotting 
Target antigen Antibody species Vendor Clone or product number Dilution 
integrin a5 Mouse Cell Signaling Technology 98204; clone D7B7G 1:1000 
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integrin b1 Mouse Cell Signaling Technology 34971; clone D6S1W 1:1000 
E-cadherin Rabbit Cell Signaling Technology 3195S; clone 24E10 1:200 
CD44 Mouse BD Biosciences 550990; clone 515 1:1000 




Rabbit Cell Signaling Technology 5125S; clone 13E5 1:1000 
 
Table 4-5. Secondary antibodies used for western blotting 
Species reactivity Host Conjugate Vendor Dilution 
Mouse Goat HRP G21040; ThermoFisher 1:6000  
Rabbit Goat HRP 7074S; Cell Signaling Technology 1:2000 
 
Cell viability test. The Live/Dead cell viability assay (Thermo Fisher Scientific L3224) 
and alamarBlue assay (Thermo Fisher Scientific DAL10250) were performed as previously 
described[179] to evaluate the toxicity of graphene-based materials to the LP-9 cell 
monolayer.  
Mesothelial clearance test. SKOV-3 spheroids were been treated with 50 μg/mL of GNR-
PEG or GNR-PEG-Ce6 for 48 h before transferred on top of a confluent LP-9 cell 
monolayer in 6 well plates. The LP-9 cell layer was stained with CellTracker™ Green Dye 
(Thermo Fisher Scientific C2925) for 30 min prior to incubation with the spheroids. The 
SKOV-3 spheroids were labeled with CellTracker™ Red Dye (Thermo Fisher Scientific 
C34552) 1 h prior to seeding on top of LP-9 cells. The clearance of LP-9 cells underneath 
the spheroids was monitored and imaged using an EVOS FL Auto fluorescence microscope 
every hour.  
 
Ultrasound irradiation of adhered spheroids. SKOV-3 spheroids mixed with 50 μg/mL 
of GNR-PEG or GNR-PEG-Ce6 in 2 mL of the LP-9 cell maintenance media were 
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transferred on top of a confluent LP-9 cell monolayer in 6 well plates. The plates were 
gently rotated on the orbital shaker at 50 rpm for 48 h. After 48 h of treatment, non-adhered 
spheroids were removed and each well was filled with 10 mL of media for ultrasound 
irradiation. Since SKOV-3 spheroids completely spread out in 48 h without GNR treatment, 
untreated spheroids adhered to the LP-9 layer at 6 h of incubation were used as the control 
to achieve similar levels of adhesion and disaggregation compared to the GNR-PEG-
treated or GNR-PEG-Ce6-treated spheroids. Then, ultrasound irradiation was delivered 
using an ultrasound unit with 4 cm2 transducer (LG MedSupply LG-US1). The transducer 
was immersed in the media and 0.8 W/cm2 of ultrasound irradiation at a frequency of 1Mhz 
was delivered for 30 s. The Live/Dead assay was performed 30 min after ultrasound 
irradiation. 
 
ROS detection in SKOV-3 spheroids and LP-9 mesothelial cells. The generation of ROS 
after ultrasound irradiation was evaluated using a DCFDA (2’,7’–dichlorofluorescin 
diacetate) - Cellular ROS Assay Kit (Abcam ab113851). As in the previous adhesion test, 
SKOV-3 spheroids mixed with 50 μg/mL of GNR-PEG-Ce6 were placed on top of a 
confluent LP-9 layer in 96-well plate rotated at 50 rpm during the test. After 48 h of 
incubation, LP-9 layer and SKOV-3 spheroids were separated and washed once with ROS 
staining buffer followed by staining with 20 µM of DCFDA for 30 min (LP-9 monolayer) 
or 60 min (SKOV-3 spheroids) at 37 ℃. The stained samples were washed once with ROS 
staining buffer and the fluorescence signal was measured using a Synergy H1 
spectrophotometer (BioTek). Then, 0.8 W/cm2 of ultrasound irradiation at a frequency of 
1Mhz was delivered for 30 s. After ultrasound irradiation, fluorescence signal was 
measured again. The percent increase of ROS generation was determined from the increase 
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in fluorescence signal after treatment or irradiation. Tert-butyl hydrogen peroxide (TBHP) 
was used as positive control in this assay.  
Chemotherapy in combination with GNR-PEG-Ce6. Cisplatin (Sigma-Aldrich P4394) 
and paclitaxel (Sigma-Aldrich T7191) were reconstituted in DMSO to 10 % (w/v) and 
diluted in cell culture media. SKOV-3 spheroids were treated with GNR-PEG or GNR-
PEG-Ce6 for 48 h followed by exposure to 20 µM cisplatin or paclitaxel for 5 days, after 
which cell viability was evaluated using the Live/Dead assay. Imaging was performed 
using EVOS FL Auto fluorescence microscope.  
 
Statistical analysis. Statistical analysis was performed with GraphPad Prism, using an 
unpaired Student’s t test to determine P values. All data are presented as mean ± standard 
deviation of three biological replicates from one of three representative independent 
experiments. Difference between groups was considered statistically significant when a P 
value is less than 0.05. 
 
4.3. Results and discussion 
4.3.1. PEGylation of GO and GNR to reduce aggregation in the serum-rich ascites 
microenvironment. Since graphene-based materials are known to have low stability and 
exhibit significant aggregation in physiological solutions, in part due to nonspecific 
binding of proteins [164], amine-terminated 4-arm PEG was conjugated to GO and GNR 
via amide formation to reduce aggregation in ascites, a protein-rich body fluid. FTIR 
spectra revealed that the signature peaks of 4-arm PEG, a C-O stretch (red region at ~1100 
cm-1, Fig. 4-1A) and a COO-H/O-H stretch (blue region at ~2850 cm-1)[164], appeared on 
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GO-PEG and GNR-PEG. In addition, as a consequence of amide formation, a C=O peak 
in amide bond (yellow region at ~1640 cm-1) appeared in GO-PEG and GNR-PEG. 
Scanning electron microscope (SEM) images revealed no significant morphological 
changes in GO and GNR after PEGylation (Fig. 4-1B).  
 
Figure 4-1. PEGylation of GO and GNR to reduce aggregation in serum-rich ascites. (A) FTIR 
spectra of GO-PEG (left) and GNR-PEG (right). (B) Representative SEM images of GO, GO-PEG, 
GNR, and GNR-PEG revealed no significant morphological changes after PEGylation (C) 
Aggregation test in cell culture media containing 20% (v/v) serum (FBS). Graphene-based 
materials (100 µg/mL) settled over time in serum-rich media due to aggregation by non-specific 
binding of proteins.  
 
To evaluate aggregation after PEGylation, 100 µg/mL of  GO, GNR, GO-PEG and GNR-
PEG were suspended in cell culture media containing 20% (v/v) serum, to mimic serum-
rich ascites fluid, and monitored over time after brief sonication. The delayed aggregation 
of GO-PEG and GNR-PEG compared to bare GO and GNR in serum-supplemented cell 
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culture media is indicative of reduced aggregation following the addition of PEG, with no 
significant aggregation observed in GNR-PEG at 48 h (Fig. 4-1C). Then, GO-PEG and 
GNR-PEG were tested with LP-9 human mesothelial cells, a major cellular component in 
peritoneal cavity, to evaluate their cytocompatibility. While GNR-PEG did not induce any 
negative effects in viability and proliferation of LP-9 cell layer, GO-PEG significantly 
reduced the viability, integrity, and proliferation of the mesothelial cell layer at 
concentrations higher than 50 µg/mL (Fig. 4-2), suggesting that GNR-PEG is more 
cytocompatible than GO-PEG.  
 
Figure 4-2. GNR-PEG was more cytocompatible to LP-9 mesothelial cells than GO-PEG which 
significantly deteriorated the integrity and proliferation of LP-9 mesothelial layer. (A) 
Representative Live/Dead staining images of LP-9 cells treated with GO-PEG or GNR-PEG for 48 
h. Scale bars indicate 400 µm. (B) Proliferation of LP-9 cells after 48 h of incubation with GO-
PEG or GNR-PEG (*P < 0.05). 
 
4.3.2. GO-PEG and GNR-PEG adsorb to ovarian cancer spheroids and disrupt their 
adhesion to ECM proteins abundant in mesothelial layer. The SKOV-3 cell line was 
used to evaluate the interactions between GO-PEG or GNR-PEG and ovarian cancer cells, 
since this cell line was derived from the ascites fluid of an ovarian cancer patient [180]. 
Cancer spheroids were generated using an established method [42,181,182]; SKOV-3 cells 
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placed in culture on a non-adhesive poly(2-hydroxyethyl methacrylate) (pHEMA) surface 
spontaneously aggregated and formed spheroids. After 24 h, the spheroids ranged from 55 
to 330 µm in size, which is in the clinically observed size range of cancer spheroids in the 
ascites of ovarian cancer patients (30-200 µm [46,161]). Thus, the spheroid formation step 
was performed for 24 h for all remaining studies. After formation, spheroids were 
incubated with GO-PEG or GNR-PEG at various concentrations (50-100 µg/mL) for 48 h.  
 
Figure 4-3. GO-PEG and GNR-PEG disrupt adhesion of SKOV-3 spheroids to ECM proteins 
abundant in mesothelial layer. (A) Representative phase contrast and SEM (LM; low magnification, 
HM; high magnification) images of SKOV-3 spheroids. Scale bars indicate 400 µm in phase 
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contrast images, 50 µm (LM), and 10 µm (HM) in SEM images. The white arrows in SEM(HM) 
images indicate the exposed cell surfaces. (B) SEM images revealed that entangled strands of GNR-
PEG formed a barrier with thickness in micrometer range while the thickness of GO-PEG layer 
was in nanometer range. (C) Percentage of total spheroids that have adhered after 1 and 3 days of 
incubation on collagen I/IV and fibronectin.  
 
Optical microscope and SEM images revealed that GO-PEG and GNR-PEG adsorbed onto 
SKOV-3 spheroids, forming a barrier layer covering the surface of the spheroids (Fig. 4-
3A). One-dimensional strands of GNR-PEG entangled on the surface formed a dense thick 
layer, while two-dimensional flat GO-PEG stacked along with the surface formed a thin 
layer (Fig. 4-3B). These barrier layer of GO-PEG and GNR-PEG were found to disrupt 
spheroid adhesion to collagen I, IV, and fibronectin, the most abundant ECM proteins on 
mesothelial layer [158]. When, GO-PEG- or GNR-PEG-treated SKOV-3 spheroids were 
transferred to ECM protein-coated surfaces in serum-free media, the spheroids displayed 
significantly inhibited adhesion to collagen I, IV, and fibronectin over 3 days, whereas all 
untreated SKOV-3 spheroids adhered (Fig. 4-3C). These results suggest that the physical 
barrier of GO-PEG/GNR-PEG on the surface could interfere with surface receptor-ECM 
protein interactions. In comparison, a conventional approach using antibody blocking of 
surface receptors such as integrin b1 or CD44, which have been shown to inhibit spheroid 
adhesion to ECM proteins for short time periods (2 h) in previous studies [46,161], did not 
have considerable blocking effects over 3 days under these conditions (Fig. 4-4). Increasing 
the concentration of GO-PEG or GNR-PEG from 50 to 100 µg/mL led to a decrease in 
adhesion rate, suggesting that higher concentrations provide better blocking effects. Since 
GNR-PEG exhibited greater adhesion blocking effects and cytocompatibility than GO-
PEG, GNR-PEG was used for the remaining studies.  
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Figure 4-4. Blocking surface receptors is not sufficient to disrupt spheroid adhesion to ECM proteins. 
(A) Percentage of total SKOV-3 spheroids that have adhered at 1 and 3 days after incubation on collagen 
I/IV and fibronectin. Antibody blocking of surface receptors was performed for 48 h prior to the 
adhesion test. (B) Representative fluorescence images of F-actin (green) and DAPI (blue) 
immunostaining in spheroids adhered to fibronectin-coated surfaces.  
 
GNR-PEG also inhibited disaggregation, the dissociation of the spheroid into single 
cells, and spreading of adhered SKOV3 spheroids (Fig. 4-5). Following adhesion, 
metastasizing ovarian cancer spheroids disaggregate and spread rapidly, with the spreading 
areas growing in size up to 200-fold in a week [54], in order to establish secondary tumors. 
While untreated SKOV-3 spheroids exhibited an average spreading distance of 58 ± 15 µm 
at 4 h, GNR-PEG-treated spheroids did not exhibit any visible spreading at this timepoint. 
Furthermore, the average spreading distance of untreated spheroids over 24 h was 
significantly higher compared to that of GNR-PEG-treated SKOV-3 spheroids, indicating 
that the barrier layer of GNR-PEG inhibits disaggregation and spreading of adhered 
spheroids. It was previously found that disaggregation and spreading of ovarian cancer 
spheroids are also mediated by interactions between surface receptors and ECM proteins, 
primarily integrin b1 and collagen I [54]. Thus, the barrier layer of GNR-PEG that 
interferes with surface receptor-ECM protein interactions in the process of spheroid 
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adhesion likely also inhibits disaggregation and spreading of spheroids once they have 
adhered. 
 
Figure 4-5. GNR-PEG disrupts disaggregation and spreading of adhered SKOV-3 spheroids. (A) 
Disaggregation and spreading of adhered SKOV-3 spheroids were evaluated at 4 and 24 h after 
adhesion. Scale bars indicate 400 µm. (B) Average spreading distance of untreated and GNR-PEG-
treated SKOV-3 spheroids at 4 and 24 h after adhesion was measured using ImageJ software (*P < 
0.05). 
 
4.3.3. Chlorin e6 (Ce6) loaded onto GNR-PEG enhances adhesion blocking effects of 
GNR-PEG by downregulating surface receptor proteins. Although coating the surface 
of ovarian cancer spheroids with GNR-PEG significantly inhibited their adhesion to ECM 
proteins, some spheroids treated with GNR-PEG were still able to adhere (Fig. 4-3C). Thus, 
we sought to develop a strategy by which the adsorption of GNR-PEG onto tumor 
spheroids attached to the mesothelial layer could be used to kill the cancer cells. To this 
end, we loaded Ce6 onto GNR-PEG via pi-pi stacking, noncovalent bonding between 
aromatic rings. Ce6 is a naturally occurring sonosensitizer, and its anti-tumor activity in 
sonodynamic therapy has been confirmed on various tumors including leukemia, breast, 
and liver cancers [183–185]. In addition, Ce6 was found to have selective accumulation in 
the tumor and rapid clearance from normal tissues in many previous studies [186,187], 
which potentially reduces the risk of side effects in normal tissues in peritoneal cavity. The 
 96 
loading of Ce6 was confirmed by UV-VIS spectrometry, in which characteristic absorption 
peaks of Ce6 at 400 nm and 660 nm appeared on the UV-VIS spectra of GNR-PEG-Ce6 
(Fig. 4-6A). Since a significant amount of undissolved Ce6 was visible at concentrations 
higher than 0.1 mg/mL due to the low solubility of Ce6 in water, 0.1 mg/mL was chosen 
as the concentration for Ce6 loading in our study to minimize wasted Ce6.   
 
 
Figure 4-6. Ce6 loading onto GNR-PEG further reduces spheroid adhesion to ECM proteins by 
downregulating surface receptor proteins. (A) UV-VIS spectra of free Ce6, GNR-PEG, and GNR-
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PEG-Ce6. (B) Percentage of total spheroids that have adhered after 3 days of incubation on collagen 
I/IV and fibronectin. (C) Representative SEM images of untreated, Ce6-treated, GNR-PEG-treated, 
and GNR-PEG-Ce6-treated SKOV-3 spheroids. Scale bars indicate 50 µm. (D) Western blot 
analysis of protein expression in untreated, GO-PEG-treated, GNR-PEG-treated, GNR-PEG-Ce6-
treated, and Ce6-treated SKOV-3 spheroids after 48 h of treatment.  
 
 Interestingly, GNR-PEG-Ce6 exhibited greater adhesion blocking effects 
compared with GNR-PEG. In the in vitro adhesion assays, none of the SKOV-3 spheroids 
treated with 50 µg/mL of GNR-PEG-Ce6 were able to adhere to any of the ECM proteins 
by 72 h. Ce6 alone had no significant blocking effects at 50 µg/mL but it significantly 
disrupted spheroid adhesion to ECM proteins (Fig. 4-6B) at 100 µg/mL. In addition, Ce6 
led to significant changes in spheroid morphology. SKOV-3 spheroids treated with Ce6 or 
GNR-PEG-Ce6 displayed a grape-like morphology with loosened cell-cell adhesion 
compared with tight cell-cell adhesion in the spheroids without Ce6 exposure (Fig. 4-6C). 
It was found that SKOV-3 spheroids treated with 100 µg/mL of Ce6 for 48 h displayed 
significantly downregulated expression of E-cadherin, which mediates cell-cell adhesion. 
Furthermore, integrin b1 and CD44 that mediate spheroid adhesion to ECM proteins also 
exhibited a significant decrease in Ce6-treated spheroids compared with untreated 
spheroids (Fig. 4-6D). Ce6 loaded onto GNR-PEG was also able to induce significantly 
reduced expression of these surface receptors in SKOV-3 spheroids, whereas GNR-PEG 
alone did not significantly decrease their expression. Thus, enhanced blocking effects of 
GNR-PEG-Ce6 are likely attributed to the downregulation of surface receptors that mediate 
spheroid adhesion. Though Ce6 alone has adhesion blocking effects at 100 µg/mL, 
significant cytotoxic effects on LP-9 mesothelial cells at this dose (Fig. 4-6E, F) limit its 
therapeutic use. In contrast, GNR-PEG-Ce6 exhibited significantly less toxicity at its 
effective concentrations (50-100 µg/mL, Fig. 4-6E, F) where no spheroid adhesion was 
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observed, as localized delivery of Ce6 to spheroids via GNR-PEG-Ce6 allows for a lower 
quantity of Ce6 to achieve similar effects, significantly reducing toxicity to mesothelial 
cells.  
 
Figure 4-7. GNE-PEG-Ce6 disrupts mesothelial adhesion of SKOV-3 spheroids and subsequent 
mesothelial clearance. (A) Representative phase contrast images of adhered and non-adhered 
spheroids in each condition after 72 h of incubation. (B) Percentage of total spheroids that have 
adhered to the LP-9 mesothelial cell layer after 4, 72, and 168 h of incubation (∗P < 0.05, ND 
indicates non-detected). (C) Percentage of total SKOV-3 spheroids that have adhered to LP-9 
mesothelial cell monolayers after 4 and 24 h of incubation. 
 99 
 
4.3.4. GNR-PEG-Ce6 inhibits spheroid adhesion to mesothelial layer and subsequent 
mesothelial clearance. To examine whether GNR-PEG-Ce6 could also disrupt 
mesothelial adhesion of ovarian cancer spheroids, GNR-PEG-Ce6 was tested in an ascites-
like in vitro microenvironment in which SKOV-3 spheroids were suspended on top of a 
confluent LP-9 mesothelial cell layer. Then, 50 µg/mL of GNR-PEG-E6 was added to the 
SKOV-3 spheroid suspension with orbital shaking at 50 rpm to mimic the movement of 
ascites in the peritoneal cavity, a crucial factor in the peritoneal microenvironment 
affecting the efficacy of therapeutic intervention [188–190]. It was found that GNR-PEG 
and GNR-PEG-Ce6 preferentially adsorbed onto SKOV-3 spheroids as opposed to the LP-
9 cells (Fig. 4-7A).Preferential accumulation of GNR-PEG and GNR-PEG-Ce6 on the 
spheroids instead of the LP-9 layer was likely attributed to the enhanced stability of the 
materials in serum-rich physiological buffers, which provided GNR-PEG and GNR-PEG-
Ce6 more time to interact with ovarian cancer spheroids before these materials settled due 
to aggregation. While 33 ± 8.2% of untreated SKOV-3 spheroids adhered to LP-9 cell layer 
at 4 h, GNR-PEG- or GNR-PEG-Ce6-treated SKOV-3 spheroids were not able to adhere 
by that timepoint (Fig. 4-7B). Furthermore, over 90% of untreated SKOV-3 spheroids and 
40% of GNR-PEG-treated spheroids adhered to LP-9 cell layer by 72 h, whereas less than 
2% of SKOV-3 spheroids treated with GNR-PEG-Ce6 were able to adhere in 72 h. This is 
likely attributed to the synergistic effects from the reduced expression of surface receptors 
by Ce6 and the barrier layer of GNR-PEG-Ce6. In comparison to GNR-PEG-Ce6, the 
conventional approach of blocking integrin b1 or CD44 with antibodies did not effectively 
inhibit mesothelial adhesion under the same experimental conditions. More than 80% of 
spheroids were able to adhere to LP-9 monolayer and spread out by 24 h in all groups 
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regardless of blocking (Fig. 4-7C), indicating that directly blocking surface receptors does 
not provide the longer-term efficacy of GNR-PEG-Ce6.   
 GNR-PEG-Ce6 also inhibited subsequent spreading of adhered spheroids on 
mesothelial layer. Following adhesion on mesothelial layer, metastasizing spheroids spread 
by clearing mesothelial cells from their path at adhesion sites, a phenomenon termed 
mesothelial cell clearance, in a talin-1- and integrin a5b1-dependent manner [48,191]. This 
has also been observed in clinical biopsies of patient tumors attached to peritoneal organs 
showing the absence of mesothelial cells underneath the attached tumor [191]. In our test, 
LP-9 cells underneath untreated SKOV3 spheroids exhibited clearance in 2 h (Fig. 4-8), 
which is consistent with the previous finding that tumor spheroids began clearing 
mesothelial layer 30 min after spheroids attachment [192]. In contrast, LP-9 cells beneath 
the SKOV-3 spheroids treated with GNR-PEG or GNR-PEG-Ce6 displayed significantly 
delayed clearance, with the lowest level of clearance observed with GNR-PEG-Ce6. After 
24 h of incubation, clearance of the LP-9 cell layer was visible in all groups except GNR-
PEG-Ce6, which displayed no sign of clearance over a 24 h period.  
 
Figure 4-8. GNE-PEG-Ce6 disrupts mesothelial clearance. Representative phase contrast images of 
SKOV-3 spheroids breaching the underlying LP-9 monolayer and corresponding fluorescence images 
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of the LP-9 monolayer (green) and SKOV-3 spheroids (red). Mesothelial clearance by SKOV-3 
spheroids was captured at 2 and 24 h after spheroid seeding. Scale bars indicate 200 µm. 
 
Western blot analysis revealed that GNR-PEG-Ce6 downregulates integrin a5 as well as 
b1 that mediate mesothelial clearance (Fig. 4-9). Thus, the delay observed in mesothelial 
clearance could be in part due to the downregulation of integrin a5b1, a key player in 
mesothelial clearance, as blocking a5b1 integrin was found to decrease mesothelial 
clearance in a previous study [191].  
 
Figure 4-9. Ce6 significantly downregulates integrin a5 as well as b1 in SKOV-3 spheroids, delaying 
the mesothelial clearance. The expression of talin-1 was not significantly affected by Ce6. b-actin was 
used as loading control. The whole protein was extracted after 48 h of the treatments. 
 
4.3.5. GNR-PEG-Ce6 can kill ovarian cancer spheroids via sonodynamic therapy and 
enhance the efficacy of adjuvant chemotherapy. To evaluate whether the sonodynamic 
therapy using GNR-PEG-Ce6 could kill adhered ovarian cancer spheroids, SKOV-3 
spheroids placed on top of a confluent LP-9 cell monolayer were treated with 50 μg/mL of 
GNR-PEG-Ce6 for 48 h, with orbital shaking at 50 rpm. Non-adhered spheroids were 
removed after 48 h of treatment, and ultrasound irradiation was delivered from the top (Fig. 
4-10A). Live/Dead images revealed no significant cell death prior to ultrasound irradiation 
in all conditions: untreated, GNR-PEG-treated, and GNR-PEG-Ce6-treated (Fig. 4-10B). 
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After 30 s of 0.8 W/cm2 ultrasound irradiation at a frequency of 1 MHz, massive cell death 
was detected in GNR-PEG-Ce6-treated spheroids adhered to the LP-9 layer (Fig. 4-10B).  
 
Figure 4-10. GNE-PEG-Ce6 can kill adhered ovarian cancer spheroids via sonodynamic therapy. 
(A) A schematic of ultrasound irradiation of adhered spheroids. (B) Representative Live/Dead 
staining images of untreated, GNR-PEG-treated, and GNR-PEG-Ce6-treated SKOV-3 spheroids 
adhered to the LP-9 mesothelial cell layer before and after ultrasound irradiation. Scale bars 
indicate 400 µm. (C, D) ROS generation in SKOV-3 spheroids (C) and LP-9 mesothelial cells (D) 
after ultrasound irradiation. (∗P < 0.05) (E) Histological cross-sectional view of untreated, GNR-
PEG-treated, GNR-PEG-Ce6-treated SKOV-3 spheroids. Scale bars indicate 50 µm. (F) 
Representative Live/Dead images of untreated, GNR-PEG-treated, GNR-PEG-Ce6-treated SKOV-
3 spheroids after 5 days of chemotherapy with 20 µM cisplatin (middle row), 20 µM of paclitaxel 
(bottom row). Scale bars indicate 400 µm. 
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Furthermore, GNR-PEG-Ce6-treated spheroids detached from the LP-9 layer 
during the ultrasound irradiation, suggesting weak adhesion between the spheroids and LP-
9 layer. In addition to the spheroids adhered to LP-9 layer, GNR-PEG-Ce6-treated 
spheroids that had not adhered to the LP-9 cells were also completely killed when ablated 
separately with the same level of ultrasound irradiation. Ultrasound irradiation alone 
triggered no significant cell death in SKOV-3 spheroids or LP-9 monolayers. Some cell 
death was also observed in GNR-PEG-treated spheroids after ultrasound irradiation, but it 
was not as significant as in the GNR-PEG-Ce6-treated spheroids, suggesting that cell death 
in GNR-PEG-Ce6-treated spheroids was primarily induced by the sonodynamic effect of 
Ce6. Cell death by sonodynamic therapy has been shown to be mediated by the generation 
of reactive oxygen species (ROS), which trigger apoptotic pathways within cells [187]. It 
was found that ROS generation upon ultrasound irradiation was significantly higher in 
GNR-PEG-Ce6-treated SKOV-3 spheroids compared with other groups (Fig. 4-10C). 
GNR-PEG also increased ROS generation upon ultrasound irradiation in SKOV-3 
spheroids but not to the same level as GNR-PEG-Ce6. In addition, ROS generation in LP-
9 cells was not significantly affected after ultrasound irradiation, likely due to the 
preferential accumulation of GNR-PEG-Ce6 on SKOV-3 spheroids over LP-9 cells (Fig. 
4-10D). Furthermore, GNR-PEG-Ce6 was not confined to the surface but actually 
penetrated deep into the SKOV-3 spheroids, allowing the delivery of Ce6-induced 
sonodynamic effects throughout the spheroids (Fig. 4-10E).  
GNR-PEG-Ce6 also enhanced the efficacy of adjuvant chemotherapy which can 
used to kill residual ovarian cancer spheroids after sonodynamic therapy. Current adjuvant 
chemotherapy for advanced stage ovarian cancer typically uses platinum- or taxane-based 
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drugs [193,194] but ovarian cancer spheroids have been found to have enhanced resistance 
to these drugs for many reasons, including poor drug penetration [195] and the presence of 
a number of cell-cell junctions in spheroids [196–198]. For example, cisplatin, a platinum-
based drug widely used for ovarian cancer, has shown limited penetration, being confined 
to the peripheral layer of cancer spheroids (0-30 µm) in previous studies [199,200]. 
Consistent with these previous findings, chemotherapy alone with cisplatin or paclitaxel 
was not able to induce significant cell death in SKOV-3 spheroids (Fig. 4-10F). However, 
a significant number of cells in GNR-PEG-Ce6-treated spheroids were killed by the same 
chemotherapy without sonodynamic therapy (Fig. 4-10F). This is likely due to the fact that 
the loosened cell-cell junctions in GNR-PEG-Ce6-treated spheroids enhanced the 
penetration of cisplatin or paclitaxel, whereas a barrier of tight cell-cell junctions in 
untreated and GNR-PEG-treated spheroids did not allow those drugs to penetrate 
throughout. Indeed, it was previously reported that epithelial junction opener (JO-1) 
improved the efficacy of co-administered chemotherapeutic drugs by loosening cell-cell 
junctions in an ovarian cancer model [197,198]. These results suggest that GNR-PEG-Ce6 
can be combined with conventional chemotherapy to kill ovarian cancer spheroids in 
peritoneal cavity, offering an additional therapeutic route with this material. 
 
4.3.6. GNR-PEG-Ce6 can disrupt mesothelial adhesion of ovarian cancer spheroids 
in patient ascites and destroy them via sonodynamic therapy.  Lastly, to demonstrate 
the translational potential of this material, GNR-PEG-Ce6 was tested with patient ascites 
spheroids. Prior to the studies, the staining of the spheroids with ovarian cancer marker 
cancer antigen 125 (CA125) and cytokeratin 7 (CK7) verified that they contained tumor 
cells (Fig. 4-11A).  
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Figure 4-11. GNE-PEG-Ce6 can disrupt mesothelial adhesion of patient ascites spheroids and 
destroy them via sonodynamic therapy. (A) Representative immunofluorescence images of CA125 
and CK7 expression in patient ascites spheroids. (B, C) Representative phase contrast (B) and SEM 
(C) images of untreated and GNR-PEG-Ce6-treated patient ascites spheroids. (D) Percentage of 
total patient ascites spheroids that have adhered to the LP-9 mesothelial cell layer after 72 h of 
incubation. (E) ROS generation in patient ascites spheroids after 30 s of 0.8 W/cm2 ultrasound 
irradiation. (F) Representative Live/Dead staining images of untreated, and GNR-PEG-Ce6 treated 
patient ascites spheroids that have adhered to LP-9 mesothelial cell layer before and after 
ultrasound irradiation.  
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GNR-PEG-Ce6 was able to adsorb onto patient ascites spheroids by 48 h of treatment (Fig. 
4-11B, C), forming a barrier layer on the outer surface. To evaluate adhesion, patient ascites 
spheroids were mixed with 50 μg/mL of GNR-PEG-Ce6 and placed on top of a confluent 
LP-9 cell layer. While the adhesion rate of untreated ascites spheroids after 72 h of 
incubation was lower compared to that of SKOV-3 spheroids, GNR-PEG-Ce6 significantly 
inhibited adhesion of patient ascites spheroids in all patient samples (Fig. 4-11D). When 
30 s of 0.8 W/cm2 ultrasound irradiation was applied to GNR-PEG-Ce6-treated spheroids, 
ROS generation significantly increased (Fig. 4-11E) and significant cell death was also 
observed in patient ascites spheroids adhered to LP-9 layers (Fig. 4-12F). GNR-PEG-Ce6-
treated patient ascites spheroids that had not adhered to LP-9 layers could be also be 
destroyed by ultrasound irradiation. These results collectively demonstrate that GNR-PEG-
Ce6 combined with sonodynamic therapy has therapeutic potential for advanced stage 
ovarian cancer patients.  
 
4.4. CONCLUSIONS 
There is an urgent need for development of alternative treatment options for ovarian 
cancer, which is typically diagnosed at advanced stages in which tumor spheroids are 
spreading throughout the abdominal cavity. In this study, we report a novel material-based 
therapeutic strategy using GNR functionalized with 4-arm PEG and the sonosensitizer Ce6 
to reduce metastatic spread of ovarian cancer within the peritoneal space. Our results 
demonstrate that GNR-PEG-Ce6 can adsorb to the surface of ovarian cancer spheroids, 
forming a physical barrier layer which disrupts mesothelial adhesion of the spheroids. 
GNR-PEG-Ce6 also significantly delays disaggregation and spreading as well as 
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mesothelial clearance of adhered spheroids, key steps in the establishment of ovarian 
cancer metastases. In addition, when combined with ultrasound irradiation, GNR-PEG-
Ce6 kills SKOV-3 spheroids adhered to LP-9 mesothelial cell monolayers via sonodynamic 
effects with minimal off-target damage, suggesting that this approach can eliminate 
residual tumors in peritoneal cavity. Furthermore, GNR-PEG-Ce6 can enhance the efficacy 
of conventional chemotherapy using cisplatin or paclitaxel in killing the ovarian cancer 
spheroids, offering another therapeutic route with this material. The efficacy of GNR-PEG-
Ce6 was also validated with ovarian cancer spheroids derived from patient ascites, 
demonstrating the translational potential of GNR-PEG-Ce6 in future clinical use. Given 
that GNE-PEG-Ce6 offers a new therapeutic route via minimally invasive sonodynamic 
therapy as well as enhancing conventional chemotherapy, targeting of metastatic cancer 
spheroids in the peritoneal cavity using GNR-PEG-Ce6 could provide promising strategies 
for preventing intraperitoneal spread of ovarian cancer. 
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Chapter 5 – Conclusions and future directions 
5.1. General conclusions 
 The aims of the work presented in this dissertation were (i) to establish in vitro and 
in vivo experimental platforms to study how hypoxia regulates tumor dormancy in breast 
and ovarian cancer and (ii) to develop a therapeutic strategy to target metastasizing ovarian 
cancer spheroids that is an alternative to chemotherapy, which cannot destroy dormant cells. 
The work discussed in Chapter 2 demonstrated that the hypoxia-mimetic agent CoCl2 can 
stably induce and maintain dormancy in breast and ovarian cancer cells, as evidenced by 
several hallmarks of dormancy: restrained cell growth, reversible cell cycle arrest at G0/G1 
phase, and reduced expression of cell cycling marker Ki67 in conjunction with stabilization 
of HIF1a. This was the first demonstration that CoCl2 can stably recapitulate hypoxic 
regulation of cancer dormancy, including the heterogeneity of cellular responses to hypoxia. 
This platform enables detailed investigation of the induction of dormancy under hypoxia 
in a more robust and versatile manner compared to conventional hypoxia chambers. For 
example, the CoCl2-based model can be readily integrated with previously established 
models that modulate other cellular and molecular components of the metastatic 
microenvironment. This versatility of the CoCl2 model could widen our understanding of 
the potential cellular or molecular cues regulating cancer dormancy under hypoxia. In 
addition, this platform could aid in our understanding of why the heterogeneity in cellular 
responses to pro-dormancy cues provided under hypoxia arises. Given that hypoxia and 
cancer dormancy have been associated with increasing the risk for tumor recurrence, 
resulting in poor clinical outcomes, information extracted from the CoCl2-based platform 
has the potential to identify novel therapeutic strategies for preventing recurrence. 
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In the work discussed in Chapter 3, a biomaterial platform that recapitulates an in 
vivo hypoxic metastatic niche was established to study hypoxic regulation of DTCs at 
metastatic sties. Recently, the significance of hypoxia in adaptation of DTCs to metastatic 
sites and subsequent dormancy or proliferation has been recognized in an increasing 
number of studies. However, it has been challenging to study the detailed mechanisms 
underlying how hypoxia at the metastatic site affects DTCs in concert with other factors 
due to the lack of appropriate experimental models. In addition, it is challenging to access 
natural hypoxic metastatic sites in the body, such as bone marrow, with current imaging 
techniques. To address these issues, microporous PLG scaffolds that were previously 
shown to recruit DTCs when implanted in mice by recapitulating the local immune 
microenvironment of actual metastatic sites was used in combination with CoCl2. CoCl2 
was incorporated into the PLG scaffolds to generate a hypoxic microenvironment within 
the metastatic niche created by PLG scaffolds. When implanted into mice beneath the skin, 
Co-PLG scaffolds established hypoxic microenvironments, as evidenced by the 
stabilization of HIF1a and increased blood vessel formation in vivo. Furthermore, the 
recruitment of 4T1 metastatic breast cancer cells to Co-PLG scaffolds was confirmed by 
evaluating the gene expression of MT2, which is known to be highly expressed in 4T1 
breast tumors. These results demonstrate that Co-PLG scaffolds can establish a hypoxic 
metastatic site in an experimentally accessible area beneath the skin, providing a novel 
platform to investigate hypoxic regulation of DTCs at metastatic sites. 
Lastly, a therapeutic strategy using GNR functionalized with PEG and Ce6 to target 
dormant ovarian cancer spheroids was developed in Chapter 4. Recurrent ovarian cancer 
has limited therapeutic options due to the widespread metastasis driven by extensive 
seeding of ovarian cancer spheroids in the peritoneal cavity, which in most cases are 
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resistant to standard chemotherapy. Thus, there has been an urgent need for alternative 
treatment options for advanced stage ovarian cancer in which tumor spheroids are 
spreading throughout the abdominal cavity. This work demonstrates that sonosensitizer 
functionalized GNR (GNR-PEG-Ce6) can disrupt mesothelial adhesion of ovarian cancer 
spheroids as well as kill ovarian cancer spheroids via sonodynamic ablation. GNR-PEG-
Ce6 formed a physical barrier on the outer surface of the spheroid and downregulated 
surface adhesion receptors, significantly inhibiting spheroid adhesion to the LP-9 
mesothelial layer. More importantly, localized delivery of Ce6 to ovarian cancer spheroids 
via GNR-PEG-Ce6 enabled sonodynamic ablation of spheroids adhered on the LP-9 cell 
monolayer, with significantly reduced cytotoxic effects compared with free Ce6. In 
addition, GNR-PEG-Ce6 also enhanced the efficacy of adjuvant chemotherapy using 
cisplatin or paclitaxel, which typically have difficult penetrating ovarian cancer spheroids, 
by loosening cell-cell adhesions within the ovarian cancer spheroids. Most importantly, 
GNR-PEG-Ce6 exhibited the same efficacy with ovarian cancer spheroids derived from 
patient ascites, demonstrating the translational potential in future clinical use. Thus, this 
approach could provide promising strategies for preventing intraperitoneal spread of 
ovarian cancer. 
 
5.2. Future directions 
5.2.1. Identification of key molecular mechanisms of heterogeneity in cell responses 
to hypoxia using the CoCl2-based in vitro platform combined with computational 
modeling 
Cancer cells frequently display substantial heterogeneity, which gives rise to 
differential sensitivity to anti-cancer drugs, and this heterogeneity is also found in cellular 
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responses to hypoxia. For instance, MCF-7 breast cancer cells became dormant while 
MDA-MB-231 breast cancer cells remained proliferative under hypoxia or hypoxia-
mimicking microenvironments in Chapter 2. Given that this heterogeneity often poses 
challenges in therapeutic efficacy, a better mechanistic understanding of what leads to the 
heterogeneity is critical to designing more effective therapies to reduce tumor recurrence.  
The experimental results from qRT-PCR and western blot analysis in Chapter 2 
revealed differential expression of p21 and its target CDK2-cyclin complexes in MCF-7 
and MDA-MB-231 under hypoxia, suggesting that p21 could be a major driver of 
heterogeneity under hypoxia. However, p21 is involved in complex signaling networks, 
and its activity is regulated by a number of upstream and downstream factors. For instance, 
p21 activation under hypoxia is regulated by p53, a tumor suppressor protein that has 
different functional status in MCF-7 and MDA-MB-231 cells. Thus, the complex networks 
regulating p21 activity need to be investigated to understand what drives the heterogeneity 
observed in MCF-7 and MBA-MB-231 cells under hypoxia.  
While experimental data extracted from the CoCl2-based in vitro platform could 
provide the mechanistic information needed to model the p21 regulation under hypoxia, 
the challenge lies in the large number of hypotheses that needs to be experimentally tested. 
To reduce the experimental conditions that need to be probed, computational analysis using 
mathematical modeling could be used to rapidly test multiple hypotheses on underlying 
biochemical processes. Reducing the number of experimental conditions will result in a 
faster and more efficient workflow that can be used to understand cell behavior and develop 
better strategies to effectively target the tumor population. Combined with computational 
analysis, experimental data extracted from the CoCl2-based in vitro platform can provide 
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the mechanistic information necessary for analyzing how the behavior of cancer cells 
varies depending on key molecular cues under hypoxia.   
Computational simulations with a mathematical model could also be used to 
explain cell-to-cell heterogeneity in dormancy induction observed in MCF-7 population in 
Chapter 2; some MCF-7 cells became dormant but others did not under the same hypoxic 
stresses. Since the CoCl2 platform can provide a facile, higher-throughput and well-
controlled hypoxic microenvironment compared to conventional hypoxia chambers, 
minimizing extrinsic variability, it can be also used to draw conclusions about cell-to-cell 
heterogeneity due to genetic and epigenetic variability as well as intrinsic noise, 
specifically, stochasticity due to low molecule numbers, cell cycle position, transcription 
and translation variability, as well as differing initial concentrations of the components. 
With experimental data extracted using CoCl2 platform, computational simulation could 
predict how these intrinsic factors affecting p21 lead to the cell-to-cell heterogeneity in 
dormancy induction.   
 
5.2.2. Identification of key therapeutic targets in dormant cancer cells under hypoxia 
using the CoCl2-based in vitro platform  
Based on the findings in Chapter 2, therapeutic approaches that target dormant 
cancer cells can be designed and tested using CoCl2-based in vitro platform. The 
experimental results in Chapter 2 revealed that the upregulated p21 inhibited its target 
CDK2-cyclin complexes in dormant MCF-7 cells and led to cell cycle arrest in G0/G1 
phase, which could allow dormant cancer cells to evade chemotherapy. It was previously 
found that p21 promotes cell cycle inhibition in response to anti-cancer drugs, protecting 
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cells from apoptosis as an active cell cycle is required to sense these drug and trigger 
apoptosis [201]. Furthermore, attenuation of p21 expression in chemotherapy-resistant 
renal cell carcinoma sensitized the cells to conventional chemotherapeutic agents. These 
finding suggests that inhibiting p21 in dormant cancer cells could be a therapeutic strategy 
that sensitizes dormant cancer cells to chemotherapeutic agents.  
To this end, small molecules inhibiting p21 could be used in combination with 
chemotherapeutic agents. Butyrolactone I, a potent inhibitor of p21 blocks p53-dependent 
activation of p21 and subsequent G1/G0 cell cycle arrest in cancer cells exposed to DNA 
damaging agents [202]. Sorafenib also significantly decreased p21 in cancer cells treated 
with doxorubicin. When combined with paclitaxel or doxorubicin, sorafenib enhanced 
cytotoxicity of treatment, suggesting that sorafenib can act as a sensitizing agent for 
conventional chemotherapeutics in the treatment of dormant cancer cells [203]. Promoting 
proteolysis of p21 could be also considered. Newly synthesized p21 upon DNA damage is 
protected from proteosomal degradation by FKBPL (FK506-binding protein-like) [204]. It 
was previously shown that inhibition of FKBPL expression by its inhibitor geldanamycin 
significantly disrupted p21 stabilization after DNA damage. Thus, inhibitors of FKBPL 
could also sensitize the dormant cancer cells to chemotherapeutic agents.  
Inhibition of p21 in dormant cancer cells could be also achieved by selectively 
targeting factors upstream or downstream of p21 that affect a particular aspect of p21 
function. For example, MYC induces overexpression of AP4 (activating enhancer binding 
protein 4), which in turn inhibits p21-mediated cell cycle arrest and sensitizes cells to DNA 
damage-induced apoptosis [201]. MYC also represses the transcription of CDKN1A, which 
encodes p21, by binding to and inhibiting the Sp1 transcription factor [205]. MYC can be 
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activated by various mitogenic signals including serum stimulation or EGF (epidermal 
growth factor) via the MAPK/ERK pathway [206]. Thus, adding mitogenic signals in 
combination with chemotherapeutic agents may also effectively kill dormant cancer cells 
under hypoxia.  
The function of p21 depends on its location within a cell. Cell cycle inhibition by 
p21 is associated with its nuclear localization, while cytoplasmic p21 activates the cell 
cycle by promoting the activity of CDK4/CDK6-cyclin D complexes [201]. Cytoplasmic 
accumulation of p21 is mediated by AKT1 kinase, which catalyzes the phosphorylation of 
p21. Since AKT1 is a downstream of HER2 (human epidermal growth factor receptor 2), 
cytoplasmic localization of p21 is observed in HER2-overexpressing cancer cells [207]. 
Thus, EGF-like ligands that bind to HER2 receptors could activate AKT1 kinase and 
sensitize dormant cancer cells to chemotherapeutic agents.  
Taken altogether, upregulated p21 expression in dormant cancer cells under 
hypoxia can be potentially exploited for a targeted therapy that sensitize the dormant cells 
to conventional chemotherapy. The CoCl2-based in vitro model will provide a platform for 
testing multiple strategies that could potentially inhibit p21 activation in dormant cancer 
cells, enabling the development of a combination therapy that could effectively kill 
dormant cancer cells. 
 
5.2.3. In situ intravital imaging of hypoxic regulation of DTCs at metastatic sites 
The in vivo platform using Co-PLG scaffolds, which is implantable in a 
subcutaneous region, could be used to provide easy access to various functional 
characterization, such as direct measurement of proliferation status of DTCs arriving at 
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hypoxic niches in metastatic organs. To this end, intravital imaging of engineered cancer 
cell lines via surgical engraftment of a skinfold window chamber above the Co-PLG 
scaffolds could be used. Oki et al. reported a modified fluorescence cell cycle indicator 
(FUCCI), developed by Sakaue-Sawano et al. [208], to effectively visualize G0, G1, and 
S/G2/M phases of the cell cycle for in vivo real time monitoring of cell proliferation status 
including quiescence [209]. Combined with intravital imaging, this modified FUCCI can 
visualize cancer cell dynamics including the transition between dormancy and proliferation, 
invasion, and metastasis. For instance, by using FUCCI and intravital imaging, Yano et al. 
found that cisplatin or paclitaxel killed only proliferating cancer cells in S and G2/M phases 
and had little effect on quiescent cancer cells in G0/G1 phase in liver tumors [210]. In 
addition, some of the quiescent cells in G0/G1 that evaded chemotherapy were found to 
resume proliferation by reentering the S and G2/M phases. Thus, intravital imaging of 
FUCCI-expressing DTCs arriving in Co-PLG scaffolds can directly visualize how hypoxia 
affects the cell fate of DTCs arriving at metastatic niches through the real time monitoring 
of cell cycle dynamics. This approach could be also used to test anti-cancer drugs targeting 
dormant DTCs in a hypoxic niche, as apoptosis can be also directly visualized in situ using 
a fluorescent probe [211]. Direct visualization of cell cycle dynamics and apoptosis of 
dormant DTCs in response to cancer drugs within the hypoxic niche could help design 
better therapeutic strategies to effectively destroy dormant cancer cells.   
Alternatively, ex vivo imaging of the Co-PLG scaffold with a tissue clearing 
technique (CLARITY) [212] could be used to investigate dormant DTCs in a hypoxic niche. 
The actual number of DTCs recruited in the scaffolds is low, and the number of dormant 
DTCs is even lower. Thus, conventional immunohistostaining and flow cytometry are not 
able to effectively detect rare DTCs due to the technical difficulties of probing entire tissue 
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volumes and potential cell loss during tissue digestion. However, CLARITY, which 
optically clears fixed tissues, enables microscopic detection of rare DTCs while retaining 
spatial resolution in the tissue microenvironment as well as minimizing cell loss. Carpenter 
et al. demonstrated that tissue clearing enabled optical imaging of microporous hydrogel 
scaffolds harvested from mice, capturing cellular signatures of the tumor 
microenvironment including immune cells, rare DTCs, and vascular networks [212]. 
Therefore, direct visualization of dormant DTCs within a hypoxic niche using Co-PLG 
scaffolds and CLARITY could be used to investigate microenvironmental features of 
dormant niches including protein enrichment, vascular networks (e.g. perivascular niche), 
and spatial distribution of pro-dormancy cues. Given that current experimental metastasis 
models are not able to capture the hypoxia-DTC interactions that are critical to the 
therapeutic response of tumors, this approach may provide a greater understanding of how 
best to target DTCs in a hypoxic niche. 
 
5.2.4. Incorporation of tumor targeting molecules onto GNR-PEG-Ce6 for effective 
sonodynamic therapy in vivo  
For successful sonodynamic therapy in vivo, the efficient delivery of Ce6 is critical 
to provide sufficient concentration at the targeted disease site. However, targeted delivery 
of nanoparticles including GNR in animal models and patients remains a challenging 
hurdle for many researchers, even if they exhibit promising outcomes in vitro. In fact, the 
peritoneal cavity where GNR-PEG-Ce6 will be applied in ovarian cancer patients contains 
many vital organs that have to be protected from lethal sonodynamic effects of GNR-PEG-
Ce6. To avoid off-target damage of these heathy tissues and organs in the peritoneal cavity 
and to concentrate sonodynamic effects onto ovarian cancer spheroids, addition of 
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targeting modalities to GNR-PEG-Ce6 can be considered. For example, folic acid 
functionalization is one of the common strategies employed for cancer cell targeting  [213–
215]. Many types of cancer including ovarian, uterine, and colon cancers overexpress folic 
acid binding proteins on the cell surface [213]. Lin et al. showed that doxorubicin (DOX) 
loaded onto folic acid-functionalized GO enhanced cytotoxicity toward OCM-1 human 
choroidal melanoma cells, while folic acid-GO exhibited significantly less cytotoxicity on 
ARPE-19 normal human retinal pigment epithelial cells after 24 h of incubation [214]. A 
similar cell-specific cytotoxic response was not observed for DOX loaded on GO without 
folic acid [214]. Importantly, folic acid-GO exhibited equivalent DOX loading capabilities 
as compared with bare GO. The folic acid-GO also selectively targeted and killed liver 
carcinoma HepG2 cells overexpressing folate receptors while not affecting healthy liver 
sinusoidal endothelial cells [215]. 
Targeting of other cancer cell surface receptors could also be used to enhance the 
cancer targeting ability of GNR-PEG-Ce6. Hyaluronic acid (HA) has been shown to target 
ovarian, breast, colon, and renal cancer cells overexpressing transmembrane glycoprotein 
CD44 [216]. Miao et al. reported that DOX loaded onto GO functionalized with cholesteryl 
HA (cHA-GO-DOX) exhibited 40.3% more cell death compared DOX loaded onto GO 
without cHA functionalization in KB epidermal carcinoma cells [217]. When 
subcutaneously injected into the mice bearing KB epidermal tumors, significant size 
reduction in tumor volume was observed after 24 days for cHA-GO-DOX compared with 
GO-DOX without cHA functionalization. Wu et al. also reported adipic acid dihydrazide 
(ADH)-HA-GO loaded with DOX where adipic acid was used to introduce amino groups 
for tethering HA to GO [218]. When ADH-HA-GO loaded with DOX was intravenously 
injected into the mice with subcutaneous HeLa tumors, it exhibited greater tumor inhibition 
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rates in mice compared with free DOX and GO-DOX. Song et al. found that cumulative 
DOX release from HA-GO-DOX was faster in the slightly acidic tumor environment at pH 
5.3 than pH 7.4. This pH responsive release led to a 20% better tumor inhibition rate than 
free DOX and GO-DOX groups in H22 hepatic tumors in mice [219]. These findings 
suggest that addition of targeting molecules such as folic acid or HA to GNR-PEG-Ce6 
could enhance selective delivery of Ce6 to ovarian cancer spheroids. 
Targeting surface receptors that are overexpressed in ovarian cancer spheroids but 
not in mesothelial cells or other cells in the ascites could also be considered. Zhang et al. 
reported that ovarian cancer cells have high level expression of ROR1, a type I orphan-
receptor tyrosine kinase-like surface protein, whereas ROR1 is not found on normal adult 
tissue, suggesting that ROR1 could be targeted for cancer cell-specific therapy [220]. 
Ziebarth et al. found that CD105 and CD106 were overexpressed in epithelial ovarian 
cancer cells or platinum-resistant ovarian cancer cells [221,222], whereas those molecules 
were expressed at low level son the surface of mesothelial cells [223]. Thus, incorporation 
of antibodies that bind to CD105 or CD106 onto GNR-PEG-Ce6 could be used to 
selectively target ovarian cancer spheroids.   
 119 
Reference 
[1] A.W. Lambert, D.R. Pattabiraman, R.A. Weinberg, Emerging Biological Principles 
of Metastasis, Cell. 168 (2017) 670–691. 
[2] P. Mehlen, A. Puisieux, Metastasis: A question of life or death, Nat. Rev. Cancer. 6 
(2006) 449–458. 
[3] C.L. Chaffer, R.A. Weinberg, A perspective on cancer cell metastasis, Science. 331 
(2011) 1559–1564. 
[4] J.A. Aguirre-Ghiso, Models, mechanisms and clinical evidence for cancer dormancy, 
Nat. Rev. Cancer. 7 (2007) 834–846. 
[5] National Cancer Institute, SEER Cancer Stat Facts: Female Breast Cancer, 
Seer.Cancer.Gov. (2018) 1. https://seer.cancer.gov/statfacts/html/breast.html 
(accessed January 13, 2020). 
[6] E. Lengyel, Ovarian cancer development and metastasis, Am. J. Pathol. 177 (2010) 
1053–1064. 
[7] S.S. Li, J. Ma, A.S.T. Wong, Chemoresistance in ovarian cancer: Exploiting cancer 
stem cell metabolism, J. Gynecol. Oncol. 29 (2018) 1–11. 
[8] Ovarian Cancer Research Alliance, Recurrence and Treatment, (n.d.). 
https://ocrahope.org/patients/about-ovarian-cancer/recurrence/ (accessed January 
13, 2020). 
[9] National Cancer Institute, SEER Cancer Stat Facts: Ovarian Cancer, 
Seer.Cancer.Gov. (2018) 1. https://seer.cancer.gov/statfacts/html/ovary.html 
(accessed January 13, 2020). 
[10] S. Pradhan, J.L. Sperduto, C.J. Farino, et al., Engineered in Vitro Models of Tumor 
Dormancy and Reactivation, J. Biol. Eng. 12 (2018) 1–19. 
[11] M. Banys, A.D. Hartkopf, N. Krawczyk, et al., Dormancy in breast cancer, Breast 
Cancer Targets Ther. 4 (2012) 183–191. 
[12] C.A. Klein, Framework models of tumor dormancy from patient-derived 
observations, Curr. Opin. Genet. Dev. 21 (2011) 42–49. 
[13] E. Butturini, A.C. de Prati, D. Boriero, et al., Tumor dormancy and interplay with 
hypoxic tumor microenvironment, Int. J. Mol. Sci. 20 (2019). 
[14] N. Linde, G. Fluegen, J.A. Aguirre-Ghiso, The Relationship Between Dormant 
Cancer Cells and Their Microenvironment, 1st ed., Elsevier Inc., 2016. 
[15] C. Morrissey, R.L. Vessella, P.H. Lange, et al., The biology and clinical implications 
of prostate cancer dormancy and metastasis, J. Mol. Med. 94 (2016) 259–265. 
 120 
[16] C.M. Ghajar, H. Peinado, H. Mori, et al., The perivascular niche regulates breast 
tumour dormancy., Nat. Cell Biol. 15 (2013) 807–17. 
[17] M.A. Lawson, M.M. McDonald, N. Kovacic, et al., Osteoclasts control reactivation 
of dormant myeloma cells by remodelling the endosteal niche, Nat. Commun. 6 
(2015) 1–15. 
[18] Y. Shiozawa, E.A. Pedersen, L.R. Patel, et al., GAS6/AXL axis regulates prostate 
cancer invasion, proliferation, and survival in the bone marrow niche, Neoplasia. 12 
(2010) 116–127. 
[19] R.S. Taichman, L.R. Patel, R. Bedenis, et al., GAS6 Receptor Status Is Associated 
with Dormancy and Bone Metastatic Tumor Formation, PLoS One. 8 (2013) 1–10. 
[20] A. Mishra, J. Wang, Y. Shiozawa, et al., Hypoxia stabilizes GAS6/Axl signaling in 
metastatic prostate cancer, Mol. Cancer Res. 10 (2012) 703–712. 
[21] R.W. Johnson, M.E. Sowder, A.J. Giaccia, Hypoxia and Bone Metastatic Disease, 
Curr. Osteoporos. Rep. 15 (2017) 231–238. 
[22] R.W. Johnson, E.C. Finger, M.M. Olcina, et al., Induction of LIFR confers a 
dormancy phenotype in breast cancer cells disseminated to the bone marrow, Nat. 
Cell Biol. 18 (2016) 1078–1089. 
[23] E.B. Rankin, A.J. Giaccia, Hypoxic control of metastasis, Science. 352 (2016) 175–
180. 
[24] E.B. Rankin, J.M. Nam, A.J. Giaccia, Hypoxia: Signaling the Metastatic Cascade, 
Trends in Cancer. 2 (2016) 295–304. 
[25] G. Fluegen, A. Avivar-Valderas, Y. Wang, et al., Phenotypic heterogeneity of 
disseminated tumour cells is preset by primary tumour hypoxic microenvironments, 
Nat. Cell Biol. 19 (2017). 
[26] A.R. Sertil, Hypoxia and tumor dormancy: Can the two tango?, Tumor Dormancy, 
Quiescence, Senescence Aging, Cancer, Noncancer Pathol. 3 (2014) 13–24. 
[27] X.F. Li, J.A. O’Donoghue, Hypoxia in microscopic tumors, Cancer Lett. 264 (2008) 
172–180. 
[28] K. Bartkowiak, K.E. Effenberger, S. Harder, et al., Discovery of a novel unfolded 
protein response phenotype of cancer stem/progenitor cells from the bone marrow 
of breast cancer patients, J. Proteome Res. 9 (2010) 3158–3168. 
[29] G. Fluegen, A. Avivar-Valderas, Y. Wang, et al., Phenotypic heterogeneity of 
disseminated tumour cells is preset by primary tumour hypoxic microenvironments, 
Nat. Cell Biol. 19 (2017) 120–132. 
[30] S.S. Rao, R.V. Kondapaneni, A.A. Narkhede, Bioengineered models to study tumor 
dormancy, J. Biol. Eng. 13 (2019). 
 121 
[31] H. Endo, H. Okuyama, M. Ohue, et al., Dormancy of cancer cells with suppression 
of AKT activity contributes to survival in chronic hypoxia, PLoS One. 9 (2014) 1–
12. 
[32] A. Carcereri de Prati, E. Butturini, A. Rigo, et al., Metastatic Breast Cancer Cells 
Enter Into Dormant State and Express Cancer Stem Cells Phenotype Under Chronic 
Hypoxia, J. Cell. Biochem. 118 (2017) 3237–3248. 
[33] L.E. Huang, Z. Arany, D.M. Livingston, et al., Activation of hypoxia-inducible 
transcription factor depends primarily upon redox-sensitive stabilization of its α 
subunit, J. Biol. Chem. 271 (1996) 32253–32259. 
[34] G. Martin, R. Andriamanalijaona, S. Grässel, et al., Effect of hypoxia and 
reoxygenation on gene expression and response to interleukin-1 in cultured articular 
chondrocytes, Arthritis Rheum. 50 (2004) 3549–3560. 
[35] E.J. Wollen, P. Kwinta, M. Bik-Multanowski, et al., Hypoxia-reoxygenation affects 
whole-genome expression in the newborn eye, Investig. Ophthalmol. Vis. Sci. 55 
(2014) 1393–1401. 
[36] D. Wu, P. Yotnda, Induction and testing of hypoxia in cell culture., J. Vis. Exp. 
(2011) e2899. 
[37] A.C.R. Epstein, J.M. Gleadle, L.A. McNeill, et al., C. elegans EGL-9 and 
mammalian homologs define a family of dioxygenases that regulate HIF by prolyl 
hydroxylation, Cell. 107 (2001) 43–54. 
[38] Y. Yuan, G. Hilliard, T. Ferguson, et al., Cobalt inhibits the interaction between 
hypoxia-inducible factor-α and von Hippel-Lindau protein by direct binding to 
hypoxia-inducible factor-α, J. Biol. Chem. 278 (2003) 15911–15916. 
[39] Y. Talukdar, J.T. Rashkow, G. Lalwani, et al., The effects of graphene 
nanostructures on mesenchymal stem cells, Biomaterials. 35 (2014) 4863–4877. 
[40] S.M. Azarin, J. Yi, R.M. Gower, et al., In vivo capture and label-free detection of 
early metastatic cells, Nat. Commun. 6 (2015) 1–9. 
[41] R.M. Gower, L.D. Shea, Biomaterial Scaffolds for Controlled, Localized Gene 
Delivery of Regenerative Factors, Adv. Wound Care. 2 (2013) 100–106. 
[42] N. Ahmed, K.L. Stenvers, Getting to know ovarian cancer ascites: Opportunities for 
targeted therapy-based translational research, Front. Oncol. 3 SEP (2013) 1–12. 
[43] E. Lou, R.I. Vogel, S. Hoostal, et al., Tumor-Stroma Proportion as a Predictive 
Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian 
Cancer, JAMA Oncol. 5 (2019) 1222–1224. 
[44] Z. Lu, R.Z. Luo, Y. Lu, et al., The tumor suppressor gene ARHI regulates autophagy 
and tumor dormancy in human ovarian cancer cells, J. Clin. Invest. 118 (2008) 
3917–3929. 
 122 
[45] R.J.M. Correa, T. Peart, Y.R. Valdes, et al., Modulation of AKT activity is 
associated with reversible dormancy in ascites-derived epithelial ovarian cancer 
spheroids, Carcinogenesis. 33 (2012) 49–58. 
[46] K.M. Burleson, R.C. Casey, K.M. Skubitz, et al., Ovarian carcinoma ascites 
spheroids adhere to extracellular matrix components and mesothelial cell 
monolayers, Gynecol. Oncol. 93 (2004) 170–181. 
[47] R.C. Casey, K.M. Burleson, K.M. Skubitz, et al., Β1-Integrins Regulate the 
Formation and Adhesion of Ovarian Carcinoma Multicellular Spheroids, Am. J. 
Pathol. 159 (2001) 2071–2080. 
[48] M.P. Iwanicki, R.A. Davidowitz, M.R. Ng, et al., Ovarian cancer spheroids use 
myosin-generated force to clear the mesothelium, Cancer Discov. 1 (2011) 144–157. 
[49] A.K. Mitra, K. Sawada, P. Tiwari, et al., Ligand-independent activation of c-Met by 
fibronectin and α5 Β1-integrin regulates ovarian cancer invasion and metastasis, 
Oncogene. 30 (2011) 1566–1576. 
[50] K.M. Bell-Mcguinn, C.M. Matthews, S.N. Ho, et al., A phase II, single-arm study 
of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with 
platinum-resistant advanced epithelial ovarian or primary peritoneal cancer, 
Gynecol. Oncol. 121 (2011) 273–279. 
[51] K. Sawada, A.K. Mitra, A.R. Radjabi, et al., Loss of E-cadherin promotes ovarian 
cancer metastasis via α5-integrin, which is a therapeutic target, Cancer Res. 68 
(2008) 2329–2339. 
[52] A. Levy, C. Leynes, M. Baig, et al., The Application of Biomaterials in the 
Treatment of Platinum-Resistant Ovarian Cancer, ChemMedChem. 14 (2019) 
1810–1827. 
[53] H. Tiwari, N. Karki, M. Pal, et al., Functionalized graphene oxide as a nanocarrier 
for dual drug delivery applications: The synergistic effect of quercetin and gefitinib 
against ovarian cancer cells, Colloids Surfaces B Biointerfaces. 178 (2019) 452–459. 
[54] K.M. Burleson, L.K. Hansen, A.P.N. Skubitz, Ovarian carcinoma spheroids 
disaggregate on type I collagen and invade live human mesothelial cell monolayers, 
Clin. Exp. Metastasis. 21 (2005) 685–697. 
[55] Y.J. Choi, S. Gurunathan, J.H. Kim, Graphene oxide-silver nanocomposite enhances 
cytotoxic and apoptotic potential of salinomycin in human ovarian cancer stem cells 
(OvCSCs): A novel approach for cancer therapy, Int. J. Mol. Sci. 19 (2018). 
[56] B. Tian, C. Wang, S. Zhang, et al., Photothermally enhanced photodynamic therapy 
delivered by nano-graphene oxide, ACS Nano. 5 (2011) 7000–7009. 
[57] P. Huang, C. Xu, J. Lin, et al., Folic Acid-conjugated Graphene Oxide loaded with 
Photosensitizers for Targeting Photodynamic Therapy, Theranostics. 1 (2012) 240–
 123 
250. 
[58] C. Dai, S. Zhang, Z. Liu, et al., Two-Dimensional Graphene Augments 
Nanosonosensitized Sonocatalytic Tumor Eradication, ACS Nano. 11 (2017) 9467–
9480. 
[59] J.A. Aguirre-Ghiso, Models, mechanisms and clinical evidence for cancer 
dormancy., Nat. Rev. Cancer. 7 (2007) 834–846. 
[60] S. Meng, D. Tripathy, E.P. Frenkel, et al., Circulating Tumor Cells in Patients with 
Breast Cancer Dormancy Circulating, Clin. Cancer Res. 10 (2004) 8152–8162. 
[61] K. Pantel, C. Alix-Panabières, Tumour microenvironment: informing on minimal 
residual disease in solid tumours, Nat. Rev. Clin. Oncol. 14 (2017) 325–326. 
[62] A.-G.J. Sosa MS, Bragado P, Debnath J, Systems Biology of Tumor Dormancy, 
Adv. Exp. Med. Biol. 734 (2013) 73–89. 
[63] P. Bragado, M.S. Sosa, P. Keely, et al., Microenvironments dictating tumor cell 
dormancy, Recent Results Cancer Res. 195 (2012) 25–39. 
[64] R. Marlow, G. Honeth, S. Lombardi, et al., A novel model of dormancy for bone 
metastatic breast cancer cells, Cancer Res. 73 (2013) 6886–6899. 
[65] B. Psaila, D. Lyden, The metastatic niche: adapting the foreign soil., Nat. Rev. 
Cancer. 9 (2009) 285–293. 
[66] K. Bartkowiak, K.E. Effenberger, S. Harder, et al., Discovery of a novel unfolded 
protein response phenotype of cancer stem/progenitor cells from the bone marrow 
of breast cancer patients, J. Proteome Res. 9 (2010) 3158–3168. 
[67] R.S. Kim, A. Avivar-Valderas, Y. Estrada, et al., Dormancy signatures and 
metastasis in estrogen receptor positive and negative breast cancer, PLoS One. 7 
(2012) 1–8. 
[68] R.W. Johnson, E.C. Finger, M.M. Olcina, et al., Induction of LIFR confers a 
dormancy phenotype in breast cancer cells disseminated to the bone marrow, Nat. 
Cell Biol. 18 (2016) 1078–1089. 
[69] M.S. Al Okail, Cobalt chloride, a chemical inducer of hypoxia-inducible factor-1α 
in U251 human glioblastoma cell line, J. Saudi Chem. Soc. 14 (2010) 197–201. 
[70] A.C.R. Epstein, J.M. Gleadle, L.A. McNeill, et al., C. elegans EGL-9 and 
mammalian homologs define a family of dioxygenases that regulate HIF by prolyl 
hydroxylation, Cell. 107 (2001) 43–54. 
[71] S.P.. D. and H.. F.B. Mark A . Goldberg, Regulation of the Erythropoietin Gene : 
Evidence that the Oxygen Sensor is a Heme Protein, Science. 242 (1988) 1412–
1415. 
 124 
[72] Ebert, B. L., Firth, J.D., Ratcliffe, P.J., Hypoxia and Mitochondrial Inhibitors 
Regulate Expression of Glucose Transporter-1 via Distinct Cis-acting Sequences, J. 
Biol. Chem. 270 (1995) 29083–29089. 
[73] B.L. Ebert, J.M. Gleadle, J.F. O’Rourke, et al., Isoenzyme-specific regulation of 
genes involved in energy metabolism by hypoxia: similarities with the regulation of 
erythropoietin., Biochem. J. 313 (Pt 3) (1996) 809–814. 
[74] Q. Ao, W. Su, S. Guo, et al., SENP1 desensitizes hypoxic ovarian cancer cells to 
cisplatin by up-regulating HIF-1α., Sci. Rep. 5 (2015) 16396. 
[75] W.G. An, M. Kanekal, M.C. Simon, et al., Stabilization of wild-type p53 by 
hypoxia-inducible factor 1α., Nature. 392 (1998) 405–408. 
[76] P. Bragado, Y. Estrada, F. Parikh, et al., TGF-β2 dictates disseminated tumour cell 
fate in target organs through TGF-β-RIII and p38α/β signalling, Nat. Cell Biol. 15 
(2013) 1351–1361. 
[77] S. Bruno, Z. Darzynkiewicz, Cell cycle dependent expression and stability of the 
nuclear protein detected by Ki-67 antibody in HL-60 cells, Cell Prolif. 25 (1992) 
31–40. 
[78] T. Scholzen, J. Gerdes, The Ki‐67 protein: from the known and the unknown, J. Cell. 
Physiol. 182 (2000) 311–322. 
[79] D. Páez, M.J. Labonte, P. Bohanes, et al., Cancer dormancy: A model of early 
dissemination and late cancer recurrence, Clin. Cancer Res. 18 (2012) 645–653. 
[80] S.-H. Wang, S.-Y. Lin, Tumor dormancy: potential therapeutic target in tumor 
recurrence and metastasis prevention., Exp. Hematol. Oncol. 2 (2013) 29. 
[81] H. Harrison, L. Rogerson, H.J. Gregson, et al., Contrasting Hypoxic Effects on 
Breast Cancer Stem Cell Hierarchy Is Dependent on ER-  Status, Cancer Res. 73 
(2013) 1420–1433. 
[82] M.S. Sosa, A. Avivar-Valderas, P. Bragado, et al., ERK1/2 and p38α/β signaling in 
tumor cell quiescence: Opportunities to control dormant residual disease, Clin. 
Cancer Res. 17 (2011) 5850–5857. 
[83] T. Abbas, A. Dutta, P21 in Cancer: Intricate Networks and Multiple Activities, Nat. 
Rev. Cancer. 9 (2009) 400–414. 
[84] L.E. Huang, Carrot and stick: HIF-α engages c-Myc in hypoxic adaptation, Cell 
Death Differ. 15 (2008) 672–677. 
[85] K.N. Weilbaecher, T.A. Guise, L.K. McCauley, Cancer to bone: a fatal attraction, 
Nat. Rev. Cancer. 11 (2011) 411–425. 
[86] H. Gao, G. Chakraborty, A.P. Lee-Lim, et al., The BMP Inhibitor Coco Induces 
Breast Cancer Cells to Undergo Reactivation at Lung Metastatic sites, Cell. 150 
 125 
(2012) 764–779. 
[87] R. Du, K. V. Lu, C. Petritsch, et al., HIF1α Induces the Recruitment of Bone 
Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and 
Invasion, Cancer Cell. 13 (2008) 206–220. 
[88] L. Yu, C.A. Hales, Long-term exposure to hypoxia inhibits tumor progression of 
lung cancer in rats and mice, BMC Cancer. 11 (2011) 331. 
[89] M. Padró, R.J. Louie, B. V. Lananna, et al., Genome-independent hypoxic 
repression of estrogen receptor alpha in breast cancer cells, BMC Cancer. 17 (2017) 
203. 
[90] H. Zhang, M. Bosch-Marce, L.A. Shimoda, et al., Mitochondrial autophagy is an 
HIF-1-dependent adaptive metabolic response to hypoxia, J. Biol. Chem. 283 (2008) 
10892–10903. 
[91] Z. Lu, R.Z. Luo, Y. Lu, et al., The tumor suppressor gene ARHI regulates autophagy 
and tumour dormancy in human ovarian cancer cells, Cell Prolif. 118 (2008) 3917–
3929. 
[92] J.A. Hickson, D. Huo, D.J. Vander Griend, et al., The p38 kinases MKK4 and 
MKK6 suppress metastatic colonization in human ovarian carcinoma, Cancer Res. 
66 (2006) 2264–2270. 
[93] K. Yamamoto, S. Inoue, A. Yamazaki, et al., Site-Specific DNA Damage Induced 
by Cobalt(II) Ion and Hydrogen Peroxide: Role of Singlet Oxygen, Chem. Res. 
Toxicol. 2 (1989) 234–239. 
[94] S.X. Chen F, Ding M, Castranova V, Carcinogenic metals and NF-κB activation, 
Mol Cell Biochem. (2001) 159–171. 
[95] H. Axelson, E. Fredlund, M. Ovenberger, et al., Hypoxia-induced dedifferentiation 
of tumor cells - A mechanism behind heterogeneity and aggressiveness of solid 
tumors, Semin. Cell Dev. Biol. 16 (2005) 554–563. 
[96] J.L. Gooch, R.E. Herrera, D. Yee, The role of p21 in interferon gamma-mediated 
growth inhibition of human breast cancer cells, Cell Growth Differ. 11 (2000) 335–
342. 
[97] M. Shanmugam, N.L. Krett, E.T. Maizels, et al., A role for protein kinase C δ in the 
differential sensitivity of MCF-7 and MDA-MB-231 human breast cancer cells to 
phorbol ester-induced growth arrest and p21 WAFI / CIP1 induction, 172 (2001) 
43–53. 
[98] M. Koshiji, Y. Kageyama, E.A. Pete, et al., HIF-1α induces cell cycle arrest by 
functionally counteracting Myc, EMBO J. 23 (2004) 1949–1956. 
[99] S.L. Green, R.A. Freiberg, A.J. Giaccia, p21 Cip1 and p27 Kip1 Regulate Cell Cycle 
Reentry after Hypoxic Stress but Are Not Necessary for Hypoxia-Induced Arrest, 
 126 
21 (2001) 1196–1206. 
[100] R. Edmondson, J.J. Broglie, A.F. Adcock, et al., Three-Dimensional Cell Culture 
Systems and Their Applications in Drug Discovery and Cell-Based Biosensors, 
Assay Drug Dev. Technol. 12 (2014) 207–218. 
[101] R. Wang, F. Jin, H. Zhong, A novel experimental hypoxia chamber for cell culture., 
Am. J. Cancer Res. 4 (2014) 53–60. 
[102] W.R. Wilson, M.P. Hay, Targeting hypoxia in cancer therapy, Nat. Rev. Cancer. 11 
(2011) 393–410. 
[103] P. Vaupel, A. Mayer, Hypoxia in cancer: Significance and impact on clinical 
outcome, Cancer Metastasis Rev. 26 (2007) 225–239. 
[104] E.L. LaGory, A.J. Giaccia, The ever-expanding role of HIF in tumour and stromal 
biology, Nat. Cell Biol. 18 (2016) 356–365. 
[105] J.T. Erler, K.L. Bennewith, T.R. Cox, et al., Hypoxia-Induced Lysyl Oxidase Is a 
Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic 
Niche, Cancer Cell. 15 (2009) 35–44. 
[106] W.R. Martin Brown, J., Wilson, Exploiting tumour hypoxia in cancer treatment, Nat. 
Rev. Cancer. 4 (2004) 437–447. 
[107] E.B. Rankin, J.-M. Nam, A.J. Giaccia, Hypoxia: Signaling the Metastatic Cascade, 
Trends Cancer. 2 (2016) 295–304. 
[108] G. Fluegen, A. Avivar-Valderas, Y. Wang, et al., Phenotypic heterogeneity of 
disseminated tumour cells is preset by primary tumour hypoxic microenvironments, 
Nat. Cell Biol. 19 (2017) 120–132. 
[109] E.B. Rankin, A.J. Giaccia, Hypoxic control of metastasis, Science. 352 (2017) 175–
180. 
[110] C.C.-L. Wong, D.M. Gilkes, H. Zhang, et al., Hypoxia-inducible factor 1 is a master 
regulator of breast cancer metastatic niche formation., Proc. Natl. Acad. Sci. U. S. 
A. 108 (2011) 16369–74. 
[111] J.T. Erler, K.L. Bennewith, M. Nicolau, et al., Lysyl oxidase is essential for hypoxia-
induced metastasis, Nature. 440 (2006) 1222–1226. 
[112] R.W. Johnson, M.E. Sowder, A.J. Giaccia, Hypoxia and Bone Metastatic Disease, 
Curr. Osteoporos. Rep. 15 (2017) 231–238. 
[113] G.Z. Qiu, M.Z. Jin, J.X. Dai, et al., Reprogramming of the Tumor in the Hypoxic 
Niche: The Emerging Concept and Associated Therapeutic Strategies, Trends 
Pharmacol. Sci. 38 (2017) 669–686. 
[114] F. Dupuy, S. Tabariès, S. Andrzejewski, et al., PDK1-dependent metabolic 
 127 
reprogramming dictates metastatic potential in breast cancer, Cell Metab. 22 (2015) 
577–589. 
[115] A.R. Nobre, D. Entenberg, Y. Wang, et al., The Different Routes to Metastasis via 
Hypoxia-Regulated Programs, Trends Cell Biol. 28 (2018) 941–956. 
[116] L. Holmgren, M.S. O’reilly, J. Folkman, Dormancy of micrometastases: Balanced 
proliferation and apoptosis in the presence of angiogenesis suppression, Nat. Med. 
1 (1995) 149–153. 
[117] S. Rafii, D. Lyden, R. Benezra, et al., Vascular and haematopoietic stem cells: Novel 
targets for anti-angiogenesis therapy?, Nat. Rev. Cancer. 2 (2002) 826–835. 
[118] B. Psaila, D. Lyden, The Metastatic Niche: Adapting the Foreign Soil, Nat. Rev. 
Cancer. 9 (2009) 285–293. 
[119] J.A. Joyce, J.W. Pollard, Microenvironmental regulation of metastasis, Nat. Rev. 
Cancer. 9 (2009) 239–252. 
[120] D.F. Quail, J.A. Joyce, Microenvironmental regulation of tumor progression and 
metastasis, Nat. Med. 19 (2013) 1423–1437. 
[121] B.A. Aguado, G.G. Bushnell, S.S. Rao, et al., Engineering the pre-metastatic niche, 
Nat. Biomed. Eng. 1 (2017) 1–12. 
[122] S. Koscielny, M. Tubiana, Parallel progression of tumour and metastases., Nat. Rev. 
Cancer. 10 (2010) 156. 
[123] H. Peinado, H. Zhang, I.R. Matei, et al., Pre-metastatic niches: Organ-specific 
homes for metastases, Nat. Rev. Cancer. 17 (2017) 302–317. 
[124] R.A. Carpenter, J.-G. Kwak, S.R. Peyton, et al., Implantable pre-metastatic niches 
for the study of the microenvironmental regulation of disseminated human tumour 
cells, Nat. Biomed. Eng. 2 (2018) 915–929. 
[125] J. Lee, M. Li, J. Milwid, et al., Implantable microenvironments to attract 
hematopoietic stem/cancer cells, Proc. Natl. Acad. Sci. 109 (2012) 19638–19643. 
[126] F. Bersani, J. Lee, M. Yu, et al., Bioengineered implantable scaffolds as a tool to 
study stromal-derived factors in metastatic cancer models, Cancer Res. 74 (2014) 
7229–7238. 
[127] S.S. Rao, G.G. Bushnell, S.M. Azarin, et al., Enhanced survival with implantable 
scaffolds that capture metastatic breast cancer cells in vivo, Cancer Res. 76 (2016) 
5209–5218. 
[128] K.M. Park, S. Gerecht, Hypoxia-inducible hydrogels, Nat. Commun. 5 (2014) 1–12. 
[129] E. Quinlan, S. Partap, M.M. Azevedo, et al., Hypoxia-mimicking bioactive 
glass/collagen glycosaminoglycan composite scaffolds to enhance angiogenesis and 
 128 
bone repair, Biomaterials. 52 (2015) 358–366. 
[130] Q. Yao, Y. Liu, J. Tao, et al., Hypoxia-Mimicking Nanofibrous Scaffolds Promote 
Endogenous Bone Regeneration, ACS Appl. Mater. Interfaces. 8 (2016) 32450–
32459. 
[131] C. Wu, Y. Zhou, W. Fan, et al., Hypoxia-mimicking mesoporous bioactive glass 
scaffolds with controllable cobalt ion release for bone tissue engineering, 
Biomaterials. 33 (2012) 2076–2085. 
[132] H.R. Lee, F. Leslie, S.M. Azarin, A facile in vitro platform to study cancer cell 
dormancy under hypoxic microenvironments using CoCl2, J. Biol. Eng. 12 (2018) 
1–15. 
[133] B.L. Ebert, J.M. Gleadle, J.F.O. Rourke, et al., Isoenzyme-specific regulation of 
genes involved in energy metabolism by hypoxia: similarities with the regulation of 
erythropoietin, 313 (1996) 809–814. 
[134] A. Namiki, E. Brogi, M. Kearney, et al., Hypoxia induces vascular endothelial 
growth factor in cultured human endothelial cells., J. Biol. Chem. 270 (1995) 
31189–95. 
[135] Y. Yuan, G. Hilliard, T. Ferguson, et al., Cobalt inhibits the interaction between 
hypoxia-inducible factor-α and von Hippel-Lindau protein by direct binding to 
hypoxia-inducible factor-α, J. Biol. Chem. 278 (2003) 15911–15916. 
[136] B.A. Aguado, J.J. Wu, S.M. Azarin, et al., Secretome identification of immune cell 
factors mediating metastatic cell homing, Sci. Rep. 5 (2015) 17566. 
[137] A. Faustino-Rocha, P.A. Oliveira, J. Pinho-Oliveira, et al., Estimation of rat 
mammary tumor volume using caliper and ultrasonography measurements, Lab 
Anim. (NY). 42 (2013) 217–224. 
[138] F. Pelaez, N. Manuchehrabadi, P. Roy, et al., Biomaterial scaffolds for non-invasive 
focal hyperthermia as a potential tool to ablate metastatic cancer cells, Biomaterials. 
166 (2018) 27–37. 
[139] M.M. Azevedo, G. Jell, M.D. O’Donnell, et al., Synthesis and characterization of 
hypoxia-mimicking bioactive glasses for skeletal regeneration, J. Mater. Chem. 20 
(2010) 8854–8864. 
[140] B. Lee, Ji-Won; Seong-Hui, J.-W.J.S.-H.K. and K.-W. Kim, Hypoxia-inducible 
factor (HIF-1), Exp. Mol. Med. 36 (2004) 1–12. 
[141] G.L. Semenza, Hypoxia-inducible factor 1: master regulator of O2 homeostasis, 
Curr Opin Genet Dev. 8 (1998) 588–594. 
[142] A.J. Majmundar, W.J. Wong, M.C. Simon, Hypoxia-Inducible Factors and the 
Response to Hypoxic Stress, Mol. Cell. 40 (2010) 294–309. 
 129 
[143] B. Keith, M.C. Simon, Hypoxia-Inducible Factors, Stem Cells, and Cancer, Cell. 
129 (2007) 465–472. 
[144] W.R.H. Chilov D., Camenisch G., Kvietikova I., Ziegler U., Gassmann M., 
Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): 
heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-
1α, J Cell Sci. 112 (1999) 1203–1212. 
[145] D. Huang, C. Li, H. Zhang, Hypoxia and cancer cell metabolism HIF-1 and Warburg 
Effect HIF-1 and Lipid Metabolism in Cancer Cells, Acta Biochim. Biophys. Sin. 
(Shanghai). 46 (2014) 214–219. 
[146] C.W. Pugh, P.J. Ratcliffe, Regulation of angiogenesis by hypoxia: role of the HIF 
system, Nat. Med. 9 (2003) 677–648. 
[147] B.L. Krock, N. Skuli, M.C. Simon, Hypoxia-Induced Angiogenesis: Good and Evil, 
Genes Cancer. 2 (2011) 1117–1133. 
[148] H.T. Yuan, E. V. Khankin, S.A. Karumanchi, et al., Angiopoietin 2 Is a Partial 
Agonist/Antagonist of Tie2 Signaling in the Endothelium, Mol. Cell. Biol. 29 (2009) 
2011–2022. 
[149] E.L. Lund, A. Høg, M.W.B. Olsen, et al., Differential regulation of VEGF, HIF1α 
and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human 
glioblastoma, Int. J. Cancer. 108 (2004) 833–838. 
[150] G. Krikun, F. Schatz, T. Finlay, et al., Expression of angiopoietin-2 by human 
endometrial endothelial cells: Regulation by hypoxia and inflammation, Biochem. 
Biophys. Res. Commun. 275 (2000) 159–163. 
[151] H.-P. Gerber, F. Condorelli, J. Park, et al., Differential regulation of the two vascular 
endothelial growth factor receptor genes, J. Biol. Chem. 272 (1997) 23659–23667. 
[152] P. Pichiule, J.C. Chavez, J.C. LaManna, Hypoxic Regulation of Angiopoietin-2 
Expression in Endothelial Cells, J. Biol. Chem. 279 (2004) 12171–12180. 
[153] S. Al-Maawi, A. Orlowska, R. Sader, et al., In vivo cellular reactions to different 
biomaterials—Physiological and pathological aspects and their consequences, 
Semin. Immunol. 29 (2017) 49–61. 
[154] Q. Yao, Y. Liu, J. Tao, et al., Hypoxia-Mimicking Nanofibrous Scaffolds Promote 
Endogenous Bone Regeneration, J Biomed Mater Res Part A. 104 (2016) 2515–
2527. 
[155] P. Jia, H. Chen, H. Kang, et al., Deferoxamine released from poly(lactic-co-glycolic 
acid) promotes healing of osteoporotic bone defect via enhanced angiogenesis and 
osteogenesis, J. Biomed. Mater. Res. - Part A. 104 (2016) 2515–2527. 
[156] M.B. Asparuhova, C. Secondini, C. Rüegg, et al., Mechanism of irradiation-induced 
mammary cancer metastasis: A role for SAP-dependent Mkl1 signaling, Mol. Oncol. 
 130 
9 (2015) 1510–1527. 
[157] B.A. Aguado, J.R. Caffe, D. Nanavati, et al., Extracellular matrix mediators of 
metastatic cell colonization characterized using scaffold mimics of the pre-
metastatic niche, Acta Biomater. 33 (2016) 13–24. 
[158] E. Lengyel, Ovarian cancer development and metastasis, Am. J. Pathol. 177 (2010) 
1053–1064. 
[159] D.S. Tan, R. Agarwal, S.B. Kaye, Mechanisms of transcoelomic metastasis in 
ovarian cancer, Lancet Oncol. 7 (2006) 925–934. 
[160] L. Moffitt, N. Karimnia, A. Stephens, et al., Therapeutic targeting of collective 
invasion in Ovarian cancer, Int. J. Mol. Sci. 20 (2019) 1–17. 
[161] R.C. Casey, K.M. Burleson, K.M. Skubitz, et al., β1-Integrins Regulate the 
Formation and Adhesion of Ovarian Carcinoma Multicellular Spheroids, Am. J. 
Pathol. 159 (2001) 2071–2080. 
[162] S.M. Chowdhury, C. Surhland, Z. Sanchez, et al., Graphene nanoribbons as a drug 
delivery agent for lucanthone mediated therapy of glioblastoma multiforme, 
Nanomedicine Nanotechnology, Biol. Med. 11 (2015) 109–118. 
[163] S.C. Patel, S. Lee, G. Lalwani, et al., Graphene-based platforms for cancer 
therapeutics, Ther. Deliv. 7 (2016) 101–116. 
[164] Z. Liu, J.T. Robinson, X. Sun, et al., PEGylated nanographene oxide for delivery of 
water-insoluble cancer drugs, J. Am. Chem. Soc. 130 (2008) 10876–10877. 
[165] Y.J. Lu, C.W. Lin, H.W. Yang, et al., Biodistribution of PEGylated graphene oxide 
nanoribbons and their application in cancer chemo-photothermal therapy, Carbon N. 
Y. 74 (2014) 83–95. 
[166] X. Shi, H. Chang, S. Chen, et al., Regulating cellular behavior on few-layer reduced 
graphene oxide films with well-controlled reduction states, Adv. Funct. Mater. 22 
(2012) 751–759. 
[167] J. Park, B. Kim, J. Han, et al., Graphene oxide flakes as a cellular adhesive: 
Prevention of reactive oxygen species mediated death of implanted cells for cardiac 
repair, ACS Nano. 9 (2015) 4987–4999. 
[168] S. Kang, J. Lee, S. Ryu, et al., Gold Nanoparticle/Graphene Oxide Hybrid Sheets 
Attached on Mesenchymal Stem Cells for Effective Photothermal Cancer Therapy, 
Chem. Mater. 29 (2017) 3461–3476. 
[169] X. Yang, X. Zhang, Z. Liu, et al., High-efficiency loading and controlled release of 
doxorubicin hydrochloride on graphene oxide, J. Phys. Chem. C. 112 (2008) 17554–
17558. 
[170] Z. Liu, X. Sun, N. Nakayama-Ratchford, et al., Supramolecular chemistry on water- 
 131 
Soluble carbon nanotubes for drug loading and delivery, ACS Nano. 1 (2007) 50–
56. 
[171] S. Mullick Chowdhury, S. Zafar, V. Tellez, et al., Graphene Nanoribbon-Based 
Platform for Highly Efficacious Nuclear Gene Delivery, ACS Biomater. Sci. Eng. 2 
(2016) 798–808. 
[172] C. Dai, S. Zhang, Z. Liu, et al., Two-Dimensional Graphene Augments 
Nanosonosensitized Sonocatalytic Tumor Eradication, ACS Nano. 11 (2017) 9467–
9480. 
[173] K. Yang, L. Hu, X. Ma, et al., Multimodal imaging guided photothermal therapy 
using functionalized graphene nanosheets anchored with magnetic nanoparticles, 
Adv. Mater. 24 (2012) 1868–1872. 
[174] Y. Li, H. Dong, Y. Li, et al., Graphene-based nanovehicles for photodynamic 
medical therapy, Int. J. Nanomedicine. 10 (2015) 2451–2459. 
[175] Y.W. Chen, T.Y. Liu, P.H. Chang, et al., A theranostic nrGO@MSN-ION 
nanocarrier developed to enhance the combination effect of sonodynamic therapy 
and ultrasound hyperthermia for treating tumor, Nanoscale. 8 (2016) 12648–12657. 
[176] A.M. Dimiev, J.M. Tour, Mechanism of graphene oxide formation, ACS Nano. 8 
(2014) 3060–3068. 
[177] D. V. Kosynkin, A.L. Higginbotham, A. Sinitskii, et al., Longitudinal unzipping of 
carbon nanotubes to form graphene nanoribbons, Nature. 458 (2009) 872–876. 
[178] E.R. Fischer, B.T. Hansen, V. Nair, et al., Scanning electron microscopy, Curr 
Protoc Microbiol. 25 (2012) 2B.2.1-2B.2.47. 
[179] H.R. Lee, F. Pelaez, A.M. Silbaugh, et al., Biomaterial Platform To Establish a 
Hypoxic Metastatic Niche in Vivo, ACS Appl. Bio Mater. 2 (2019) 1549–1560. 
[180] J. Fogh, G. Trempe, New Human Tumor Cell Lines, in: Hum. Tumor Cells Vitr., 
1975. 
[181] E.A. White, H.A. Kenny, E. Lengyel, Three-dimensional modeling of ovarian 
cancer, Adv. Drug Deliv. Rev. 79 (2014) 184–192. 
[182] K. Lawrenson, B. Grun, S.A. Gayther, Heterotypic three-dimensional in vitro 
modeling of stromal-epithelial interactions during ovarian cancer initiation and 
progression, J. Vis. Exp. (2012) 1–8. 
[183] H. Shi, Q. Liu, X. Qin, et al., Pharmacokinetic study of a novel sonosensitizer 
chlorin-e6 and its sonodynamic anti-cancer activity in hepatoma-22 tumor-bearing 
mice, Biopharm. Drug Dispos. 32 (2011) 319–332. 
[184] Y. Li, P. Wang, X. Wang, et al., Involvement of mitochondrial and reactive oxygen 
species in the sonodynamic toxicity of chlorin e6 in human leukemia K562 cells, 
 132 
Ultrasound Med. Biol. 40 (2014) 990–1000. 
[185] Q. Li, X. Wang, P. Wang, et al., Efficacy of chlorin e6-mediated sono-photodynamic 
therapy on 4T1 cells, Cancer Biother. Radiopharm. 29 (2014) 42–52. 
[186] H. Wang, X. Wang, P. Wang, et al., Ultrasound enhances the efficacy of chlorin E6-
mediated photodynamic therapy in MDA-MB-231 Cells, Ultrasound Med. Biol. 39 
(2013) 1713–1724. 
[187] G.Y. Wan, Y. Liu, B.W. Chen, et al., Recent advances of sonodynamic therapy in 
cancer treatment, Cancer Biol. Med. 13 (2016) 325–338. 
[188] T. Masiello, A. Dhall, L. Hemachandra, et al., A Dynamic Culture Method to 
Produce Ovarian Cancer Spheroids under Physiologically-Relevant Shear Stress, 
Cells. 7 (2018) 277. 
[189] I. Rizvi, U.A. Gurkan, S. Tasoglu, et al., Flow induces epithelial-mesenchymal 
transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer 
nodules, Proc. Natl. Acad. Sci. U. S. A. 110 (2013). 
[190] L. Avraham-Chakim, D. Elad, U. Zaretsky, et al., Fluid-Flow Induced Wall Shear 
Stress and Epithelial Ovarian Cancer Peritoneal Spreading, PLoS One. 8 (2013) 0–
8. 
[191] H.A. Kenny, K.M. Nieman, A.K. Mitra, et al., The first line of intra-abdominal 
metastatic attack: Breaching the mesothelial cell layer, Cancer Discov. 1 (2011) 
100–102. 
[192] M.P. Iwanicki, R.A. Davidowitz, M.R. Ng, et al., Ovarian cancer spheroids use 
myosin-generated force to clear the mesothelium, Cancer Discov. 1 (2011) 144–157. 
[193] W. Mcguire Iii, M. Markman, Primary ovarian cancer chemotherapy: current 
standards of care, Br. J. Cancer. 89 (2003) 3–8. 
[194] K. Shield, M.L. Ackland, N. Ahmed, et al., Multicellular spheroids in ovarian cancer 
metastases: Biology and pathology, Gynecol. Oncol. 113 (2009) 143–148. 
[195] G. Mehta, A.Y. Hsiao, M. Ingram, et al., Opportunities and challenges for use of 
tumor spheroids as models to test drug delivery and efficacy, J. Control. Release. 
164 (2012) 192–204. 
[196] S.K. Green, G. Francia, C. Isidoro, et al., Antiadhesive antibodies targeting E-
cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro, Mol. 
Cancer Ther. 3 (2004) 149–159. 
[197] E. Sokolova, O. Kutova, A. Grishina, et al., Penetration efficiency of antitumor 
agents in ovarian cancer spheroids: The case of recombinant targeted toxin DARPin-
LoPE and the chemotherapy drug, doxorubicin, Pharmaceutics. 11 (2019). 
[198] I. Beyer, H. Cao, J. Persson, et al., Coadministration of epithelial junction opener 
 133 
JO-1 improves the efficacy and safety of chemotherapeutic drugs, Clin. Cancer Res. 
18 (2012) 3340–3351. 
[199] I.F. Tannock, C.M. Lee, J.K. Tunggal, et al., Limited penetration of anticancer drugs 
through tumor tissue: A potential cause of resistance of solid tumors to 
chemotherapy, Clin. Cancer Res. 8 (2002) 878–884. 
[200] W. Fayad, S. Brnjic, D. Berglind, et al., Restriction of cisplatin induction of acute 
apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model, 
Int. J. Cancer. 125 (2009) 2450–2455. 
[201] T. Abbas, A. Dutta, P21 in cancer: Intricate networks and multiple activities, Nat. 
Rev. Cancer. 9 (2009) 400–414. 
[202] R. Liu, H.I. Wettersten, S.-H. Park, et al., Small-molecule inhibitors of p21 as novel 
therapeutics for chemotherapy-resistant kidney cancer, Futur. Med Chem. 5 (2013) 
991–994. 
[203] H. Inoue, S.H. Hwang, A.T. Wecksler, et al., Sorafenib attenuates p21 in kidney 
cancer cells and augments cell death in combination with DNA-damaging 
chemotherapy, Cancer Biol. Ther. 12 (2011) 827–836. 
[204] T. Jascur, H. Brickner, I. Salles-Passador, et al., Regulation of p21WAF1/CIP1 
stability by WISp39, a Hsp90 binding TPR protein, Mol. Cell. 17 (2005) 237–249. 
[205] A.L. Gartel, K. Shchors, Mechanisms of c-myc-mediated transcriptional repression 
of growth arrest genes, Exp. Cell Res. 283 (2003) 17–21. 
[206] J. Campisi, H.E. Gray, A.B. Pardee, et al., Cell-cycle control of c-myc but not c-ras 
expression is lost following chemical transformation, Cell. 36 (1984) 241–247. 
[207] B.P. Zhou, Y. Liao, W. Xia, et al., Cytoplasmic localization of p21 CIP1/WAF1 by 
Akt-induced phosphorylation in HER-2/neu-overexpressing cells, Nat. Cell Biol. 3 
(2001) 245–252. 
[208] A. Sakaue-Sawano, H. Kurokawa, T. Morimura, et al., Visualizing Spatiotemporal 
Dynamics of Multicellular Cell-Cycle Progression, Cell. 132 (2008) 487–498. 
[209] T. Oki, K. Nishimura, J. Kitaura, et al., A novel cell-cycle-indicator, mVenus-p27K 
2 , identifies quiescent cells and visualizes G0–G1 transition, Sci. Rep. (2014) 4012. 
[210] S. Yano, Y. Zhang, S. Miwa, et al., Spatial-temporal FUCCI imaging of each cell in 
a tumor demonstrates locational dependence of cell cycle dynamics and 
chemoresponsiveness, Cell Cycle. 13 (2014) 2110–2119. 
[211] A. Xiao, A.E. Gibbons, K.E. Luker, et al., Fluorescence Lifetime Imaging of 
Apoptosis, Tomography. 1 (2015) 115–124. 
[212] R.A. Carpenter, J.G. Kwak, S.R. Peyton, et al., Implantable pre-metastatic niches 
for the study of the microenvironmental regulation of disseminated human tumour 
 134 
cells, Nat. Biomed. Eng. 2 (2018) 915–929. 
[213] J.F. Ross, P.K. Chaudhuri, M. Ratnam, Differential regulation of folate receptor 
isoforms in normal and malignant tissues in vivo and in established cell lines. 
Physiologic and clinical implications, Cancer. 73 (1994) 2432–2443. 
[214] Q. Lin, X. Huang, J. Tang, et al., Environmentally friendly, one-pot synthesis of 
folic acid-decorated graphene oxide-based drug delivery system, J. Nanoparticle 
Res. 15 (2013). 
[215] X. Zhao, P. Liu, Biocompatible graphene oxide as a folate receptor-targeting drug 
delivery system for the controlled release of anti-cancer drugs, RSC Adv. 4 (2014) 
24232–24239. 
[216] A.K. Yadav, P. Mishra, G.P. Agrawal, An insight on hyaluronic acid in drug 
targeting and drug delivery, J. Drug Target. 16 (2008) 91–107. 
[217] W. Miao, G. Shim, C.M. Kang, et al., Cholesteryl hyaluronic acid-coated, reduced 
graphene oxide nanosheets for anti-cancer drug delivery, Biomaterials. 34 (2013) 
9638–9647. 
[218] H. Wu, H. Shi, Y. Wang, et al., Hyaluronic acid conjugated graphene oxide for 
targeted drug delivery, Carbon N. Y. 69 (2014) 379–389. 
[219] E. Song, W. Han, C. Li, et al., Hyaluronic acid-decorated graphene oxide 
nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery, 
ACS Appl. Mater. Interfaces. 6 (2014) 11882–11890. 
[220] S. Zhang, B. Cui, H. Lai, et al., Ovarian cancer stem cells express ROR1, which can 
be targeted for anti -cancer-stem-cell therapy, Proc. Natl. Acad. Sci. U. S. A. 111 
(2014) 17266–17271. 
[221] A.J. Ziebarth, S. Nowsheen, A.D. Steg, et al., Endoglin (CD105) contributes to 
platinum resistance and is a target for tumor-specific therapy in epithelial ovarian 
cancer, Clin. Cancer Res. 19 (2013) 170–182. 
[222] J. Zhang, B. Yuan, H. Zhang, et al., Human epithelial ovarian cancer cells expressing 
CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and 
drug resistance, Oncol. Lett. 17 (2019) 5351–5360. 
[223] J.A. Ross, I. Ansell, J.T. Hjelle, et al., Phenotypic mapping of human mesothelial 
cells., Adv. Perit. Dial. 14 (1998) 25–30. 
 
 
 
